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Abstract
Class I phosphoinositide 3-kinases (PI3K) and mammalian target of rapamycin complexes 1/2
(mTORC1/2) are enzymes that play important roles in elementary biology and disease. As a
consequence, numerous small-molecule inhibitors of their catalytic activity have been developed
and these have shown clinical utility in certain cancers. Unfortunately, acquired resistance to
these therapies is a common phenomenon and often occurs relatively quickly following treatment.
Our understanding of how resistance develops is hampered by the difficulty of measuring
the circuitry and plasticity of the signalling networks that these and other kinases signal within.
Advances in mass spectrometric technologies have rendered the routine quantitative interrogation
of the phosphoproteome (the set of phosphorylated proteins expressed in a particular biological
system at a specific time) more tractable than ever before. The aim of this project therefore, was
to improve upon existing mass spectrometry (MS)-based phosphoproteomics methods, and to
utilise these to contribute to our understanding of kinase signalling networks and examine their
plasticity in models of acquired resistance to PI3K and mTORC1/2-targeted therapies.
Novel approaches for the enrichment of phosphopeptides from complex biological matrices
(and their analysis by MS) were designed, tested and optimised. These methods were then
used to systematically characterise a kinase signalling network comprising the Akt/PI3K/mTOR
and MEK/ERK signalling axes in MCF7 breast cancer cells. The biological relevance of this
network was confirmed through the assessment of its dynamics upon EGF and IGF-1 stimulation.
Finally, the plasticity of this network following chronic treatment with targeted PI3K and mTORC1/2
inhibitors (GDC-0941 and KU-0063794) was examined in cell-line models of acquired resistance
to these two compounds. This revealed that these cells each remodelled this network in a different
manner, thus indicating that the initial conditions of the system were not the sole determinant of
how resistance was acquired.
5
Contents
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1 Introduction 16
1.1 Phosphoinositide 3-kinases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.1.1 PI3Ks – class I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.1.2 PI3Ks – class II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.1.3 PI3Ks – class III . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.1.4 Class I – mechanisms of activation . . . . . . . . . . . . . . . . . . . . . . . 19
1.1.5 Class I – mechanisms of regulation . . . . . . . . . . . . . . . . . . . . . . . 20
1.1.6 Class I – downstream signalling . . . . . . . . . . . . . . . . . . . . . . . . 22
1.2 Mammalian Target of Rapamycin (mTOR) - function, activation and regulation . . . 22
1.2.1 mTORC1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
1.2.2 mTORC2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.3 Class I PI3Ks and mTORC1/2 – cancer roles and therapeutic potential . . . . . . . 27
1.3.1 Development of targeted inhibitors against PI3Ks, mTORC1/2 and other ki-
nases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.4 Kinase inhibitor resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.4.1 Intrinsic resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
1.4.2 Acquired resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
1.4.3 Understanding resistance mechanisms and kinase signalling at a systems
level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
1.5 Proteomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
1.5.1 Mass spectrometry – applications to proteomics . . . . . . . . . . . . . . . 33
1.5.2 Mass spectrometers for proteomics . . . . . . . . . . . . . . . . . . . . . . 34
1.5.3 Experimental strategies and sample preparation in proteomics . . . . . . . 36
1.5.4 Liquid chromatography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
1.5.5 MS analysis – qualitative proteomics . . . . . . . . . . . . . . . . . . . . . . 38
1.5.6 MS analysis – quantitative proteomics . . . . . . . . . . . . . . . . . . . . . 42
1.6 Sub-proteomics: the phosphoproteome . . . . . . . . . . . . . . . . . . . . . . . . 48
1.6.1 The function of phosphorylation events . . . . . . . . . . . . . . . . . . . . 48
1.6.2 Enrichment of phosphorylated proteins/peptides . . . . . . . . . . . . . . . 50
1.6.3 MS2 ion activation methods for phosphopeptide ions . . . . . . . . . . . . . 54
1.6.4 Bioinformatic considerations for the sequencing of phosphopeptide ions . . 56
6
2 Materials and Methods 57
2.1 Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
2.2 Miscellaneous reagents and materials . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.3 Kinase/phosphatase inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
2.4 Cell culture – MCF7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
2.4.1 Cell seeding for experimentation . . . . . . . . . . . . . . . . . . . . . . . . 60
2.4.2 Cryopreservation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
2.4.3 Treatment with kinase/phosphatase inhibitors . . . . . . . . . . . . . . . . . 61
2.4.4 Creation and maintenance of resistant cell-lines . . . . . . . . . . . . . . . 61
2.4.5 MTS proliferation assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
2.4.6 Crystal violet assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
2.5 Cell lysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
2.6 SDS-PAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
2.6.1 Western blotting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
2.7 LC-MS sample preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
2.7.1 Tryptic digestion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
2.7.2 Peptide desalting by solid-phase extraction . . . . . . . . . . . . . . . . . . 63
2.7.3 TiO2-Metal Oxide Affinity Chromatography (MOAC) – on-line method . . . . 63
2.7.4 TIO2-MOAC – off-line method . . . . . . . . . . . . . . . . . . . . . . . . . . 64
2.7.5 TiO2-MOAC – final enrichment method . . . . . . . . . . . . . . . . . . . . 64
2.8 Liquid Chromatography-Mass Spectrometry (LC-MS) . . . . . . . . . . . . . . . . . 64
2.8.1 Sample reconstitution and LC separations . . . . . . . . . . . . . . . . . . . 64
2.8.2 Mass spectrometric analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 65
2.8.3 Thermo LTQ-Orbitrap-Velos and -XL mass spectrometers . . . . . . . . . . 65
2.9 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
2.9.1 Mascot database searches . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
2.9.2 Phosphopeptide quantification . . . . . . . . . . . . . . . . . . . . . . . . . 68
2.9.3 Quantitative data: pre-processing and differential abundance analysis . . . 68
3 Enhancement of “single-shot” phospho-enrichment and mass spectrometric method-
ologies to maximise phosphoproteome coverage 71
3.1 Introduction and aims of the study . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
3.2 Optimisation of phospho-enrichment conditions . . . . . . . . . . . . . . . . . . . . 74
3.2.1 Effects of on-line desalting on phosphopeptide recovery . . . . . . . . . . . 74
3.2.2 Effects of “off-line” desalting . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.2.3 Optimisation of off-line desalting conditions . . . . . . . . . . . . . . . . . . 78
3.2.4 Effects of removing phosphopeptide acidification . . . . . . . . . . . . . . . 80
3.3 Comparison of mass spectrometric methods for phosphoproteomics . . . . . . . . 83
3.3.1 Effects of gas-phase fractionation on precursor ion selection . . . . . . . . 83
3.3.2 Comparison of CID-MSA and HCD for phosphopeptide fragmentation . . . 85
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4 Empirical determination of a kinase signalling network 89
4.1 Introduction and aims of the study . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
4.2 Qualitative data analysis and quality controls . . . . . . . . . . . . . . . . . . . . . 91
4.3 Quantitative data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.3.1 Differential abundance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
7
4.3.2 Examination of kinase inhibitor relationships . . . . . . . . . . . . . . . . . 95
4.4 Derivation of compound-target activity markers (CTAMs) from phosphoproteomics
data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
4.5 Inference of a kinase signalling network from phosphoproteomics data . . . . . . . 100
4.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5 Analysis of signalling network plasticity in response to network perturbation 106
5.1 Introduction and aims of the study . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
5.2 Quantitative data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
5.2.1 Differential abundance of phosphopeptides over the growth factor time-courses108
5.2.2 Examination of positive controls and validation of MS data . . . . . . . . . . 108
5.3 Analysis of network plasticity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.3.1 Temporal behaviour of CTAM groups . . . . . . . . . . . . . . . . . . . . . . 112
5.3.2 Intra-CTAM group homogeneity . . . . . . . . . . . . . . . . . . . . . . . . . 116
5.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
6 Signalling network plasticity in models of acquired resistance to chronic PI3K or
mTORC1/2 inhibition 120
6.1 Introduction and aims of the study . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
6.2 Defining the sensitivity of parental cells . . . . . . . . . . . . . . . . . . . . . . . . 123
6.3 Profiling of the resistant cell-lines . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
6.3.1 Determination of acquired resistance . . . . . . . . . . . . . . . . . . . . . . 125
6.3.2 Phosphoproteomic and proteomic profiling of the resistant and pare-ntal
models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
6.3.3 CTAM network analysis of the resistant cell-lines . . . . . . . . . . . . . . . 128
6.3.4 Validation of the MS and CTAM analyses . . . . . . . . . . . . . . . . . . . 130
6.4 Linking network activities to phenotypic outputs . . . . . . . . . . . . . . . . . . . . 132
6.4.1 Responses of resistant and parental cells to a panel of kinase inhibitors . . 132
6.5 Rewiring of the signalling network in MCF7-G cells . . . . . . . . . . . . . . . . . . 135
6.5.1 Differences in EGF-induced phosphorylation kinetics between MCF7-G and
-P cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
6.5.2 Degradation and recycling of EGFR in GDC-0941-resistant cells . . . . . . 139
6.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
7 Discussion 142
7.1 Phospho-enrichment and mass spectrometric methods for maximising phospho-
proteome coverage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
7.1.1 Principles of single-shot phospho-enrichment methods . . . . . . . . . . . . 144
7.1.2 Technical considerations and limitations of the developed phospho-enrichment
methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
7.1.3 Principles of gas-phase fractionation . . . . . . . . . . . . . . . . . . . . . . 146
7.1.4 Principles of MS2 ion activation methods . . . . . . . . . . . . . . . . . . . . 147
7.1.5 Implications and future work . . . . . . . . . . . . . . . . . . . . . . . . . . 148
7.2 Empirical determination of a kinase signalling network . . . . . . . . . . . . . . . . 149
7.2.1 Technical considerations of the MS and computational methods . . . . . . . 149
7.2.2 Validation of kinase inhibitor efficacy . . . . . . . . . . . . . . . . . . . . . . 150
7.2.3 Analysis of kinase relationships . . . . . . . . . . . . . . . . . . . . . . . . . 150
7.2.4 Derivation of CTAMs from phosphoproteomics data . . . . . . . . . . . . . 151
8
7.2.5 CTAM identification: limitations of the methodology . . . . . . . . . . . . . . 152
7.2.6 Implications and future work . . . . . . . . . . . . . . . . . . . . . . . . . . 153
7.3 Analysis of signalling network plasticity in response to EGF/IGF-1 stimulation . . . 153
7.3.1 Phosphoproteomics of growth factor-treated MCF7 cells . . . . . . . . . . . 154
7.3.2 Utility of CTAM-based network analysis of independent experiments . . . . 154
7.3.3 Strengths and limitations of CTAM measurement . . . . . . . . . . . . . . . 155
7.3.4 Implications and future work . . . . . . . . . . . . . . . . . . . . . . . . . . 156
7.4 Plasticity of the defined kinase signalling network in models of acquired resistance 156
7.4.1 Development of models of acquired resistance . . . . . . . . . . . . . . . . 156
7.4.2 Phosphoproteomic, CTAM network and phenotypic analyses of the resistant
cell-lines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
7.4.3 Rewiring of the signalling network in cells resistant to GDC-0941 . . . . . . 158
7.4.4 Evolutionary routes to acquired resistance: lessons from chaos theory . . . 159
7.5 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Appendix 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Appendix 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
Appendix 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
Appendix 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
Appendix 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
9
Abbreviations
ACN Acetonitrile
ALK Anaplastic lymphoma kinase
AMPK 5’-AMP-activated protein kinase
APEX Absolute protein expression
AR Androgen receptor
BSA Bovine serum albumin
CAMK2 Calcium/calmodulin-dependent protein kinase II
CID Collision-induced dissociation
CML Chronic myeloid leukaemia
DC Direct current
DDA Data-dependent acquisition
DIA Data-independent acquisition
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethyl sulphoxide
DTT Dithiothreitol
ECL Enhanced chemiluminescence
EDTA Ethylenediamine tetra-acetic acid
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ER Oestrogen receptor
ERK Extracellular-regulated kinase
ERLIC Electrostatic repulsion-hydrophilic interaction chromatography
ESI Electrospray ionisation
(F)ETD (Front-end) electron-transfer dissociation
EThcD Electron-transfer/higher-energy collision dissociation
FA Formic acid
FBS Foetal bovine serum
FDR False discovery rate
FWHM Full-width half-maximum
GDP Guanosine diphosphate
GPCR G-protein coupled receptor
GPF Gas-phase fractionation
GTP Guanosine triphosphate
HCD Higher-energy collision dissociation
HER2 Human epidermal growth factor receptor 2
HILIC Hydrophilic interaction chromatography
IAM Iodoacetamide
ICAT Isotope-coded affinity tag
IGF Insulin-like growth factor
IGFR Insulin-like growth factor receptor
InsR Insulin receptor
IMAC Immobilised metal affinity chromatography
INPP4B Inositol polyphosphate-4-phosphatase
IRS-1 Insulin receptor substrate 1
iTRAQ Isobaric tag for relative and absolute quantification
10
KSEA Kinase-substrate enrichment analysis
LC (nLC) Liquid chromatography (nanoflow liquid chromatography)
LC-MS Liquid chromatography-mass spectrometry
LC-MS/MS Liquid chromatography-tandem mass spectrometry
LTQ Linear trap quadrupole
MALDI Matrix-assisted laser desorption ionisation
MAPK Mitogen-activated protein kinase
MAP2K Mitogen-activated protein kinase kinase
MOAC Metal oxide affinity chromatography
MS Mass spectrometry
MSA Multi-stage activation
mAb Monoclonal antibody
mSIN Mammalian stress-activated protein kinase interacting protein 1
mTOR Mammalian target of rapamycin
NSCLC Non-small-cell lung cancer
pAb Polyclonal antibody
PAGE Polyacrylamide gel electrophoresis
PBS Dulbecco’s phosphate-buffered saline
PDK1 Phosphoinositide-dependent kinase 1
PESCAL Peak statistic calculator
PI3K Phosphoinositide 3-kinase
PI Phosphoinositide
PKC Protein kinase C
PP2A Protein phosphatase 2
PRAS40 Proline-rich Akt substrate (40 kDa)
PTEN Phosphatase and tensin homolog
Q-TOF Quadrupole time-of-flight
QqQ Triple quadrupole
RF Radio frequency
ROCK Rho-associated protein kinase
RP Reversed-phase
RPS6KB1 Ribosomal S6 protein kinase B1
RTK Receptor tyrosine kinase
SCX Strong-cation exchange
SD Standard deviation
SDS Sodium dodecyl sulphate
SEM Standard error of the mean
SGK3 serum/glucocorticoid-regulated kinase 3
SHIP SH2 domain-containing inositol 5-phosphatase
SILAC Stable isotope-labelled amino acids in culture
SIMAC Sequential elution from IMAC
SRM/MRM Selected reaction monitoring/multiple reaction monitoring
TBS Tris-buffered saline
TFA Trifluoroacetic acid
TMT Tandem mass tag
TOF Time-of-flight
TRIS Tris(hydroxymethyl)aminomethane
11
TSC Tuberous sclerosis protein complex
ULK1 Unc-51-like kinase 1
UPLC Ultra-performance liquid chromatography
XIC Extracted ion chromatogram
12
List of Figures
1.1 Phosphatidylinositol metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.2 PI3K activation mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.3 PI3K regulation mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.4 mTOR complex 1 and 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
1.5 mTOR complex 1 activation and regulation mechanisms . . . . . . . . . . . . . . . 24
1.6 mTOR complex 2 activation and regulation mechanisms . . . . . . . . . . . . . . . 26
1.7 Structures of GDC-0941 and KU-0063794 . . . . . . . . . . . . . . . . . . . . . . . 28
1.8 Intrinsic resistance mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
1.9 Acquired resistance mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
1.10 The process of electrospray ionisation . . . . . . . . . . . . . . . . . . . . . . . . . 35
1.11 Principles of liquid chromatography . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
1.12 Principles of tandem mass spectrometry . . . . . . . . . . . . . . . . . . . . . . . . 38
1.13 Collision-induced dissociation principles . . . . . . . . . . . . . . . . . . . . . . . . 40
1.14 Labelling methods for quantitative proteomics . . . . . . . . . . . . . . . . . . . . . 43
1.15 Label-free methods for quantitative proteomics . . . . . . . . . . . . . . . . . . . . 45
1.16 PESCAL methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
1.17 Kinase-phosphatase pairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
1.18 MOAC and IMAC phospho-enrichment methods . . . . . . . . . . . . . . . . . . . 52
1.19 MS2 fragmentation for phosphopeptide ions . . . . . . . . . . . . . . . . . . . . . . 55
2.1 Schematics of the orbitrap-XL and -Velos mass spectrometers . . . . . . . . . . . 66
2.2 Example ion trap and orbitrap mass spectra . . . . . . . . . . . . . . . . . . . . . . 67
2.3 Specimen XIC produced by PESCAL . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.4 Linear models for differential expression analysis . . . . . . . . . . . . . . . . . . . 70
3.1 Montoya et al. phospho-enrichment methodology . . . . . . . . . . . . . . . . . . . 73
3.2 Improvement to existing phospho-enrichment methodology . . . . . . . . . . . . . 74
3.3 Effect of an additional ammonium acetate wash . . . . . . . . . . . . . . . . . . . . 75
3.4 Effects of “off-line” desalting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.5 Optimisation of off-line desalting conditions . . . . . . . . . . . . . . . . . . . . . . 78
3.6 Effect of the removal of phosphopeptide acidification . . . . . . . . . . . . . . . . . 81
3.7 Peptide length and ionisable residue distributions . . . . . . . . . . . . . . . . . . . 82
3.8 Efficacy of gas-phase fractionation . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.9 Comparison of ion fragmentation methods . . . . . . . . . . . . . . . . . . . . . . . 86
4.1 Network determination experimental design . . . . . . . . . . . . . . . . . . . . . . 91
4.2 Network determination experiment quality control . . . . . . . . . . . . . . . . . . . 92
4.3 Confirmation of inhibitor action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.4 Phosphoproteomic classification of kinase inhibitors . . . . . . . . . . . . . . . . . 96
13
4.5 CTAM selection criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
4.6 Algorithm used for CTAM selection . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.7 Analysis of the relationships between CTAMs and their upstream kinases. . . . . . 101
4.8 Inference of a kinase signalling network using CTAMs . . . . . . . . . . . . . . . . 103
5.1 CTAM group enrichment methodology . . . . . . . . . . . . . . . . . . . . . . . . . 107
5.2 Growth factor time-course controls . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.3 Growth factor time-course validation . . . . . . . . . . . . . . . . . . . . . . . . . . 111
5.4 Network plasticity with EGF and IGF-1 stimulation . . . . . . . . . . . . . . . . . . 113
5.5 Global snapshots of network activity under EGF/IGF-1 treatment . . . . . . . . . . 114
5.6 PCA of the EGF/IGF-1 time-course data . . . . . . . . . . . . . . . . . . . . . . . . 115
5.7 EGF/IGF-1 CTAM group CV distributions . . . . . . . . . . . . . . . . . . . . . . . . 116
5.8 Intra-CTAM group homogeneity of response . . . . . . . . . . . . . . . . . . . . . . 117
6.1 Resistant cell-line creation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
6.2 Sensitivity of MCF7-P cells to GDC-0941 and KU-0063794 . . . . . . . . . . . . . 124
6.3 Resistant cell-line proliferation assays . . . . . . . . . . . . . . . . . . . . . . . . . 126
6.4 Resistant cell-line CTAM network analyses . . . . . . . . . . . . . . . . . . . . . . 128
6.5 Resistant cell-line network analysis PCA . . . . . . . . . . . . . . . . . . . . . . . . 129
6.6 Validation of the resistant cell-line MS data . . . . . . . . . . . . . . . . . . . . . . 131
6.7 Responses of resistant cells to a panel of kinase inhibitors . . . . . . . . . . . . . . 133
6.8 PCA of the resistant cell-line viability data . . . . . . . . . . . . . . . . . . . . . . . 134
6.9 Growth factor time-course heat map . . . . . . . . . . . . . . . . . . . . . . . . . . 136
6.10 Growth factor time-course CTAM analysis . . . . . . . . . . . . . . . . . . . . . . . 137
6.11 Multivariate analysis of the time-course dataset . . . . . . . . . . . . . . . . . . . . 138
6.12 EGFR degradation in the resistant and parental cells . . . . . . . . . . . . . . . . . 139
7.1 EGFR recycling and degradation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
7.2 Illustration of chaos theory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
14
List of Tables
1.1 PI3K family summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.1 Antibodies used for Western blotting . . . . . . . . . . . . . . . . . . . . . . . . . . 58
2.2 Miscellaneous materials and reagents . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.3 Kinase and phosphatase inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
2.4 Lysis buffer and constituents wherein . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.1 Network differential abundance analysis . . . . . . . . . . . . . . . . . . . . . . . . 93
5.1 EGF/IGF-1 time-course differential abundance analysis . . . . . . . . . . . . . . . 108
6.1 Resistant cell phosphopeptide differential abundance analysis . . . . . . . . . . . . 127
6.2 Resistant cell proteomics differential abundance analysis . . . . . . . . . . . . . . 127
6.3 EGF time-courses for the MCF7-G and -P cells . . . . . . . . . . . . . . . . . . . . 135
15
Chapter 1
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1.1 Phosphoinositide 3-kinases
Phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) have been iden-
tified, amongst other kinases, as having critical importance in both fundamental and disease
biology. PI3Ks are a family of enzymes that catalyse the transfer of a phosphate group from the
 position on adenosine triphosphate (ATP) to the 3-hydroxyl groups of phosphatidylinositol lipids
at the plasma membrane. They have been shown to be involved in a diverse array of cellular
processes including: proliferation, migration, intracellular trafficking and differentiation. The eight
currently recognised members of the PI3K family are grouped into three distinct classes according
to the phospholipid products that they produce, their pathways of activation and their regulatory
subunits: class I (p110, ,  and ), class II (,  and ), and class III (Vps34)1,2. Table 1.1
provides an overview of the three classes and a brief summary of the distinctions between them
(discussed in further detail subsequently). The functions and roles of the class I PI3Ks are the
best-characterised of the three classes. Emerging data focused on class II and III, however, are
beginning to reveal their impact on normal and disease biology in more detail.
Class Structural features/functional domains Catalytic products Regulators Activators
I
PI(3)P,
PI(3,4)P2,
PI(3,4,5)P3
p85/,
p55/,
p50,
p101,
p84,
p87
RTKs,
Ras,
GPCRs
II PI(3)P,
PI(3,4)P2
-
RTKs,
GPCRs(?),
Ca2+
III PI(3)P Vps15,
p150
GPCRs(?)
Amino acids(?)
Table 1.1: A summary of the PI3K enzyme family. The PI3K enzyme family consists of three main classes; I, II and
III. The differences in catalytic products, regulatory protein partners and modes of activation are highlighted. PI(3)P,
phosphatidylinositol-3-phosphate; PI(3,4)P2, phosphatidylinositol-3,4-bisphosphate; PI(3,4,5)P3, phosphatidylinositol-
3,4,5-trisphosphate.
1.1.1 PI3Ks – class I
The first class of PI3K enzymes is that which has been studied in most depth and consists of
four distinct isoforms which are further subdivided into class IA (p110, , and ) and IB (p110)
catalytic subunits3,4. Their mechanisms of activation, regulation and downstream signalling are
relatively well-characterised (discussed further in Section 1.1.4, 1.1.5 and 1.1.6). In addition, their
substrate specificity has been well-defined, as it has been shown that they selectively phosphory-
late PI(4,5)P2 to produce PI(3,4,5)P3 in vivo 4 (summarised in Fig 1.1). Importantly, their roles in
fundamental biological processes (including proliferation, migration, growth, and metabolism) and
disease states (e.g. PIK3CA [p110] mutations in various cancers and overgrowth syndromes)
have also been elucidated to some extent5,6.
1.1.2 PI3Ks – class II
As shown in Table 1.1, the second class of PI3K enzymes consists of three members, each
representing single catalytic subunits devoid of associated regulatory proteins: C2, , and  2.
Due to the lack of regulatory subunits, the three enzymes are believed to be regulated, and their
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Figure 1.1: An overview of the metabolism of phosphatidylinositols. A host of enzymes catalyse the production and
further metabolism of phosphatidylinositols in human cells. Each phosphatidylinositol species possesses an important
signalling role, and the equilibria between them is tightly regulated. CDP, cytosine diphosphate; DAG, diacylglycerol; IP3,
inositol phosphate; PI, phosphatidylinositol; PI3K, phosphoinositide 3-kinase; PI4K, phosphoinositide 4-kinase; PIPK I/II,
phosphatidylinositol phosphate kinase 1/2; PLC, phospholipase C; PS, phosphatidylinositol synthase.
activity modulated, by their comparatively extended N- and/or C-terminal domains2. Evidence
suggests that class II PI3Ks interact with a number of cell-surface proteins, namely: clathrin
(essential for the endocytosis of multiple cell-surface receptors), epidermal growth factor receptor
(EGFR – a cell-surface receptor responsible for activating multiple signalling cascades), and Grb2
(a signalling protein essential for linking Ras signalling to EGFR)2. These interactions, amongst
other experimental data, point to RTKs and GPCRs being involved in the activation of class II
PI3Ks7.
In contrast to class I PI3Ks, C2, , and  have been shown to possess substrate specificity
for PI and PI(4)P, and to subsequently phosphorylate this to produce PI(3)P or PI(3,4)P2 (Fig
1.1)8,9. The majority of the class II-produced PI(3)P is thought to be localised to endosomal
compartments where it functions to recruit PX and/or FVYE domain-containing proteins in order
to facilitate their downstream signalling events10.
1.1.3 PI3Ks – class III
The third class of PI3Ks consists of a sole isoform, originally identified in yeast (S. cevervisiae),
named Vacuolar Protein Sorting 34 (Vps34 – encoded by the PIK3C3 gene in H. sapiens). Vps34
has been shown to utilise PI as its substrate and to catalyse its phosphorylation to form PI(3)P (Fig
1.1). As discussed with regards to class II PI3Ks, the PI(3)P product serves to recruit proteins
possessing FYVE and/or PX domains to the intracellular face of the plasma membrane, thus
facilitating their roles in downstream signalling pathways and networks10. Recent data utilising
a selective inhibitor of Vps34 revealed that serum/glucocorticoid regulated kinase 3 (SGK3) is a
downstream target of Vps34; this being mediated through its production of PI(3)P and subsequent
18
binding of SGK3 to these phospholipids via its PX domain11.
Despite the similarities with class II PI3Ks in terms of the phospholipid products of Vps34’s
activity, unlike Class II, Vps34 forms a constitutive complex with a regulatory protein, Vps15.
Vps15 is a protein kinase that facilitates the activation of the lipid kinase function of Vps34. Vps15
also acts to anchor Vps34 to the plasma and other membranes through its N-terminal myristoyl
group – thus bringing it into close proximity to its membrane-embedded PI substrates2,12. Along-
side Vps15’s role in the activation and spatial distribution of Vps34, the complex formed between
these two proteins nucleates three different multi-protein complexes and the constituents of these
act to determine the signalling output produced2,12. For example, Vps34 complex I, consisting of
Vps34, Vps15, Beclin-1, ATG-14L and NRBF2 is responsible for the regulation of autophagy13.
The mechanisms of activation of Vps34 still lack clarity; however, amino acids and GPCRs
may play a significant role14,15. Despite the lack of knowledge regarding the activation of Vps34,
several sources of evidence point clearly towards it possessing an important role in biological
processes. Firstly, the mammalian and yeast forms of the protein are largely homologous, having
been highly conserved through evolution. Secondly, experimental data suggest that it is involved in
the regulation of intracellular trafficking and therefore processes such as autophagy, phagocytosis
and endocytosis. One recent study determined that AMP-activated protein kinase (AMPK) directly
regulates distinct Vps34 complexes – via the phosphorylation of Beclin-1 at Ser91 and Ser94 – in
order to induce autophagy in periods of nutrient stress16. Finally, alongside the above, Vps34
homozygous knock-out models in yeast and D. melanogaster are not viable, thus highlighting its
importance in embryonic development2.
1.1.4 Class I – mechanisms of activation
Members of PI3K class I are activated by a number of different signalling proteins and their related
extracellular factors (summarised in Fig 1.2); the first of which being by stimulation of receptor
tyrosine kinases at the plasma membrane (e.g. EGFR and FGFR). RTKs, when stimulated by
a multitude of different imflammatory molecules, growth factors, and hormones, are known to
activate the p110, , and  isoforms. Stimulation of these receptors by their cognate ligand
causes them to dimerise and auto-phosphorylate key tyrosine residues within their intracellular
domains, allowing the recruitment of SH2 domains – present within the regulatory subunits of
class I PI3Ks – to the receptor. This association induces a conformational change in the dimeric
PI3K regulatory-catalytic subunit complex and, as a consequence, the regulatory subunit is no
longer able to inhibit the catalytic subunit’s activity.
The second mechanism by which a subset of PI3K class I enzymes are activated is via GPCRs.
GPCRs, when stimulated to release the G  subunit by chemokines, cytokines and hormones,
have been shown to selectively activate p110. Although mechanistically unclear, this mode of
activation is believed to involve the interaction of p110’s regulatory subunits, p101/p84/p87, with
G  ; thus localising the  catalytic-regulatory heterodimer at the plasma membrane17. Alongside
p110, recent evidence suggests that p110 is also associated with GPCRs, although this is
thought to be regarding its involvement in signalling downstream of the receptors, as opposed to
a direct activation mechanism of the kinase18.
The final class I PI3K activation mechanism, known to activate all isoforms, involves the Ras
family of GTPases. Ras interacts with class I PI3Ks via their Ras-binding domains (present in
all p110 isoforms – Table 1.1) and a significant body of in vitro evidence supports Ras’s role
in the activation of PI3Ks2. Moreover, despite the universality of class I activation by Ras, the
combinatorial specificity of Ras and p110 isoforms is functionally relevant; altering the cellular
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Figure 1.2: Class I PI3Ks are activated by Ras, RTKs and GPCRs. Ras GTPases are involved in the activation of all
four class I isoforms, itself being regulated by the action of the relevant GTPase Activating Proteins (GAPs) and Guanine
nucleotide Exchange Factors (GEFs). RTKs are responsible for the activation of three of the isoforms when stimulated
by growth factors (, , and ). Finally, GPCRs are also involved in the activation of some class I PI3K isoforms; the
interaction between G  , p110, and potentially p110, for exmaple. RTK, Receptor Tyrosine Kinase; GPCR, G-Protein
Coupled Receptor; EGF, Epidermal Growth Factor; IGF, Insulin-like Growth Factor; PDGF, Platelet Derived Growth Factor;
FGF, Fibroblast Growth Factor
response to stimuli accordingly19.
1.1.5 Class I – mechanisms of regulation
PI3Ks possess vital roles in the normal homeostasis of cellular proliferation and tissue main-
tenance. This necessitates tight regulation of the p110 subunits’ catalytic functions; ensuring
efficient and appropriate growth and proliferative signals to be transmitted. The main mecha-
nism of regulation is via the regulatory subunits’ interaction with their respective catalytic subunits
(e.g. p85 and p110 – shown to be present in equimolar intracellular concentrations in vitro)20.
Crystal structures of the p85-p110 complex have been solved and demonstrate that p85 interacts
with p110 through its C-terminal region (the C-SH2 domain); this binding the N-terminal region of
p11021. This functions to protect the catalytic subunit from Ras activation and degradation, whilst
also inhibiting the catalytic subunit’s enzymatic activity in unstimulated cells22. Upon stimulation
of RTKs, and the subsequent binding of p85 SH2 domains to the key phosphorylated tyrosine
residues, this interaction allows p85 to transmit a confirmational change to the p110 subunit, in-
creasing its catalytic activity.
Alongside the direct subunit interactions discussed above, p85 serves as a signal mediator
for integrating multiple cellular signals in order to modulate the catalytic subunit’s activity. For
example, phosphorylation on Tyr688 by Src family kinases increases p85-p110 heterodimer activ-
ity. Conversely, p85’s interaction with the SHP-1 phosphatase has been shown to down-regulate
the heterodimer’s activity, demonstrating that this regulation is bidirectional23. Another example
of such an interaction is that recently shown to exist between the tumour suppressor BRD7 and
p85. In this scheme, BRD7 has been shown to enable nuclear translocation of p85, removing it
from the cytosol and therefore preventing its interaction with p11024. Interestingly, evidence sug-
gests that the extent of inhibition provided by the p85 regulatory subunits is dependent upon the
p85 and p110 isoforms involved. Therefore, the combinatorial flexibility of different isoforms may
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be a mechanism of regulation in and of itself25,26. In addition to the regulatory role of p85 subunits,
class I PI3Ks have also been shown to be regulated by calpains. Recent data has demonstrated
that calpains 1 and 2 are responsible for the proteolytic cleavage of the p110 and p85 subunits;
reducing the enzyme’s catalytic activity and therefore inhibiting PI3K/Akt signalling27.
Aside from the regulatory impact of the p85 subunits and calpains, another key mechanism
of regulation involves several lipid phosphatase enzymes, namely: PTEN (phosphatase and
tensin homologue), SHIP1/2 (SH2 domain-containing inositol phosphatase), and INPP4B (inositol
polyphosphate-4-phosphatase, type II). These enzymes are responsible for the dephosphoryla-
tion of the phospholipids produced both directly and indirectly by class I PI3Ks and therefore
provide the antithesis to PI3K activity. A summary of these interactions is shown in Fig 1.3.
Figure 1.3: Class I PI3Ks are regulated by the phosphatases PTEN, SHIP1/2, and INPP4B. Several lipid phosphatases
are known to regulate PI3K activity. This is as a result of their direct dephosphorylation of the phosphoinositols respon-
sible for downstream signalling events (Akt, PDK1, and SGK3 are given as examples). The diagram demonstrates the
relationship between RTK stimulation, PI3K activation and the subsequent production of PI(3,4,5)P3, and how this is then
converted by each of the three phosphatases to provide regulation of downstream signalling from PI3K. Akt/PKB, Protein
Kinase B; PDK1, 3-Phosphoinositide Dependent protein Kinase-1; SGK3, Serum/Glucocorticoid regulated Kinase-3
PTEN, both a protein and lipid phosphatase, negatively regulates PI3K-based phospholipid
signalling by catalysing the dephosphorylation of PI(3,4,5)P3 to produce PI(4,5)P2; thus, con-
trolling proliferation, migration and growth signalling3,28. It has also been shown that PTEN is
negatively regulated by p110 (signalling through the RhoA/ROCK pathway), giving reciprocity to
the relationship between PI3K and PTEN29. SHIP1 and 2 also utilise PI(3,4,5)3 as their substrate;
however, they catalyse its dephosphorylation on the 5’ hydroxyl group to produce PI(3,4)P2 3. Both
SHIP1 and 2 are known to interact with a considerable number of RTKs at the plasma membrane,
alongside the serine/threonine protein phosphatase PP2A, and phosphorylation on key tyrosine
residues (and potentially serine/threonine residues – perhaps regulated by the interaction with
PP2A) is thought to be vital in their regulation30. INPP4B, unlike both PTEN and SHIP1/2, is not
involved in the dephosphorylation of PI(3,4,5)P3 directly produced by class I PI3Ks, but is instead
responsible for the removal of the 4’ phosphate group from PI(3,4)P2 to produce PI(3)P. There-
fore, as a result of its catalytic activity, INPP4B negatively regulates PI3K/Akt signalling (as both
PDK1 and Akt are activated by the PI(3,4)P2 and PI(3,4,5)P3 produced by PI3K/SHIP)31. De-
spite this negative impact on Akt signalling downstream of PI3K, INPP4B may be involved in the
activation of serum/glucocorticoid regulated kinase 3 (SGK3) – through production of PI(3)P to
which SGK3 can bind – thus allowing the propagation of PI3K signalling through Akt-independent
routes. INPP4B is found to be selectively expressed in oestrogen receptor (ER)-positive breast
cancer cells, and not in ER-negative phenotypes. In addition, INPP4B’s role as a tumour sup-
pressor is supported by the strong correlation between INPP4B loss and breast tumours of high
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clinical grade and size31.
1.1.6 Class I – downstream signalling
The phosphatidylinositol lipids produced by PI3K serve to recruit signalling proteins to the plasma
membrane and form the major link between membrane signalling proteins (e.g. GPCRs, RTKs,
etc.) and cytosolic protein signalling cascades. This recruitment is facilitated by the binding of
phosphatidylinositol lipids to pleckstrin homology (PH) domains present in a number of key sig-
nalling proteins (e.g. PDK1, Akt, insulin receptor substrate-1 [IRS-1], and the mu isoform of protein
kinase C [PKC])32,33. The crystal structures of several PH domains have been solved, demon-
strating the robust presence of two, anti-parallel  sheets, arranged perpendicularly, followed by
a C-terminal amphipathic -helix34. PH domains, alongside facilitating interactions with phos-
pholipids, have been shown to bind to certain PKC isoforms and G  subunits of GPCRs35,36.
The recruitment of such proteins to the plasma membrane via their PH domains often facilitates
their activation and propagation of downstream signalling (Fig 1.3). A classic example of this is
Akt, whereby upon binding to PI(3,4)P2/PI(3,4,5)3, it can become phosphorylated by downstream
kinases to complete its activation (Thr308 by PDK1 and Ser473 by mTORC2 – the latter being
discussed further in Section 1.2)36,37.
Alongside the direct facilitation of downstream signalling provided by PI3K through its catalytic
activity, it has been proposed that specific isoforms also function as scaffold proteins for multi-
protein signalling complexes. For example, evidence suggests that p110 binds to some PKC
isoforms and phosphodiesterase 3B (PDE3B), regulating the respective complexes’ functions in
a kinase-independent manner38,39. Protein-protein interactions of other class I PI3K isoforms
are as yet unknown; however, the potential protein kinase activity of PI3Ks suggests that these
interactions do exist in vivo 3.
PI3Ks’ clear impacts as crucial signalling proteins and well-connected nodes of intracellular
signalling networks, as evidenced by the rapidly growing body of in vitro, in vivo, and clinical
data supporting this notion, highlights their importance in normal biology whilst concomitantly
emphasising their now known role in multiple diseases. PI3Ks’ roles in disease are explored
further, alongside the closely related mTOR kinase, in Section 1.3.
1.2 Mammalian Target of Rapamycin (mTOR) - function, activation and reg-
ulation
mTOR, unlike the PI3K family of enzymes, consists of only one distinct protein kinase molecule;
however, it functions to nucleate and provide the catalytic activity for two protein signalling com-
plexes. Each of these complexes possesses a unique set of complex members: mTOR complex
1 (mTORC1; mTOR, mLST8/GL, Deptor, Raptor, and PRAS40)40,41 and complex 2 (mTORC2;
mTOR, GL, Rictor, mSIN, and PRR5/PRR5L)42. These complexes integrate signalling inputs
from a variety of different sources (including growth factors, extracellular amino acids, and insulin)
in order to regulate the core, cellular biosynthetic pathways. Despite the similarity in the input
signals they receive, their signalling outputs and downstream effectors are quite distinct, but also
provide a degree of cross-communication between the two complexes (summarised in Fig 1.4)40.
Alongside the individual functions of both complexes, the two are deeply embedded in large,
multi-protein signalling networks, and cross-talk between them and their downstream effectors
has been shown to be key in maintaining cellular and tissue homeostasis.
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Figure 1.4: The mTOR complexes (1 and 2) and their members. The two mTOR complexes possess both distinct
substrates (and therefore biological responsibilities) and complex members; however, significant cross-talk between the
two complexes exists. For example, the phosphorylation of PRAS40 (Proline-Rich Akt Substrate 40 kDa) as a part of
mTORC1 by Akt, which is itself regulated by mTORC2. mLST8, GTPase  subunit like protein; Deptor, disheveled Egl-10
pleckstrin domain containing mTOR interacting protein; Raptor, regulatory associated protein of mTOR; p70S6K, 70 kDa
ribosomal S6 kinase; 4E-BP1, eIF4E-binding protein-1; SIN1, stress-activated protein kinase interacting protein-1; PKC,
protein kinase C; Rictor, rapamycin insensitive companion of mTOR.
1.2.1 mTORC1
The first complex mTOR forms is that which has been studied in most depth, primarily due to the
discovery that its function is inhibited by the naturally occurring compound rapamycin. mTORC1,
as shown in Fig 1.4, is directly responsible for the phosphorylation and activation of several pro-
teins involved in the regulation of cap-dependent translation initiation, namely: eIF4E-binding
proteins (the most extensively studied in relation to mTOR being 4E-BP1) and ribosomal S6 ki-
nases (e.g. p70S6Ks)43. Through its interaction with the aforementioned substrates, mTORC1
activity is responsible for the stimulation of translation and protein synthesis. One of the mech-
anisms by which this is mediated is via phosphorylation of 4E-BP1 at Thr37 and Thr46; directly
leading to 4E-BP1’s dissociation from eIF4E. This facilitates the formation of the eIF4F translation
initiation complex, and therefore subsequent translation events and protein synthesis44,45. The
second mechanism involves the mTORC1-regulated phosphorylation of p70S6Ks (RPS6KB1 and
2) at several sites associated with an increase in p70S6Ks’ kinase activities (Ser394, Thr412, and
Ser434 in isoform 1)43. Once activated, p70S6Ks are then responsible for the phosphorylation
of the S6 protein housed within the 40S ribosomal subunit (Ser235, Thr236, Ser240, and Ser244),
eIF4B (Ser422), and programmed cell-death 4 protein (PDCD4 – Ser67), which are believed to reg-
ulate translation and protein synthesis45. Finally, mTORC1 is also believed to be involved in the
indirect activation of RNA polymerases I and III (via MAP1), which are themselves responsible
for the transcription of transfer and ribosomal RNAs46. Alongside its role in controlling protein
synthesis, mTORC1 has also been determined to regulate autophagy. Autophagy is the catabolic
process by which cells recycle non-essential cellular machinery in order to survive periods of
stress and/or nutrient starvation, and to recycle redundant/malfunctioning cellular components.
mTORC1’s control of the autophagic process is primarily enacted through its phosphorylation of
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ULK1 (Unc-51-Like Kinase 1) at Ser757. This phosphorylation acts to inhibit the interaction of
ULK1 with its activatory kinase AMPK (5’-AMP-activated protein kinase) and therefore inhibits
overall autophagic flux47.
Figure 1.5: The mechanisms of activation and regulation of mTORC1. mTORC1 receives stimulatory and regulatory
inputs from four major sources: amino acid levels, growth factor receptor signalling, energy stress, and hypoxia. Regard-
less of the input, the main regulator of mTORC1 is Rheb, a small GTPase, that when bound to GTP, stimulates mTORC1
activity. TSC1/2, tuberous sclerosis protein 1/2; AMPK, AMP-activated protein kinase; REDD1, regulated in development
and DNA damage responses 1; LAMTOR, late endosomal/lysosomal adaptor and MAPK and mTOR activator.
mTORC1 is activated by numerous cellular processes, including: growth factors and hor-
mones (e.g. IGF-1 and insulin), amino acids, energy levels (i.e. ATP/AMP), and hypoxia (Fig
1.5). mTORC1’s activity – independent of stimulatory input – is regulated by the small GTPase
Rheb (Ras homolog enriched in brain). When Rheb is present in its GTP-bound state, it is repon-
sible for the activation of mTORC148. Rheb is regulated by numerous proteins; however, the best
characterised is the tuberous sclerosis protein (TSC1/2) complex. TSC2 functions as a GAP and
thus catalyses the conversion of Rheb-GTP to Rheb-GDP, resulting in a suppression of mTORC1’s
signalling output49. In the context of growth-factor signalling, Akt directly phosphorylates TSC2
(at Ser939 and Thr1462), leading to its inactivation, thus providing a direct mechanism by which the
PI3K/PDK1/Akt axis activates mTORC150. In addition, Akt also directly phosphorylates PRAS40
(at Thr246 – Fig 1.4), which facilitates mTORC1’s phosphorylation of PRAS40 at Ser183 (51). These
phosphorylation events result in an increased association of PRAS40 with 14-3-3 proteins and its
subsequent degradation, thereby activating mTORC152.
The ability of mTORC1 to respond to changes in intracellular energy levels also occurs through
the activity of the TSC1/2 complex; however, in this context its activity is regulated by AMPK. As
previously mentioned, AMPK, a kinase sensitive to the intracellular ratio of ATP:AMP, is responsi-
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ble for the phosphorylation of ULK1 (at Ser317 and Ser777), leading to an increase in its activity and
therefore autophagy47,53. AMPK is also responsible for the phosphorylation of TSC2 at several
serine residues (including Ser1387), providing one mechanism by which it functions to suppress
mTORC1 activity. Further data suggest however that AMPK also directly phosphorylates Rap-
tor at Ser722 and Ser792, which results in an increased association between Raptor and 14-3-3
proteins, which, similarly to PRAS40, result in Raptor’s inactivation54.
mTORC1’s amino acid sensitivity is regulated by another protein complex, the Ragulator com-
plex. This consists of three proteins, LAMTOR1-3 (late endosomal/lysosomal adaptor and MAPK
and mTOR activator 1), and is reponsible for the recruitment of the Rag GTPases, RagA-D, to
lysosomal membranes. As mTORC1 relocates to lysosomal membranes upon the detection of
amino acids, it is brought into contact with Rag GTPases by the Ragulator complex, which is then
necessary for its activation by Rheb55,56.
Alongside its previously discussed activation through growth factor receptors, energy levels
and amino acids, mTORC1 is also responsive to hypoxia. This responsiveness is derived from
mTORC1’s interaction with REDD1 (regulated in development and DNA damage responses 1)
and AMPK. The expression of REDD1, a HIF-1-regulated gene, is enhanced in response to
hypoxia and DNA damage. The translated protein binds to TSC2, preventing its degradation and
therefore inhibiting mTORC1 signalling. REDD1 is itself regulated by GSK-3 (through phos-
phorylation at Thr23=25) and the CUL4A (Cullin 4A)-ROC1 (regulator of cullins 1)-DDB1 (DNA
damage-binding protein 1) ubiquitin ligase degradation system57. AMPK, activated by hypoxia,
regulates mTORC1 through both TSC1/2-dependent and -independent mechanisms, depending
on the cellular context. Experiments have demonstrated that in a MEF model, hypoxia-induced
AMPK-mTORC1 regulation is TSC2-dependent; however, in a hepatocyte model, this regulation
was determined to be TSC2-independent but Raptor and LKB-dependent58.
1.2.2 mTORC2
It has been observed that not all of mTOR’s functions are inhibited when model systems are
treated with rapamycin. The discovery of a second mTOR complex opened up the possibility
that any rapamycin-insensitive functions of mTOR could be mediated by mTORC2. mTORC2,
unlike mTORC1, is not involved in the phosphorylation of substrates whose activities regulate the
energy-intensive processes of translation and protein synthesis. Instead, mTORC2 is responsi-
ble for the phosphorylation of multiple members of the AGC kinase family (e.g. Akt, SGK1, and
PKC)40,59,60. The phosphoryation of Akt (at Ser473) by mTORC2 facilitates Akt’s complete activa-
tion, thus directly linking mTORC2 to the cellular processes downstream of Akt (e.g. cell survival
and apoptosis regulation)59. Similarly, mTORC2 phosphorylates and activates SGK1 (at Ser422),
which is implicated in the regulation of multiple processes such as proliferation, apoptosis and cell
volume control60. Furthermore, mTORC2’s link with PKC (specifically through Rictor) renders it
a key regulator of cytoskeletal dynamics, involving several small GTPases such as Rac1, RhoA,
and Cdc4261.
The mechanisms by which mTORC2 is activated and regulated lack the clarity of those that
have been delineated for mTORC1; however, some data have served to elucidate these in recent
years. As is the case for mTORC1, evidence suggests that mTORC2 is activated by growth fac-
tors in a PI3K-dependent manner; however, the components linking PI3K signalling to mTORC2
remain elusive. One mechanism by which mTORC2 can be activated by growth factor-mediated
PI3K signalling that has been delineated however, is via mTORC2’s association with the ribo-
some62. Evidence suggests that an increase in insulin/IGF-1-induced PI3K signalling results in an
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Figure 1.6: The mechanisms of activation and regulation of mTORC2. The mechanisms of activation and regulation
of mTORC2 are less clear than those for mTORC1; however, growth factors/insulin receptor signalling and direct ribosome
binding are known to cause mTORC2’s activation. Unlike mTORC1, mTORC2 is not regulated by Rheb, yet its activation
in response to growth factor receptor signalling is TSC1/2-dependent, although the full mechanism of this is not yet
understood. There is a large degree of cross-talk between the two mTOR complexes, as evidenced by the negative
feedback loop existing from mTORC1’s activity through p70S6K and GRB10/IRS-1 working to suppress growth factor-
mediated PI3K signalling and p70S6K/Akt’s phosphorylation and subsequent destabilisation of mSIN1. IRS-1: insulin
receptor substrate-1; GRB10: growth factor receptor-bound protein 10.
26
increased association of mTORC2 with ribosomes – in a protein synthesis-independent manner
– and an increase in its activity as a result (via Akt – Fig 1.6). mTORC2’s activity in this context
has been demonstrated to be indirectly regulated by mammalian nuclear pre-rRNA processing
protein 7 (mNIP7), which is directly involved in the control of ribosome maturation62. Interestingly,
this activation of mTORC2 via insulin and growth factors has been shown to require the TSC1/2
complex, independent of its GAP activity and therefore independent of Rheb63,64; the opposite to
mTORC1.
The mechanisms of mTORC2 regulation, similar to those regarding its activation, are much
less well-characterised than mTORC1. Despite this, several mechanisms have been elucidated
in recent years. Phosphorylation of IRS-1 (insulin receptor substrate-1) and GRB10 (growth fac-
tor receptor-bound protein 10) by mTORC1 (and p70S6K) has been shown to provide a nega-
tive feedback mechanism to prevent insulin/IGF-1-mediated activation of both mTORC1 and 2
(Fig 1.6)65. In addition, recent data has delineated a second mechanism, independent of IRS-
1/GRB10, involving mSIN1. In this model, both Akt and p70S6K are responsible for the phos-
phorylation of mSIN1 at Thr86 and Thr398, in a context-dependent manner (Fig 1.6)66. These
phosphorylation events encourage the dissociation of mSIN1 from mTORC2, thus reducing its
activity and signalling output.
1.3 Class I PI3Ks and mTORC1/2 – cancer roles and therapeutic potential
Dysregulation of protein kinase signalling is thought to occur in all cancers. Many examples of
such deregulation have now been delineated, including: BRAF activating mutations in melanoma,
over-activation of the RTKs epidermal growth factor receptor (EGFR/ERBB1) and human epider-
mial growth factor receptor 2 (HER2/ERBB2) in lung and breast cancers respectively, and the
constituitive activation of the BCR-Abl fusion kinase in leukaemias67. Amongst their roles in other
diseases, class I PI3Ks and mTOR have also been shown to possess roles in the development
of cancers. Firstly, amidst the contributions of all class I PI3K isoforms to carcinogenesis, that of
the p110 isoform (PIK3CA) is the most well-documented and well-established6,68–70. Evidence
suggests that there are several routes by which p110 signalling can contribute to tumourigene-
sis: over-expression of upstream activators, over-expression of p110 itself, activating mutations
in the PIK3CA gene, and through loss of tumour suppressors (e.g. PTEN loss-of-function mu-
tations)71. The involvement of other isoforms is not negligible however, as several studies have
reported the differential expression of other class I isoforms in various cancers (p110 in haema-
tological malignances, for example)72,73.
Alongside class I PI3Ks, multiple data support the notion that mTORC1 signalling is also
frequently aberrant in cancer40,74. This dysregulation is thought to be mediated by the loss of
key tumour suppressors (e.g. the TSC1/2 complex), which increase mTORC1 activation through
PI3K/Akt75,76. Experimental data suggest that the phosphorylation states of multiple mTORC1
substrates are dysregulated in cancer (e.g. 4E-BPs and p70S6K) – these correlating with poor
prognoses and tumour malignancy40,74. The role of mTORC2 in cancer is less well-defined; how-
ever, as mTORC2 is potentially activated through EGFR/PI3K signalling, loss of tumour suppres-
sors such as PTEN, could also increase mTORC2’s phosphorylation of Akt and other substrates
whose downstream cellular processes are implicated in carcinogenesis76. The complex relation-
ship that exists between mTOR and PI3K clearly has an important impact on their roles in disease,
the extent of the interaction between these kinases and their inter-dependency has yet to be fully
explored.
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1.3.1 Development of targeted inhibitors against PI3Ks, mTORC1/2 and other kinases
Since the discovery of the involvement of kinases in cancer, malignancies have often been con-
ceptualised as being ’addicted’ to the pro-survival signals that they provide when over-activated/
dysregulated. In this, constitutive activation of a pro-survival signalling pathway renders can-
cer cells reliant on these signals for survival; thus, therapeutic targeting of the over-active path-
way inevitably leads to cancer cell death. As a result of these observations, a vast array of
antibody-based and small-molecule inhibitors – specific to the deregulated kinase in question –
have been developed in recent years. Such inhibitors have become a popular and therapeutically
promising area of research; aiming to provide targeted therapy, reduce the side-effects of existing
chemotherapies, and overall improve treatment efficacy77.
Due to the increasing clarity of the roles of mTOR and PI3K in the development of multiple
cancers, a selection of the aforementioned small-molecule inhibitors has been developed against
their kinase activities. A number have been shown to be successful in vitro, in pre-clinical models
(e.g. KU-0063794 [dual mTORC1/2]78, Fig 1.7A) and even in clinical trials (e.g. GDC-0941 [pan
class I PI3K]79, Fig 1.7B). Despite this, several issues have emerged regarding their and other
kinase inhibitors’ clinical use, including: inter-patient and inter-/intra-tumour heterogeneity, the
choice of target for specific cancers, patient stratification, and tumour resistance77,80–82. The latter
has become a significant clinical problem as sub-populations of patients fail to respond (despite
being predicted to respond based on their genotype), and others that may initially respond well to
treatment can relapse, often within a relatively short time-frame80,81. As a result, patient survival
and quality of life are severely affected. It is important therefore to: (i) understand how only select
populations of patients respond to PI3K, mTOR and other kinase-targeted therapies; (ii) predict
better those which will benefit from treatment; (iii) elucidate the subsequent mechanisms by which
initially responsive cancers are able to evade targeted therapies and become resistant.
Figure 1.7: The skeletal formulae of KU-0063794 and GDC-0941. (A) rel-5-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-4-
(4-morpholinyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-benzenemethanol: mTORC1/2 inhibitor, KU-0063794. (B) 2-(1H-
indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-thieno[3,2-d]pyrimidine: pan-class I PI3K in-
hibitor, GDC-0941. Both inhibitors are ATP-competitive, catalytic inhibitors, thus binding to the ATP-binding pocket of
their respective enzyme.
1.4 Kinase inhibitor resistance
Resistance to kinase inhibitor therapies is generally classifed into two, broad categories: intrinsic
(primary) or acquired (secondary). Intrinsic resistance, a lack of response to initial treatment,
implies that the cellular populations within a tumour are pre-resistant to targeted therapy. Mecha-
nisms of such resistance have been explored and involve numerous cellular processes, including:
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inhibition of negative feedback loops and pre-existing compensatory pathways. In contrast to in-
trinsic resistance, acquired resistance is the process by which cancerous cells initially respond to
therapy, yet develop resistance following prolonged treatment, thus escaping the cytostatic and
cytotoxic effects of the inhibition of the targeted kinase. The route by which cancerous cells ac-
quire this resistance is often facilitated by de novo genetic changes to the target kinase and/or
up-regulation of parallel signalling pathways. Both classes of resistance are discussed in detail in
the subsequent sections.
1.4.1 Intrinsic resistance
Despite their success in both pre-clinical and clinical settings, a significant proportion of clinical
cohorts do not respond to therapies targeting the kinase that their tumours have been rationalised
as being ’addicted’ to. As appealing a concept as oncogene addiction is, and despite its canonical
success with regards to the treatment of chronic myeloid leukaemia (CML) with imatinib, it can only
partially explain the responses to kinase-targeted therapies that are over-active in other cancer
types. For example, activating mutations on EGFR are frequent occurrences in non-small-cell
lung cancers (NSCLCs). Despite this, clinical trial data demonstrate that the rate of response
to an EGFR inhibitor (gefitinib) was only 71.2% in those patients with an activating mutation and
23.5% in those with the wild-type gene83. Similarly, clinical data regarding the treatment of V600E
mutant BRAF melanomas demonstrated that only 48% of these patients responded to targeted
therapy84. Moreover, clinical trials of class I PI3K inhibitors demonstrated that only 30% of patients
with activating mutations in the PIK3CA gene responded to therapy85. These examples serve
to demonstrate that intrinsic resistance is indeed a significant clinical problem. Furthermore,
these data highlight that stratification of patients based upon genetic markers, albeit generally
statistically successful, gives rise to a large proportion of false positives (patients that receive
treatment but that show no response: 29%, 52% and 70% in the EGFR, BRAF and PI3K studies
respectively) and false negatives (patients with wild-type genes that may have benefited from
treatment: 23.5% in the EGFR study).
Evidently, the model of oncogene addiction, when invoked in isolation, is not sufficient to ac-
count for the observed responses of cancer cells to targeted therapies. Consequently, a more
sophisticated model is required in order to rationalise how cancer cells respond to different ther-
apies. A logical assumption is that the wiring of the kinase signalling network in its entirety de-
termines whether a cancer cell population may respond to a given inhibitor. Therefore a concept
that is beginning to gain traction is that the activation of both target and parallel pathways con-
tributes to intrinsic resistance. Target and parallel pathways may be activated by feedback loops
regulated by the target kinase or may be activated independently. Furthermore, heterogeneous
genetic polymorphisms and intrinsically high expression of certain key effector proteins may also
allow the continued activation of target and/or parallel pathways and therefore lead to intrinsic
resistance.
1.4.1.1 The role of feedback loops in intrinsic resistance
In untransformed cells and tissues, signals are robustly propagated and processed as a result of
feedback loops86. Emerging data suggest that disruption of negative feedback loops possesses
an important role in intrinsic resistance. For example, inhibition of mTORC1 with ATP-competitive
inhibitors or with rapamycin and its analogues (rapalogs), results in an alleviation of a negative
feedback loop that involves the phosphorylation of IRS-1, an event that decreases the latter’s
stability. Treatment with mTORC1 inhibitors, in some systems, can therefore lead to sustained
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IRS-1 signalling and subsequent activation of PI3K and Akt upstream of mTORC187. A gener-
alised schematic of this is shown in Fig 1.8A. Inhibition of both mTOR complexes prevents this
mode of resistance; however, treatment of some breast cancer cells with the mTORC1/2 inhibitor
Everolimus has been shown to lead to an S6K-directed feedback loop acting on Ras, PI3K and
IRS-1, that results in an up-regulation of MAPK signalling (Fig 1.8B)88. The disruption of feed-
back inhibition has also been observed in HER2 and EGFR-driven cancers treated with a MEK
inhibitor. In these systems, MEK inhibition removes the negative feedback from ERK signalling to
HER3/ERBB3, thus leading to its hyperactivation and subsequent stimulation of downstream Akt
signalling89. Therapeutic targeting of Raf has also been observed to cause rapid feedback acti-
vation of EGFR90. Similar examples have been observed with respect to PI3K inhbiition in PTEN
negative prostate cancers, whereby reduced PI3K signalling removes the feedback inhibition from
mTOR to the androgen receptor (AR) signalling axis – this being found to lead to a rebound in AR
pathway activity mediated by an increase in heterodimeric HER2/3 signalling91. Data exploring
resistance to the dual PI3K/mTOR inhibitor BEZ235 has shown an increase in signalling from
IGF-1R to the JAK2/STAT5 axis, thereby leading to an increase in the production and secretion of
IL-8. This secretion of IL-8 was found to provide two functions; increasing CXCR1-JAK2/STAT5
signalling and promoting metastasis92. Feedback activation of downstream pathway members
has also been shown to occur as a response to HER2 or PI3K blockade, whereby the resultant
decrease in Akt signalling leads to an increase in FOXO3a nuclear translocation (this normally
being inhibited by Akt), thereby up-regulating the expression of several RTKs (e.g. IGF-1R and
HER3/ERBB3) and thus restoring Akt signalling93,94.
Figure 1.8: Mechanisms of intrinsic resistance to kinase inhibition. (A) Indirect inhibition of an intrinsic negative
feedback loop upon targeted inhibition leads to rescued pathway signalling. (B) Indirect inhibition of a negative feedback
loop activates a parallel pathway. (C) Inherently high expression of a nuclear protein synergises with the increased nuclear
translocation of a transcription factor to maintain a pro-tumourigenic gene expression programme. PM, plasma membrane;
NM, nuclear membrane; P, phosphate group. Thick arrows represent increased signalling output; dashed arrows represent
indirect activation or multiple signalling steps; solid arrows represent direct activation; flat-headed arrows represent direct
inhibition.
1.4.1.2 Parallel factors that contribute to intrinsic resistance
Alongside the disruption of feedback loops associated with resistance, certain tumours also pos-
sess resistance due to an intrinsically high activity of certain parallel pathways that can com-
pensate for the inhibition of the target kinase. For example, Akt inhibition with API-2 leads to
increased translocation of FOXO3a into the nucleus where it is responsible for the transcription
of pro-apoptotic genes (e.g. BCL2L11). Intrinsic hyperactivation of wnt--catenin signalling (and
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therefore high levels of nuclear -catenin), however, confers the cells resistance to FOXO3a-
mediated apoptosis. Once more, the simultaneous nuclear sequestration of FOXO3a and -
catenin appears to lead to the up-regulation of a specific subset of genes that function to promote
metastasis (Fig 1.9C)95. Further examples also serve to highlight the importance of identified
co-activated pathways, as tumours unresponsive to RAF inhibitors demonstrated constitutive Akt
activation96, and AML cells intrinsically resistant to PI3K inhibitors demonstrated concomitant ac-
tivation of ERK and PKC97,98. Adjacent to intrinsic parallel pathway activity, aberrations at the
genetic level can also play a role in conferring resistance. For example, recent data have high-
lighted a common deletion polymorphism in the gene encoding BIM (BCL2L11). Due to BIM’s
pro-apoptotic function, this deletion confers resistance to EGFR therapies in NSCLC and imatinib
in CML99.
1.4.2 Acquired resistance
1.4.2.1 Secondary mutations on the targeted kinase
Cancer cells that do initially respond to targeted kinase inhibition almost inevitably develop resis-
tance after prolonged exposure to the drug. The first mechanism of acquired resistance to be un-
derstood regarded mutation of the targeted kinases themselves, preventing the drug from inhibit-
ing pathway signalling (Fig 1.9A and B). Many examples of this phenomenon have now emerged
and often involve mutations in the kinase domain that maintain catalytic activity whilst reducing
the kinase’s affinity for the compound in question100. For example, following long-term treatment
with Imatinib, CML patients have been shown to often development mutations of a key “gate-
keeper” residue near the kinase domain of the over-active Abl kinase (e.g. M351T, T315I, and
E255K)100,101. This has also been observed in response to Crizotinib (an anaplastic lymphoma
kinase [ALK] inhibitor) in NSCLC, whereby patients acquired mutations on ALK (e.g. L1196M and
L1152R)102,103. EGFR inhibition has also been observed to produce secondary mutations; for ex-
ample 50% of patients with NSCLC that develop resistance to Erlotinib or Gefitinib presented with
the T790M gatekeeper mutation in EGFR104,105, and colorectal cancers treated with Cetuximab
(a monoclonal antibody) presented with mutations in EGFR’s extracellular domain (S492R) upon
relapse106.
Figure 1.9: Mechanisms of acquired resistance to kinase inhibition. (A) When first treated, the initial inhibition results
in reduced pathway signalling. (B) Acquired, secondary mutations on the target kinase abrogates binding of the inhibitor,
leading to a rescuing of pathway activity. (C) Secondary mutations on downstream components of the signalling pathway
serve to restore activity. (D) Mutation, alteration and/or over-expression of upstream pathway components results in
compensatory pathway activation. (E) Kinase inhibition leads to an abrogation of pathway signalling; however, over time
the increased expression of compensatory RTKs activates parallel pro-proliferation signalling. P, phosphate group. Thick
arrows represent increased signalling output; dashed arrows represent indirect activation or multiple signalling steps; solid
arrows represent direct activation; flat-headed arrows represent direct inhibition.
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1.4.2.2 Kinase signalling network reprogramming
Several further mechanisms of acquired resistance, independent of mutations on the target ki-
nase, have been described in recent years. Firstly, it has been shown that an increase in the ex-
pression/activity of effectors or kinases downstream of the target can compensate for the latter’s
reduced signalling output. For example, an acquired amplification of eIF4E (at both the genetic
and protein level) in response to the PI3K/mTOR inhibitor BEZ-235 has been observed, which
provides resistance to this compound107. BRAF inhibitor-resistant melanomas have been shown
to restore MAPK signalling activity by means of expression of splice variants of the targeted kinase
(e.g. p61-V600E-BRAF), mutation of kinases downstream of BRAF (e.g. C121S and Q90P on
MEK – Fig 1.9C), and over-expression, mutation, or substitution of upstream pathway activators
(e.g. COT, CRAF, NRAS and EGFR/SOS – Fig 1.9D)108–112.
Cancers are also able to acquire resistance to a targeted compound through the activation of
network branches and parallel pathways that are independent (canonically) of the targeted path-
way. One such mechanism that has been observed on numerous occasions is the up-regulation
of RTKs that then activate compensatory pathways and thus facilitate circumvention of the anti-
proliferative effects of the drug. For example, Gefitinib-based anti-EGFR treatment has been
shown to lead to the amplification of Met (an RTK) which subsequently activates PI3K/Akt sig-
nalling via HER3/ERBB3 (Fig 1.9E)113. c-Met amplification has also been observed with respects
to resistance to anti-VEGF therapy in glioblastoma114. Other data have shown that HER2/ERBB2
is up-regulated in response to Cetuximab-based anti-EGFR therapy; this being mutually exclusive
to the T790M secondary mutation on EGFR115. Similarly, numerous data have demonstrated
that several RTKs are up-regulated in response to BRAF inhibitor therapy in melanoma, namely:
EGFR, IGF-1R, and PDGFR 110,116,117. Further studies have also shown the acquired activation
of intracellular kinases in response to therapy. For example, PTEN and RB1 deletion/inactivation
in BRAF-inhibitor treated melanoma, therefore bypassing ERK signalling reliance through the
activation of Akt. Such phenomena have also been observed in the context of long-term PI3K
inhibition involving several kinases and pathways such as: MEK in murine lung cancers118 and
PAK1 in lymphoma cell-lines (being activated by PI(4,5)P2 pools at the plasma membrane)119.
1.4.3 Understanding resistance mechanisms and kinase signalling at a systems level
A concerted research effort has revealed, as discussed above, that there is a plethora of mech-
anisms by which cancer cells can intrinsically circumvent, or indeed evolve resistance to, the
anti-proliferative/pro-apoptotic effects of a particular kinase inhibitor. This renders the prediction
of cancer patients’ responses to different therapies a serious challenge. These studies have also
highlighted the substantial and functionally important cross-talk that exists between signalling
pathways that have previously been conceptualised as being secular and linear120–122. Conse-
quently, it has become apparent that in order to fully understand the way in which kinases signal
at a fundamental level – and indeed how this signalling is remodelled in disease states – the
networks that these kinases form must be studied as a whole123,124.
Analysis of kinase signalling networks – products of millions of years of evolution – has re-
vealed that they are highly robust and plastic structures125. As such networks are responsible
for the integration and processing of signals, one could argue that the translation of the concepts
of kinase inhibitor resistance over to the robust clinical analysis of patient samples would require
a method (or methods) that allow(s) the profiling of the topology and activity of kinase signalling
networks in their entirety, without bias. The ultimate aim of such a method would be to transition
the field towards the measurement of individuals’ malignancies and to facilitate successful ther-
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apeutic decisions therefrom. Amongst several methods being used to tackle these challenges,
those based on mass spectrometry have proven invaluable in the provision of a more sophisti-
cated understanding of kinase signalling. This is primarily due to their high-content nature, which
has allowed a departure from pre-conceptions of which kinases and signalling pathways may be
important in a particular system. This provides a move away from inherent bias concerning par-
ticularly well-characterised signalling nodes. The impact of MS-based proteomics methods in this
context is discussed further in the remainder of this chapter.
1.5 Proteomics
1.5.1 Mass spectrometry – applications to proteomics
Proteomics is the study of the entire complement of proteins within a biological system at a spe-
cific point in time or under a specific, controlled condition. Amongst other techniques that have
been applied to proteomics, mass spectrometry is one that has revolutionised the field. At its most
fundamental level, mass spectrometry is the measurement of the mass-to-charge ratio (m/z) of
gas-phase ions. From this conceptually simple information it is possible to determine, when cou-
pled to chromatographic techniques, the composition of complex mixtures of compounds. Due
to its inherent specificity, capacity and unbiased nature, it has relevance in numerous areas of
research and industry and is used for the analysis of a wide variety of chemical and biochemical
moieties.
Despite some application-specific variations, all mass spectrometers are comprised of the
same, fundamental units: an ion source, a mass analyser, and a detector. As mentioned above,
the analyte of interest must be in the gas-phase in order to be analysed by the mass spectrometer.
The first element of a mass spectrometer, the ion source, is responsible for the introduction of gas-
phase ions into the instrument – this process often involving the transfer of the analyte from solid
or liquid phase to the gas phase. Ions are then introduced into the mass spectrometer through
the use of a voltage and pressure gradient (e.g. a large negative voltage and pressure being
applied to the ion transfer capillary when positive ions are being analysed). Once in the mass
spectrometer, ions are separated according to their specific m/z in the mass analyser; this step
being of great importance, as it allows the distinction of the different molecular species in the
sample. The ions then pass on to the detector where their relative abundance in the sample can
be measured by monitoring the charge or current produced as each ion hits the detector. Plotting
the relative abundance of the ions detected in the mass spectrometer versus their unique m/z
produces a mass spectrum. Once constructed, mass spectra can then subsequently be used to
calculate the charge (z) of each ion of interest and thus the absolute mass (m) of each ion can be
determined.
Mass spectra produced from the process outlined above contain both qualitative (the unique
m/z peaks present) and quantitative (relative peak abundances) information, and are thus invalu-
able in the study of chemical and biochemical mixtures. As a result, the application of mass
spectrometry to the field of proteomics has flourished over the last decade; particularly as the
resolution, sensitivity, speed, and availability of instruments has greatly increased126. The use of
mass spectrometry in proteomics has largely, but not exclusively, been involved in the analysis
of purified peptide mixtures (a so-called “bottom-up” approach)127. This is because – along-
side the previously mentioned quantitative capabilities of mass spectrometers – the introduction
of tandem-mass spectrometry (MS/MS or MS2) and the polymeric nature of peptide structures
have made it possible to sequence peptides in an unbiased and relatively high-throughput man-
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ner. Consequently, it became possible to analyse the proteome of biological systems without
prior knowledge of their protein composition. This not only allowed the sequencing of novel
protein variants, but also, with the advent of additional tandem-MS fragmentation methods (e.g.
MS3 and collision-induced dissociation–multi-stage activation [CID-MSA]), the robust identifica-
tion of multiple known and novel post-translational protein modifications128. Taken together, mass
spectrometry-based proteomics overcomes many of the limitations present in genomics or tran-
scriptomics analyses, and thus presents itself as a powerful tool for the study of complex biological
systems.
1.5.2 Mass spectrometers for proteomics
Before its application to proteomics, mass spectrometry was used (and remains popular) for the
analysis of small molecules. This generally involves the separation of analytes via gas chromatog-
raphy, whereby the molecules of interest are passed through and separated on a column in the gas
phase by exchanging with a stationary phase according to their specific physico-chemical prop-
erties. Gas chromatography is not well-suited to proteomics analyses however, as peptides are
relatively non-volatile. As a result, the development of ionisation techniques that could produce
gas phase ions from aqueous, liquid phase samples was a major boon for the proteomics field.
Electrospray ionisation (ESI) is such a method, and is that which is most often used in proteomics
studies. ESI, summarised in Fig 1.10, involves the application of a high voltage to the analytes as
they pass through an electrically conductive capillary in the liquid-phase. As a result, an aerosol
of multiply charged solvent droplets forms129. Two models have been developed to describe the
process by which individual ions are ejected from the solvent droplets that form: the ion evapora-
tion and charge residue models. Both models end with the production of desolvated, gas-phase
ions by Coulombic repulsion; however, both propose slightly different parameters which influence
the rate of solvent evaporation130–132. Nevertheless, the gas-phase ions that are produced are
then encouraged to enter the mass spectrometer via a voltage and pressure gradient imposed on
the ion transfer capillary (Fig 1.10).
Several variants of standard ESI exist; however, perhaps the most important with respects
to proteomics analyses is nano-ESI (nESI). This technique involves identical principles to that of
standard ESI, but is performed at much lower flow rates (typically 0.3-0.8 Lmin 1). nESI has
been shown to greatly increase the sensitivity of LC-ESI-MS analyses and reduce ion suppression
artefacts133,134. As a result, it is now commonplace in proteomics experiments.
Another popular ionisation method utilised for proteomics is Matrix-Assisted Laser Desorption
Ionisation (MALDI). MALDI requires the sample to be embedded in a solid-phase matrix (com-
monly 2,5-dihydroxybenzoic acid – DHB), which is then vapourised by a laser beam to produce
protonated (and therefore charged) matrix molecules in the gas phase. The matrix molecules
then transfer this charge to the analyte molecules, producing gas-phase, charged analyte ions
which can then be analysed in the mass spectrometer135. Unlike ESI, MALDI is not easily cou-
pled to liquid-chromatography, and the matrix:analyte ratio – which is often highly variable – has
severe impacts on the reproducibility of the method136. Furthermore, although both methods are
“soft” ionisation techniques, ESI produces more multiply charged ions (typically 2+ or 3+ for tryp-
tic peptides), which are better suited for subsequent MS/MS fragmentation and therefore peptide
identification.
A large variety of mass analysers are utilised for the study of peptides and proteins, namely:
time-of-flight (TOF), quadrupole (Q), linear ion-trap (LIT), orbitrap, and Fourier-transform ion cy-
clotron resonance (FT-ICR) instruments. TOF instruments rely on the principle that when ions
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Figure 1.10: The electrospray (ESI) process. Peptide or other analytes are directly infused into the MS or undergo
chromatographic separation. The solution then passes through a silica or metallic emitter which has a large voltage
applied to it. Charged droplets begin to form on the tip of the emitter; gradually decreasing in size as solvent evaporates.
Eventually, single, desolvated, gas-phase analyte ions are formed, and they enter the mass spectrometer via the ion
transfer capillary down a pressure (red) and voltage (blue) gradient. The ions are then available for mass analysis and
detection.
are accelerated by an electric field and then allowed to drift through a vacuum, they will sepa-
rate/resolve according to differences in their m/z. The flight time (t) of an ion is related to the
square-root of the m/z of the ion multiplied by a proportionality constant defined by particular in-
strument characteristics (k ). Due to this known relationship, it is possible to calculate the m/z of
any ion given its measured time-of-flight137.
Quadrupole mass analysers consist of, at their most fundamental level, four, symmetrically-
spaced, parallel rods. They rely on the application of radio frequency (RF) voltages between each
pair of rods and subsequent superimposition of a direct current (DC) voltage on the rods. At any
given combination of voltages that are applied, only ions of a particular m/z will be able to travel
with a stable trajectory to reach the detector, and thus, by manipulating these voltages, ions can
be separated based upon their unique m/z.
Linear and 3D ion-traps are so-called because they are able to trap ions in space through the
application of oscillating alternating current (AC) and DC electric fields. The trapped ions can
then be ejected from the trap in a m/z-specific manner. Furthermore, linear ion traps are able
to operate both as a mass-selective filter (i.e. like a quadrupole) or as an actual trap. FT-ICR
instruments trap ions using a magnetic field (unlike a linear or 3D ion trap), and then utilise an
electric field orthogonal to the magnetic field to excite the ions. This excitation causes the ions to
rotate at their specific cyclotron frequency, which is directly related to their m, z, and the magnetic
field strength (B). Once excited, the rotating ions induce a charge on the detection electrodes,
which is subsequently detected as an image current; critically this can then be converted by
a Fourier transform to produce a mass spectrum. The operating principle of orbitraps is very
similar; however, they use an electric field to trap the ions, which, when injected into the orbitrap,
begin to oscillate around the central electrode at a frequency directly related to their m/z 138. Much
like FT-ICR instruments, the image current induced by the oscillating ions passing the detection
electrodes is converted by Fourier transform to produce a mass spectrum. Due to their high mass
accuracy (1-2 ppm), high resolution (as high as 480,000 FWHM), amenability to hybridisation with
other MS analysers, high sensitivity (especially given technological advancements in the ion traps
and optics preceding the orbitraps themselves), and relatively high dynamic range, Orbitraps have
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become a staple of proteomics analyses in recent years.
1.5.3 Experimental strategies and sample preparation in proteomics
Correct sample preparation is key to the success of any proteomics experiment. There are three
conceptual methods by which proteomics experiments can be performed and the samples pre-
pared: bottom-up, middle-down, and top-down127,139. The large majority of proteomics exper-
iments to date have employed a bottom-up strategy, whereby the protein mixture of interest is
enzymatically digested using a protease of known specificity to yield a complex peptide mixture
(each peptide usually being approximately 8-25 residues long, depending on the protease used
to create them). The abundance and identity of the analysed peptides are then extrapolated to
make inferences as to the quantitative and qualitative properties of the proteins within the sample.
Numerous methods by which proteins can be enzymatically digested have been developed.
These methods employ several different proteases, each with their own complement of advan-
tages and disadvantages. Despite this, all the aforementioned methods fall into two main groups:
immobilised or in-solution digests. A key consideration of both of these is the way in which inter-
fering substances in popular lysis buffers used for protein analysis can be removed or their action
abrogated prior to digestion.
Immobilised digestions rely on the immobilisation of proteins on a solid support in order to allow
the liquid-phase removal of contaminants and inferring detergents or chaotropes, and increase the
efficiency of digestion. Two classic examples of this are: in-gel digests (where the proteins are
embedded in a polyacrylamide gel) and filter-assisted sample preparation (FASP – where the
proteins are immobilised on a solid filter support)140.
In-solution digestions instead rely on the dilution of interfering chaotropes (e.g. urea or guani-
dine hydrochloride) prior to digestion, so as to abrogate their impact on the enzyme being used.
The disadvantage of these methods is that the enzyme remains in the sample and thus slightly
increases the peptide complexity of the sample. To counteract this, in-solution reactions can be
carried out with an immobilised-bead form of the enzyme of choice, which can be removed by
centrifugation at the end of the reaction141.
Alongside whether the digestion is performed with immobilised or in-solution proteins, another
vital consideration is the proteolytic enzyme being used. By far the most popular enzyme used to
date is trypsin, a pancreatic serine protease which selectively cleaves peptides at the carboxyl (C)
terminus of either arginine (R) or lysine (K) residues142. Despite its clear utility, trypsin is not the
optimum enzyme to use in all experiments; particularly when the post-translational modifications
of interest lie on R/K residues, or when the protein of interest has very few R/K residues (ap-
proximately 10% of the theoretical proteome)143. As a result, other enzymes have been used, for
example: Arg-C, Lys-C, chymotrypsin, pepsin, and Glu-C139,144. Recent data has highlighted that
the results obtained from a proteomics experiment are highly dependent on the protease used145.
Moreover, it has become increasingly appreciated that, due to the complementarity of the informa-
tion gained with the available proteases, a combination is required to reach the required proteome
depth143.
Top-and middle-down proteomics experiments differ from bottom-up strategies in that they in-
volve the analysis of whole proteins or very large peptides respectively. Top-down approaches,
often analysing intact, folded proteins, can be used to obtain 3D structural information and the
binding affinities of the protein of interest with small molecules or other proteins – this being made
particularly accessible in recent years with the mainstream availability of ion-mobility cells and
hydrogen-deuterium exchange (HDX) platforms146–148. Middle-down methods employ an enzy-
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matic digestion step; however, the peptides produced are usually much bigger than those in a
bottom-up strategy (2-20 kDa)144. This can be particularly useful in distinguishing isoform vari-
ants and the study of combinatorial post-translational modifications. Despite their advantages,
the complexity of whole-protein and large peptide fragmentation patterns can be a hindrance in
the analysis of very complex biological samples. Recent developments in whole protein fragmen-
tation and ion excitation methods (e.g. front-end ETD [FETD] and ion-ion proton transfer [IIPT]),
however, have drastically improved the sequencing of proteins in a top-down manner149.
1.5.4 Liquid chromatography
Due to their inherent complexity, protein or peptide mixtures must be separated before they enter
the mass spectrometer for analysis. This is due to the fact that the dynamic range and resolution
of mass spectrometers are limited, and thus distinguishing between both high and low abundance
species and peptides of similar mass in a single spectrum would be extremely difficult, or indeed
impossible. Such separations can be done “on-line” and “off-line”, each with their strengths, limita-
tions, and appropriate uses. A common and powerful separation method is liquid chromatography
(LC), which is amenable to both on-line and off-line use.
Figure 1.11: The overall principles of reversed-phase liquid chromatography (not to scale). The sample (A) is
injected into the sample loop (B). The sample is then loaded onto the column under aqueous conditions (C: t = 0).
Peptides bind to the stationary phase (D [orange] – all peptides will bind under aqueous conditions), and are eluted-off
at different time-points along the gradient of increasing ACN (C), their individual retention times being a function of their
hydrophobicity. As the peptides elute off the column they are directed to the electrospray source (E) and enter the mass
spectrometer (or other detector) for analysis.
Liquid chromatography is the process of separating molecular species according to their dif-
ferential physico-chemical properties in liquid phase. A number of peptide properties can be
exploited for this purpose: e.g. pK A, hydrophobicity (ﬃ), and charge, for example. The most com-
monly exploited peptide property in proteomics – by means of reversed-phase chromatography
– is hydrophobicity. The general principle is that when peptides are loaded onto a column con-
taining a hydrophobic stationary phase under aqueous conditions, they will bind to it with different
affinities according to their overall hydrophobicity. When a linearly increasing gradient of organic
solvent (commonly acetonitrile [ACN/MeCN]) is then passed over the stationary phase, peptides
elute along the gradient as a function of their hydrophobicity; the less hydrophobic peptides eluting
earlier in the gradient, and vice versa (Fig 1.11). Each peptide is then assigned a retention time
(tR) depending on when it elutes from the stationary phase and is detected in the mass spectrom-
eter (or an alternate detector). This chromatographic separation results in a much less complex
mixture of peptides entering the mass spectrometer at any given time, and thus increases the
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sensitivity, dynamic range, and therefore the amount of information that can be determined from
the sample.
Alongside the on-line approaches outlined above, a number of orthogonal, off-line pre-fractionation/
separation methods have been used to reduce sample complexity prior to on-line LC-MS analy-
sis. Such methods include 1D or 2D chromatographic or electrophoretic separations, or the use
of affinity purification (e.g. metal oxide or antibody) to enrich the sample for proteins/peptides
of particular interest. Recent studies have shown that extensive pre-fractionation of particular
proteomes with 2D chromatographic methods (commonly strong cation exchange [SCX] and hy-
drophilic interaction chromatography [HILIC]) can drastically improve the depth of analysis150.
This, however, comes at the cost of greatly increased sample preparation and MS analysis time,
and a substantial increase in the complexity of downstream data analysis. Moreover, a certain
amount of sample loss is inherent in such a lengthy method, thus increasing the amount of starting
material required.
1.5.5 MS analysis – qualitative proteomics
The power of MS when applied to proteomics is its ability to be used for both targeted and un-
targeted global analyses. Targeted analysis of proteins and peptides permits their now routine
identification; however, current state-of-the-art technology allows for the identification of tens of
thousands of peptides and thousands of the corresponding proteins in a comparatively small
time-frame, in a unbiased manner. As briefly mentioned in Section 1.5.2, this is mainly due to
the introduction of tandem mass spectrometry (MS/MS or MS2), whereby the mass analysis of
different populations of ions is separated. The mass analysis of the ions can be either separated
in space (i.e. the mass analysers are physically distinct, although connected) or in time (the ions
are measured, separated, and then measured again in the same analyser at t + x)151. Fig 1.12
provides an overview of the principle of tandem MS in space.
Figure 1.12: The principles of tandem MS. Peptides eluting from the LC system at a particular retention time (x) are
introduced to the mass spectrometer and their m/z values are measured in the first mass analyser (MS1). A particular
precursor ion (either targeted or non-targeted) is selected and fragmented to yield its constituent fragment ions (a mixture
of different sequences that make-up the original peptide). The m/z values of these fragment ions are then measured in
the second mass analyser (MS2), and using these data, the sequence of the precursor peptide ion can be determined;
either through comparison to peptide databases or de novo from manual interpretation of the spectrum.
Fragmentation of ions between MS scans revolutionised the study of proteins, peptides, and
their post-translational modifications. Two main varieties of ion fragmentation exist: in-source and
post-source. In-source fragmentation describes the process by which ions are given sufficient
internal vibrational energy during ionisation to fragment as they enter the mass spectrometer. In
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proteomics experiments, however, in-source fragmentation is rarely applied, and post-source frag-
mentation is the most commonly used. Post-source fragmentation involves the addition of energy
to the ions after the ionisation/first mass analysis step. Several methods have been employed
to transfer the energy required: transfer of electrons from a donor molecule (electron transfer
dissociation [ETD] or electron capture dissociation [ECD]), exposure to electromagnetic radia-
tion (photodissociation), and collision with a non-reactive gas or other molecule (collision-induced
dissociation [CID] or higher-energy collision dissociation [HCD]). Each of the methods has its
advantages and disadvantages, and the appropriateness of their use is dependent on the type
of ions being fragmented (size, charge, modifications, etc.) and the instrumentation available.
Moreover, the methods often provide complementary information, especially with regards to the
analysis of post-translational modifications and can therefore be used in tandem or hybridised to
maximise the information output (e.g. EThcD and decision-tree fragmentation methods). These
methods are discussed with respects to phosphopeptide analysis in Section 1.6.3.
Collision-induced dissociation has been the most popular method for use in peptide sequenc-
ing in the last decade, and involves the excitation of selected ions by collision with a neutral gas
(usually He, N, or Ar)152,153. As the selected ions collide with the gas, the energy of the colli-
sion is internalised, and the precursor ions begin to vibrate at a higher frequency and fragment
(Fig 1.13A). The covalent bonds that break first are those that possess the lowest enthalpies,
and at the collision energies often used in proteomics experiments (30-35 eV), these are the
amide bonds that form the peptide backbone. Thus, in CID experiments, depending on where
the positive charge remains (either on the carboxyl or amino group), two types of daughter ions
(predominantly) form: b- and y -ions (Fig 1.13)154. HCD is very similar to ordinary CID; however,
it employs a higher voltage to trap fragment ions within the C-trap and thus allow their mass anal-
ysis within an orbitrap. This results in an increase in the accuracy, mass range and resolution of
the measurement of these ions. Moreover, this allows the measurement of low-mass ions which
is not possible in an ordinary ion trap-CID experiment155.
MS2 spectra obtained from the fragmentation methods discussed above can be utilised for the
sequencing of peptides without prior knowledge of their sequences – so-called de novo sequenc-
ing. This is performed (often manually) by calculating the difference in m/z between sequential
peaks of the same ion type in the spectrum (usually b- or y -ion series), as by definition, the m/z
between two peaks in an ion series represent the loss of a single amino acid from the peptide se-
quence. Some fragmentation methods have biases towards creating more b- than y -ions and vice
versa; however, as the two ion series run anti-parallel to each other along the peptide backbone
(b running from N ! C terminus, and y from C ! N), spectra possessing both series give greater
confidence in the determined sequence of the peptide152–154,156. A number of other ion types are
also produced as peptide ions are fragmented (e.g a- and x-ions corresponding to fragmentation
of the C-C bond prior to the amide bond); however, b- and y -ions are the most predominant in
scans acquired using CID-based methods.
Although arguably the most accurate way of determining a peptide’s sequence from MS2 data,
de novo sequencing is very time-consuming and thus not suitable for large-scale, global pro-
teomics experiments, although efforts to automate this process have been initially successful (e.g.
PEAKS software)157. As an alternative, MS2 spectra can be processed and condensed compu-
tationally to yield raw peak lists, which can then be searched against a protein/peptide database
of known sequences and predicted tryptic (or other protease) sequences calculated from in silico
digests158. Amongst other similar methods, this can be achieved by first matching the parent ion’s
m/z from the MS1 data to peptides within the database that could share that m/z – usually at a
high accuracy (e.g. 10 ppm). As current instruments do not possess the mass accuracy re-
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Figure 1.13: The principles of collision-induced dissociation. (A) A simplified equation demonstrating the process of
collision-induced dissociation of peptide precursor ions. M = neutral gas molecule; IJ+ = positively charged precursor ion;
I = neutral fragment ion; J+ = charged fragment ion. (B) Skeletal structures demonstrating the formation and differences
between b- and y -ions. If the positive charge remains on the nitrogen it is noted as a y -ion, if it remains on the double-
bonded oxygen it is noted as a b-ion. The two ion types produce ion series (multiple ions representing the incremental
losses of a single amino acid) that are anti-parallel to one another.
quired to unambiguously assign peptide IDs from their parent ion m/z, peptides sharing the same
m/z value are then scored according to how well the MS2 spectrum peaks match those that would
theoretically be produced from each of the potential peptide sequences159. Many different soft-
ware packages are now available that have this capability, each with their unique way of scoring
peptides; however, the most popular are arguably Mascot, Sequest, X!Tandem, and Andromeda.
Mascot generates probabilistic scores based on the probability that the peptide match given by
the algorithm occurred by chance. The final score is expressed as the  10  log10(P ) where P
is the probability score previously mentioned159. The main advantage of this database-searching
method is the speed at which large MS datasets can be searched and peptide identifications
made. However, due to the size of the search-space (the vast number of possible sequences and
post-translational modifications) and the size of the datasets, the number of type I errors (false
positives) can be substantial. Due to the flexibility of the scoring algorithms used, the user is able
to set which m/z and significance scoring thresholds they are willing to accept; however, this can
still sometimes result in a large number of false positives. To further reduce this, many software
packages now include the ability to generate a false-discovery rate (FDR), with the aim of reducing
the rate of type I errors and increasing the confidence in the qualitative data160,161. This process
usually involves searching the data against a scrambled or reversed protein/peptide database to
estimate the number of hits that are false positives. Other methods also take into account other
parameters; the accuracy with which the precursor mass was identified, for example. The overall
database of identified peptides can then be reduced to include a FDR below a certain percentage
– this usually being set to between 1 and 5%.
Independent of the fragmentation and computational identification methods used, there are
two main methods by which MS2 scans are triggered: data-dependent acquisition (DDA) and
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data-independent acquisition (DIA). DDA involves the process outlined in Fig 1.12, whereby pre-
cursor ions are scanned in MS1, and then based on particular criteria, a distinct population of
these ions is selected and fragmented successively in a semi-random manner. This cycle is then
repeated for the length of the MS run. For example, the top 10 most intense parent ions from
the MS1 scan (at tR = x) may be selected for fragmentation and potentially identified; however,
the remaining precursor ions are ignored by definition (often the least abundant ones), leading to
the issue of under-sampling. Several factors influence the rate of under-sampling in a DDA-MS
run: instrument sensitivity, precursor ion intensity and isolation, and the instrument duty cycle
(how quickly it can complete a full MS1 and subsequent MS2 scans)162. Although it remains a
pertinent issue with DDA methods, the problem of under-sampling is constantly being reduced
with advancements in instrument technology, which are consistently improving the duty cycles
and sensitivity of current mass spectrometers.
DIA methods, developed to circumvent the impact of under-sampling on MS experiments, in-
volve the fragmentation and mass measurement at the MS2 level of all the parent ions present in
the MS1 scan. Thus, unlike DDA, the collected MS2 spectra represent a composite of all the pre-
cursor ions that were fragmented within a particular mass window. Theoretically then, sequence
information is obtained for all the parent ions present in a sample and thus a digital representation
of all the proteins present in the sample is produced. Two methods that have been particularly suc-
cessful in the pursuit of DIA are MSE and SWATH. MSE utilises a Q-TOF instrument to fragment
all the precursor ions present in an initial MS1 scan, while cycling between low and high collision
energies163. Based on a similar principle, SWATH, involves the cycling of the instrument through
multiple m/z windows over the entire chromatographic run time and fragmentation of everything
within those windows at each particular tR 164. Therefore, similar to MSE , every ion in the sample
is subjected to fragmentation and thus the resulting digital file theoretically contains a record of
every peptide in the sample. The peptides within the sample are then identified through reference
to peptide spectral libraries produced via DDA methods – these ever increasing in size and public
availability. These methods present multiple advantages, the most prominent of which being the
depth with which the proteome can be analysed (as everything is fragmented). Furthermore, as
the bias inherent in DDA methods is removed, there are much fewer missing data-points where
peptides were not identified165. Lastly, these methods allow retrospective analysis of the data,
allowing datasets to be interrogated in the context of new biological information as it becomes
available. Alongside these benefits, there are distinct limitations to these methods. Firstly, the
volume of data produced is orders of magnitude larger than that produced via DDA methods, and
therefore data storage is limited by technological and monetary capabilities. Secondly, the data-
mining and peptide identification algorithms rely on spectral libraries produced from DDA data,
and therefore, although these are now sizeable and easily available, they do not yet represent the
entire human proteome. Lastly, due to its unselective nature, the MS2 spectra produced through
these methods are often convoluted, especially with the wide isolation windows required to sam-
ple the entire proteome in a reasonable chromatographic time-frame. As a result, the confident
identification of peptides from such spectra is a computationally demanding challenge. Despite
these, numerous technological advances in recent years have continuously improved DIA meth-
ods and increased their availability to the proteomics community, particularly with regards to cloud
computing and open-source softwares166–168
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1.5.6 MS analysis – quantitative proteomics
Qualitative proteomic analysis is of profuse value to biological research; however, the ability of
mass spectrometers to collect quantitative data is that of most worth to proteomics experiments
and our understanding of biochemical processes. The methods and technologies that have been
developed for quantitative analysis of proteins by mass spectrometry are grouped into classes:
label-mediated and label-free, both discussed in more detail in the subsequent sections.
1.5.6.1 Labelling methods
Labelling approaches often involve the attachment of tags of known, differential masses to the
proteins of interest. The protein samples to be compared are then mixed – at different stages of
the workflow depending on the method being used – and analysed by LC-MS/MS. This process is
summarised in Fig 1.14. The samples can then be distinguished on the basis of their differential
masses; the differences being attributable to the known masses of the tags.
One of the first labelling methods to be developed, isotope-coded affinity tagging (ICAT), in-
volves the post-harvesting labelling of proteins with either a “light” or “heavy” version of the tag.
The tag consists of a reactive group (which reacts with a specific amino acid), an isotope-coded
linker region, and a biotin affinity tag (Fig 1.14A). The protein extract of interest is incubated with a
tag, digested with a protease, affinity purified to extract only the labelled proteins, and the resulting
samples analysed by LC-MS/MS169. The difference in mass between the two “heavy” and “light”
tagged samples is then resolved at the MS1 level. Several other post-harvest labelling methods
have also been developed: isobaric tags for relative and absolute quantification (iTRAQ)170, tan-
dem mass tags (TMT)171, and dimethyl labelling172. Unlike ICAT, these methods involve labelling
at the peptide level, post-digestion. Identical to ICAT, dimethyl labelling involves the quantifica-
tion of peptide abundances at the MS1 level, based on a known mass difference between heavy,
medium and light peptides. iTRAQ and TMT, however, involve quantification at the MS2 level. The
latter relies on the production of characteristic reporter ions (of known mass) that are released
from the peptides as they undergo fragmentation. The relative abundances of these reporter
ions can then be used to compare the quantitative differences of the fragmented peptide between
samples.
Despite their popularity and success, the aforementioned labelling methods have several limi-
tations. Firstly, the efficiency of labelling can vary in a manner that is dependent upon the labelling
conditions, protein/peptide abundance, and label manufacturer; all of which introduce significant
variability in the quantitative measurements made173. Secondly, recent studies have suggested
that the addition of tags to peptides increases the number of protons they accrue in the electro-
spray process, thus reducing their fragmentation efficiency and therefore the number of useful
sequence ions produced174. Thirdly, peptides have to be identified to allow their quantification,
thus significantly reducing the depth of analysis due to under-sampling. Lastly, and perhaps most
pertinently, co-isolation of precursor ions selected for fragmentation has been shown to influence
the quantitative accuracy and precision of MS2-level based methods (as two ions of similar mass
are fragmented, contaminating both the qualitative sequence information and the ratios of re-
porter ions)175. This has been improved with additional fragmentation steps (i.e. MS3) to confirm
the identity of the precursor ion; however, this adds time to already relatively lengthy analysis
times176. Several distinct advantages of these latter methods exist, however, such as: their an-
alytical simplicity, availability, and because they do not rely on MS1 data, the instrument can run
with a high top N spacing (the number of ions chosen to be fragmented between MS1 scans)
therefore reducing the impact of under-sampling.
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Figure 1.14: An overview of the labelling methods used for quantitative proteomics. (A) Samples are prepared
independently and are labelled either at the protein (e.g. ICAT and dimethyl labelling) or peptide level (e.g. TMT and
iTRAQ). The samples are then mixed, processed and run on the mass spectrometer. The relative differences in protein
abundance between the samples being compared is then inferred at the MS1 (e.g. ICAT) or MS2 levels (e.g. iTRAQ and
TMT). The latter relies on the dissociation of reporter ions from the isobaric tags following MS/MS fragmentation (shown
with dashed lines with respects to TMT and iTRAQ labels). (B) Heavy and light isotopes of arginine and lysine are added
to the growth media of the biological system of interest (SILAC and Neucode). As a result, proteins are labelled during
synthesis, and upon mixing, digestion and LC-MS/MS analysis, the quantitative differences between the conditions can
be inferred at the MS1 level. ICAT = isotope-coded affinity tagging; TMT = tandem mass tagging; iTRAQ = isobaric tags
for relative and absolute quantification; SILAC = stable isotope-labelled amino acids in cell culture; Neucode = neutron-
encoded mass signatures.
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Alongside the labelling of proteins after they have been harvested from the biological system
of interest, an alternative approach is to label the proteins as they are synthesised in vivo. By far
the most popular technique, termed stable isotope-labelled amino acids in cell culture (SILAC),
involves the addition of heavy or light isotopes of lysine and arginine to the culture medium, al-
lowing them to be incorporated into newly synthesised proteins as the cells grow and divide (Fig
1.14B)177. This removes the biases introduced from affinity purification and from labelling re-
action kinetics. Moreover, as the samples are mixed as soon as the lysates are produced, any
downstream variability in sample handling is removed. Despite this, there are numerous disad-
vantages with this technique. Firstly, the incorporation efficiency of each labelled amino acid can
vary substantially. Secondly, some cells are unable to grow in heavy medium due to the dialysed
foetal bovine serum required (as the dialysis of the FBS often removes important growth factors
and other molecules). Thirdly, the technique is not applicable to primary tissue samples, as direct
labelling is impracticable. Lastly, the number of different conditions that can be compared simulta-
neously is very small (typically 2-3), greatly reducing the number of biological questions that are
tractable with this method. Neucode (neutron-encoded mass signatures) have been developed to
overcome this latter limitation, by using super-resolution mass spectrometry (480,000 FWHM) to
allow the resolution of labels that differ in mass over several different isotopic atoms178. Further-
more, several of the aforementioned limitations of SILAC have been improved through the use
of so-called “Super”-SILAC, whereby SILAC-labelled cell-lines were utilised to generate tissue-
specific proteomes that can be used as references for comparisons with other tissues/model
systems179. Moreover, to counter the in vivo/whole-organism limitations of the method, a SILAC
mouse was also developed by labelling mice over several generations to incorporate the amino
acid labels180.
Taken together, the different labelling methods discussed above, provide useful methods by
which proteomes and sub-proteomes of different biological systems can be compared. The major
limitations, however, are the lack of multiplexing afforded – although this is being improved with
developments in the physicochemical properties of the labels being used – paired with the inability
to apply the methods to clinical/in vivo samples, thus drastically limiting the applicability of the
method to many biological questions.
1.5.6.2 Label-free methods
In contrast to labelling methods and to counter the limitations associated with them, a number of
label-free methodologies have been developed for use in quantitative proteomics. As the name
suggests, these methods rely not on the chemical labelling of proteins and peptides, but rather
computational/analytical methods to make quantitative comparisons between sample proteomes
(summarised in Fig 1.15A). The first of such methods, spectral counting, involves the use of the
number of MS2 scans a peptide triggers to infer its relative abundance in the sample; i.e. the more
scans triggered, the more abundant the peptide. This method is particularly useful due its sim-
plicity; however, the accuracy of the quantitative output is particularly susceptible to several con-
founding factors which have lead to the method often being described as semi-quantitative181,182.
The most pertinent of these is the variability observed in peptide detection probabilities; this being
dependent upon the physicochemical properties of the peptide in question. Moreover, it relies on
the phenomenon of under-sampling as, by definition, it correlates the MS2 selection bias with pep-
tide abundance. Several methods to improve spectral counting data have been proposed and one
such method, the Absolute Protein EXpression (APEX) algorithm, was designed to incorporate
these confounding factors into the analysis by correcting the count data for variations in peptide
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detection probability (which can be predicted from in silico digests)183.
In contrast to spectral counting, a number of label-free methods utilise extracted ion chro-
matograms (XICs) and the respective height/area of the peaks generated to infer protein/peptide
abundance. XICs are constructed by monitoring the abundance of a particular ion and often its
isotopes – selected either computationally or physically in the mass spectrometer – over multiple
scans, as a function of retention time (Fig 1.15B). Selective reaction monitoring (SRM) or multi-
ple reaction monitoring (MRM) is a targeted label-free method where specific precursor ions of
known mass are selected, fragmented and the abundance of their specific fragment ions moni-
tored184,185. This method, usually performed in triple quadrupoles (QqQ), is very specific (given
that the fragment ions/transitions are known) and very sensitive. Due to its specificity, the method
affords short run-times and therefore relatively high throughput. As a result of this however, only
a selection of analytes can be quantified in each run, although this has been improved through
the use of scheduled SRMs. Scheduling allows the more efficient multiplexing of SRMs, as the
instrument is set to only scan for a particular mass and/or fragment(s) at that analyte’s known
retention time. This drastically increases the overall number of analytes that can be measured in
a single run. In a similar vein, parallel reaction monitoring (PRM) allows the monitoring of mul-
tiple transitions simultaneously, as the third quadrupole is substituted for a high-resolution mass
analyser (e.g. an orbitrap)186.
Figure 1.15: An overview of the label-free methods used for quantitative proteomics. In label-free methodologies,
samples are lysed, processed and run on the mass spectrometer independently. After having identified the peptides by
means of MS2 data, the peptide can be quantified at the MS2 level (e.g. spectral counting, where the number of times
a peptide is fragmented is used to infer its relative abundance) (A) or at the MS1 level (e.g. XIC targeted quantification,
whereby the targeted peptide’s abundance is inferred from its elution peak height or area (B). Blue, first isotope [all 12C];
red, second isotope [1 x 13C]; green, third isotope [2 x 13C]). The latter method is advantageous as, by using the accurate
m/z and tR data, peptide XICs can be constructed and quantified even in samples where the peptide was not subjected
to fragmentation and identified.
Another label-free method, PESCAL (PEak Statistic CALculator) – developed in the Cutil-
las lab and similar to the accurate mass tag (AMT) approach described by the Smith lab187 –
also constructs MS1 XICs to quantify peptides/proteins, but in a more high-content manner. To
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achieve this, a central database of peptides is constructed from the MS2 data gathered from the
experiment in question (or other experiments run on the same instrumentation). To account for
chromatographic variations, the retention times of peptides common to each sample (or peptides
from an internal standard protein) are calculated. These retention times are then used to form a
linear model between each sample (Fig 1.16A). The quantification of peptides then requires sev-
eral computational steps. First, the peptide to be quantified is located within the database and its
m/z ( 5-7 ppm), charge state (z), tR ( 1-2 min), and sample within which it was identified (e.g.
samplex ) are stored. PESCAL then creates XICs at that specific m/z and tR in the sample(s) in
which the peptide is to be quantified (e.g. sampley – Fig 1.16B). In order to account for chromato-
graphic variability, the tR window at which it creates the XIC is sample-specific. These predicted
tR values are computed through interpolation of the linear models formed between the peptide
standards in each sample (Fig 1.16A). In this manner, a peptide can be quantified in a sample
in which it may not have been selected for MS2 and identified (as a result of under-sampling).
To increase the specificity of this peak-picking, the ratios of the second and third isotopes are
correlated with the theoretical distributions for the peptide being quantified. Moreover, in order
to improve the accuracy of the quantification, only peaks with a minimum number of data-points
are accepted (to ensure accurate peak shapes). Following the picking of the peak of interest and
assuming it adheres to the necessary criteria, the height or area of the peak is calculated and
taken for further analysis188.
Figure 1.16: An overview of the PESCAL method of label-free quantification. (A) The retention times of known
peptide standards (either endo- or exogenous) are aligned for each sample combination. A linear model is formed between
the enolase standard retention times in the sample in which the peptide was identified (samplex ) and the sample within
which the peptide is being quantified (sampley ). This model is then used to predict the retention time of a peptide identified
in samplex in the sample being quantified (in this case sampley ) – red arrows. (B) XICs are constructed from the MS1
data for the first (blue), second (red), and third (green) isotope of each peptide in the central database formed from all the
samples in the experiment (or others), within user-defined m/z and tR windows.
The main advantage of this approach is its high-content nature and its ability to compare a
theoretically unlimited number of samples, without needing to identify the peptide in every sam-
ple. In this regard, it helps to overcome the issue of under-sampling in DDA methods, increases
the scope of the biological questions that are tractable with the method, and is easily applied to
clinical/in vivo samples. Alongside these however, are several disadvantages. Firstly, the speci-
ficity of the peak-picking. As the peptide may not have been identified in the sample in which it is
being quantified, there is a certain margin of error in the assignment of an MS1 peak to a partic-
ular peptide. The increased availability of very high mass-accuracy instruments (sub-ppm), more
robust liquid chromatography, and the added layer of isotope distribution correlation has rendered
this less of an issue than it once was however. Moreover, the increased availability of ion mobility
cells provides the potential to add a fourth dimension of specificity (i.e. ion drift time). Secondly,
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as with all label-free methods, each of the samples must be prepared independently, therefore
increasing the length of the preparative work-flow and introducing potential sources of variation.
This is compensated for by the ability to compare as many conditions as the experiment requires
however, and in the same vein, many biological and technical replicates can be included in the
experimental design to account for this. Despite this, many studies published from this and other
groups have demonstrated the accuracy and reproducibility of the method27,97,98,125,188–193, one
study reporting an average CV of 34% and error of 6%194, and work from the Cutillas lab demon-
strating an average CV of 22%141. A number of other softwares from several labs, utilising similar
principles, have recently been developed and made freely available (e.g. MaxLFQ and Skyline
from the Mann and MacCoss labs respectively)195,196.
1.5.6.3 Absolute quantification in proteomics
Regardless of the methodology employed, the large majority of proteomics experiments per-
formed only require relative quantification of peptides and proteins in order to draw biologically
relevant information from the data. In contrast to this, however, techniques exist for the absolute
quantification of peptides and proteins. These are of distinct interest to several fields of study;
particularly with regards to diagnostic and forensic applications. Several absolute quantification
methods have been developed, involving both labelled and label-free strategies, and these have
been applied to numerous biological systems.
Label-free methods for absolute quantification include: APEX (absolute protein expression
profiling), TOP3, iBAQ (intensity-based absolute quantification), and the “proteomic ruler” method.
APEX, as previously mentioned is based on spectral counting coupled to a probabilistic model of
peptide observation frequencies. Contrary to this, the TOP3 method utilises the mean or sum
of the MS1 intensities of the three most intense peptide ions corresponding to a protein. Similar
to the TOP3 method, iBAQ also utilises the intensities of the observed peptides; however, this
method instead uses every observed peptide and normalises this to the total number of theoreti-
cally observable tryptic peptides for a particular protein. Each of these methods has been applied
successfully in multiple studies, and their utility has been reviewed extensively126,197–199. A more
recent method, termed the “proteome ruler”, is based on the concept that the MS-signal of his-
tone proteins is proportional to the amount of DNA and therefore the number of cells present in
the sample. As a result, the absolute amount of a particular protein can be estimated from the
relationship between its MS signal and the MS signal of the histone proteins200.
Labelled strategies for absolute quantification are generally more complex, and include: ab-
solute quantification (AQUA), protein standard absolute quantification (PSAQ), quantification con-
catemer (QconCAT), and protein epitope signature tags (PrEST), amongst others. Stable isotope-
based methods have been the staple for the absolute quantification of a range of analytes for
many years. In the context of proteomics, this involves the addition/chemical synthesis of a stable
isotope-labelled version of the peptide/protein (e.g. an AQUA peptide or full-length PSAQ pro-
tein) of interest directly to the sample, and subsequent comparison of its abundance to that of the
endogenous analyte201,202. As the absolute amount of synthetic peptide/protein that is added is
known, the ratio of the synthetic and endogenous signals can be used to calculate the absolute
amount of the analyte. Although highly accurate and conceptually simple when applied to a single
protein, this method is less scalable than label-free methods, primarily due to the cost and vali-
dation of the synthetic peptide required. Despite this, some studies have used this method – or
variations thereof – to construct a standard curve of protein abundances (e.g. using 19 proteins
spanning 2 orders of magnitude) which can then be used to interpolate the absolute abundances
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of the remaining proteome203. The QconCAT method circumvents a number of the issues present
when using stable isotope-labelled standards, allowing more economical, multiplexed analysis. To
achieve this, a synthetic protein is designed to contain concatenated proteotypic peptides (with
predicited high ionisation efficiencies) corresponding to all the proteins of interest. This protein
is then expressed in a vector system and labelled with stable isotopes. The protein can then be
spiked into the test sample at a known amount and, when digested, yields heavy-labelled internal
standard peptides that can then to be used for absolute quantification of the test proteins204,205.
More recently, the PrEST approach, an extension of absolute SILAC methods, has also been
applied to the multiplexed absolute quantification of proteins. This approach relies on the library
of peptides selected and produced by the Human Protein Atlas Project, which represent approx-
imately 100 amino acid-long sections of nearly 18,300 human genes206. These peptides are
purified via their His tags, absolute amounts determined by SILAC, and are then spiked into test
samples where they can be used to quantify the proteins they represent207.
Absolute quantification of proteins possesses a clear role in proteomics, particularly with re-
gards to clinical applications/diagnostics. Despite this, relative quantification methods, as previ-
ously discussed, are adequate for the large majority of biological experiments, particularly with
respects to discovery experiments where large numbers of proteins are required to be compared
quantitatively, and where time and cost are key considerations.
1.6 Sub-proteomics: the phosphoproteome
Numerous studies have now demonstrated that the expression of individual genes at the mRNA
level correlates poorly with the expression of the proteins they encode208–211. On a similar train
of logic, it has become increasingly apparent that the abundance of particular enzymes, in most
cases, does not correlate with their actual activities212. In contrast, knowledge of their spatial
distribution, post-translational regulation, and the abundance of the products of the reactions they
govern are now appreciated as a more representative readout of their catalytic activity. As a
result, the study of sub-proteomes – either in terms of sub-cellular distributions or specific popu-
lations of post-translationally modified (PTM) proteins – has become a popular area of research,
particularly with the increasing accessibility of the MS technologies that are able to define these.
Such studies often involve the specific enrichment of proteins possessing the PTM of interest (e.g.
phosphorylation, acetylation, or glycosylation), isolation of a particular class of protein (e.g. ki-
nases or histones), or purification of specific cellular organelles/compartments (e.g. mitochondria
or Golgi apparatus).
Due to the long-known importance of protein phosphorylation in cellular signalling, its rela-
tively simple and amenable chemistry, its relative abundance, and the development of ever more
powerful MS and LC technologies, phosphoproteomics (the study of the entire complement of
phosphorylated proteins in a biological system) has been perhaps the most studied sub-proteome
in recent years.
1.6.1 The function of phosphorylation events
The human genome encodes for 516 distinct kinases (representing approximately 2% of total hu-
man genes), and approximately 160 of these have been implicated in disease213. Whilst other
phosphorylated residues exist in nature (e.g. phospho-histidine and -arginine in prokaryotes),
human kinases preferentially phosphorylate serine and threonine residues, tyrosine residues, or
possess dual-specificity. The impact of phosphorylation on protein function is diverse in nature;
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however, the main regulatory roles that have been demonstrated experimentally include: facilita-
tion of protein-protein interactions, mediation of protein degradation and/or trafficking, regulation
of protein thermodynamic stability, and control of enzyme activity. Often these functional conse-
quences of phosphorylation events are intertwined. For example, dual-phosphorylation of Akt at
Thr308 and Ser473 results in a substantial conformational change – presumably due to the ther-
modynamic considerations regarding the addition of two hydrophilic phosphates – which leads
to the full activation of the enzyme214. Similarly, as previously discussed in Section 1.1.4, auto-
phosphorylation of RTKs forms specific binding sites that recruit multiple signalling proteins (e.g.
PI3K). Therefore, as a consequence of their chemistry, phosphorylation events play a key role in
the propagation, amplification, and correct interpretation of signals from both intra- and extracel-
lular sources and these are pivotal to the correct functioning of cellular and organismal systems.
On the contrary, however, some argue that not all phosphorylation sites (especially those that
are not evolutionarily conserved) may have no function at all215–217. Much like the paradigm of
“junk” DNA following the initial sequencing of the human genome however, it is more probable
that this is a result of an absence of evidence as opposed to a true evidence of absence.
Figure 1.17: Phosphorylation sites are governed by kinase-phosphatase pairs. The kinase, utilising available ATP,
catalyses the phosphorylation of the substrate protein (at a rate of kphos). The phosphatase catalyses the removal of the
phosphate group from the protein (at a rate of k–phos).
The occupancy of individual phosphorylation sites is governed by the kinases and phos-
phatases that phosphorylate and dephosphorylate them, respectively (Fig 1.17). The rate at
which the kinases and phosphatases catalyse their reactions, and therefore the overall equilib-
rium between protein and phosphorylated protein, is determined by numerous external processes,
including: epigenetic and genetic regulation, protein-protein interactions, activating mutations on
the kinase, and miRNA, amongst others. Furthermore, numerous kinases and phosphatases may
act on the same substrate protein, complicating this determination of kphos and k–phos. In these
cases it is thought that the specificity of kinase/phosphatase-substrate relationships (i.e. which
kinase is phosphorylating the substrate), can be stimulus-, cell-, and context-dependent. For ex-
ample, endoplasmic reticulum stress has been shown to alter the way in which Akt is regulated
(i.e. the ratio between Thr308 and Ser473) and its substrate specificity, in a severity-dependent
manner218. Similarly, other data suggest that Akt substrate specificity is also altered as a result
of its compartmentalisation to the endosome by Appl1 upon growth-factor stimulation219. As the
interaction between the kinases and phosphatases that regulate protein phosphorylation are so
complex, it may be posited that the most accurate readout of their combined functions is through
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the measurement of the abundance/concentration of the phosphorylated substrate. Although
phosphophorylated proteins can be detected by means of immunochemical methods, mass spec-
trometry has been instrumental in the unbiased and global analysis of phosphorylation events,
as tens of thousands of phosphorylation sites can be fully quantatitatively monitored in a single
experiment. There are, however, several key factors that must be considered in order to achieve
this.
1.6.2 Enrichment of phosphorylated proteins/peptides
Despite the fact that the large majority of proteins possess phosphorylation sites, the substoichio-
metric nature of most leaves them outside of the dynamic range of mass spectrometers when
measuring the total proteome. Instead, in order to reliably detect phosphorylation sites, they must
be selectively enriched from the total population of proteins representing a particular biological
system. A variety of methods have been developed for this purpose, including chromatographic
and chemical derivation strategies; however, the most popular and arguably the most efficacious
methods that have emerged are those involving either inorganic or immunological affinity purifica-
tion, and these are discussed in further detail in the following sections. Another key consideration
with regards to phosphorylation sites is their biological and chemical stability in solution. Phos-
phate groups possess a relatively long half-life in solutions within acidic or slightly basic solutions
(pH 1-11); however, at high temperature and high [OH ], (e.g. pH > 12) they can be removed
from the protein of interest via -elimination220. Furthermore, phosphate groups are very suscep-
tible to enzymatic removal due to the robustness of phosphatases in chaotropic/lysis conditions
and the high rate at which they function (approximately 10-100 times faster than that of kinases).
As a result, samples being processed for phosphoproteomics experiments must be kept at a low
temperature (< 4 oC), in relatively acidic/neutral conditions, and in the presence of several phos-
phatase inhibitors prior to enzymatic digestion.
1.6.2.1 Chemical derivatisation
One of the earliest methods utilised to identify phosphopeptides was by means of chemical
derivatisation. Perhaps the most commonly used technique involves the removal and substitu-
tion of the phosphate group(s) via -elimination and Michael addition, respectively. -elimination
is achieved through the addition of a high concentration of NaOH (to provide [OH ] ions) and in
some cases barium salts (e.g. Ba(NO3)2) or Ba(OH)2 221,222. Michael addition is then performed
through incubation of the sample with a dithiolated reducing agent (e.g. dithiothreitol [DTT] or
ethanedithiol [EDT]) in order to modify the exposed double-bond and to allow selective isolation
of these from the biological matrix of interest221,222.
Despite its inherent specificity towards phosphorylated peptides, this enrichment strategy
presents several key disadvantages. Firstly, due to the large number of reactions (and their in-
trinsic inefficiency), substantial sample-loss is observed and significant variability is introduced.
Moreover, due to the inefficiency of the reaction steps, a number of side-reactions often produce
unwanted peptide modifications, although this is reduced through the addition of EDTA221. Sec-
ondly, the biotin-avidin interaction exploited for the affinity purification is very strong, rendering
it difficult to remove the phosphopeptides once they have bound. Thirdly, the common addition
of a maleimide group for the selective isolation is unstable under common MS2 conditions, thus
increasing the complexity of the resulting spectra. Finally, many of the reactions possess a pref-
erentially higher rate for phospho-serines over phospho-threonines, and thus are biased towards
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the analysis of the former. Despite these issues, such derivation methods have been successfully
applied to analyses of both phosphopeptides and phosphoproteins221–223.
1.6.2.2 On-line liquid chromatographic methods
Alongside the susceptibility of phosphate groups to hydrolysis, further physico-chemical proper-
ties can be exploited for their enrichment. For example, liquid chromatographic separations can
exploit the pK A, charge and/or hydrophobicity of phosphopeptides, depending on the sorbent
used. To this end, several stationary phases have been used to selectively enrich for phos-
phopeptides, including strong cation exchange (SCX)/strong anion exchange (SAX), high-pH
reversed-phase (HpH), electrostatic repulsion-hydrophilic interaction chromatography (ERLIC),
and hydrophilic interaction chromatography (HILIC)224–226. SCX and SAX technologies separate
peptides (or other analytes) based upon their charge. In each case, the more charged the ana-
lyte, the greater the affinity of its association with the sorbent; SCX binding cations with greater
affinity, and SAX binding anions. Therefore, as phosphopeptides carry  1 extra negative charge,
such sorbents can be used to preferentially bind phosphopeptides (SAX) or preferentially bind
non-phosphopeptides (SCX)227. In practice however, although broadly successful at enriching for
populations of phosphopeptides, due to the wide-range of charges present on phosphopeptides
(i.e. non-phosphopeptides having the same number of positive/negative charges as phosphopep-
tides), both methods suffer from poor specificity. Recent data suggest that HpH chromatography
may be superior to SCX due to its better fractionation of singly phosphorylated peptides226. Sim-
ilar in principle to both SAX and SCX chromatography, ERLIC and HILIC-based sorbents have
also been used to enrich phosphopeptides. ERLIC and HILIC stationary phases bind peptides in
a fashion that is diametrically opposed to that of reversed-phase sorbents – i.e. it binds them by
means of hydrogen-bonding, thus binding with greater affinity to more hydrophilic/polar analytes.
In addition, ERLIC involves electrostatic repulsion of highly positively charged groups. There-
fore, as phosphopeptides tend towards greater polarity due to the extra negative charge(s) on the
phosphate group, ERLIC/HILIC can be used to preferentially select for phosphopeptides. Much
like SAX/SCX, however, the use of ERLIC/HILIC for phospho-enrichment in isolation suffers from
poor specificity, as other polar peptides (e.g. those with acidic side-groups) are concomitantly
enriched228.
In spite of their previously mentioned lack of specificity, these methods are very effective when
used in conjunction with other enrichment methods (e.g. TiO2) in an orthogonal manner. These
methods, when used off-line in conjunction with an additional enrichment step and traditional on-
line LC methods, are often referred to as two-dimensional LC (2D-LC). This process involves the
separation of the original sample material via an LC method which is orthogonal to that used
for the on-line separation (e.g. SCX/SAX/ERLIC/HILIC and RP, or two stages of RP at different
pH), and subsequent fractionation of the resulting eluents. Such strategies, when coupled to
state-of-the-art MS technologies have been shown to drastically improve the coverage and depth
of analysis of the [phospho-]proteome in many biological systems226,229,230. This is mainly due
to the large reduction in dynamic range with respects to each fraction, thus rendering phospho-
peptide enrichment more effective for low abundance species. On the contrary, however, these
methods also substantially increase analysis time (as many fractions are created from a single
sample), thus reducing the number of samples – and therefore replicates – that can be compared.
Furthermore, they are not amenable to many forms of label-free analysis as accurately tracking
peptides across multiple fractions presents a significant computational challenge. Finally, these
methods also suffer from significant sample loss due to the multiple chromatographic steps, thus
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increasing the amount of starting material that is required for each experiment231.
1.6.2.3 Immunological affinity purification
Much like traditional affinity purification of specific proteins, antibody-based affinity purification can
also be applied to the enrichment of phosphorylated proteins232. In this, antibodies are raised to
recognise and bind to pSer/pThr or pTyr residues. Although an attractive route through which
phosphopeptides can be enriched, these methods are heavily reliant on the quality of the anti-
body used and, although many pSer/pThr antibodies exist, these have been demonstrated to not
be particularly effective due to their lack of specificity. On the contrary, anti-pTyr antibodies have
enjoyed more success, perhaps due to the larger spatial footprint of the pTyr residues increas-
ing antibody specificity and the lower abundance of pTyr residues in the total phosphoproteome
(representing approximately 1.8% of all phosphorylated residues)233. Furthermore, due to the
lack of specificity of other enrichment methods for the retrieval of pTyr residues, those based on
antibodies are the most commonly used and many pTyr-focused studies have employed them
successfully234–236.
1.6.2.4 Inorganic affinity purification
Similar to the aforementioned LC methods for the enrichment of phosphopeptides, the multiple,
pH-dependent negative charges that phosphate groups possess can be utilised in order to se-
lectively enrich them from the total proteome. This can be achieved by exploiting the affinity of
phosphate groups to positively charged inorganic species ligated to solid matrices. The three
most popular schema that have emerged for this class of enrichment technology are: metal ox-
ide affinity chromatography (MOAC), immobilised metal ion affinity chromatography (IMAC), or a
combination of the two.
Figure 1.18: MOAC and IMAC methods for enrichment of phosphopeptides. (A) MOAC: phosphate groups bind to
the TiO2 sorbent via non-covalent interactions. (B) Acidic peptides also bind to TiO2 through similar mechanisms. (C) -
hydroxy acids (AHAs), such as glycolic acid (shown) bind to TiO2 with greater affinity than acidic peptides, but less affinity
than phosphate groups, therefore increasing binding specificity of phosphopeptides by blocking empty binding sites. (D)
IMAC: phosphate groups form complexes with immobilised metal ions. (E) Acidic peptides can also complex with the
metal ions.
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MOAC is based on the interaction between the partially and fully negatively charged oxygen
atoms present within the phosphate groups and group 4 metal oxides (usually TiO2 and ZrO2), as
shown in Fig 1.18A. Despite equal availability of ZrO2, TiO2 has been the medium of choice for
the large majority of experiments involving phospho-enrichment and its utility has been frequently
demonstrated and its efficacy drastically improved since its introduction in 2004237. Once the
phosphate groups are bound to the sorbent, and following any washing steps to improve specificity
of the enrichment, they can be eluted. Initial attempts to elute phosphate groups using phosphoric
and other acids were superseded by the use of basic solutions (e.g. NH4OH), as the latter have
proved more effective238. The elution process involves the flooding of the sorbent with a high
concentration of OH  ions (which possess a higher affinity for the sorbent) in order to displace
the phosphate groups.
Despite its relative success, TiO2-based MOAC suffers from several limitations. Firstly, along-
side its affinity for phosphate groups, other negatively charged moieties (e.g. the acidic amino
acids Glu and Asp) also bind with relatively high affinity (Fig 1.18B). A number of chemical ad-
ditives have been developed to circumvent this; for example, the addition of trifluoroacetic acid
(TFA) has been demonstrated to drastically improve the selectivity for phosphate groups238 as,
by reducing the pH it causes Glu and Asp residues to become protonated. Similarly, the addition
of -hydroxy acids (e.g. dihydrobenzoic acid [DHB], lactic acid, and glycolic acid) has also been
shown to reduce non-specific binding of acid groups, as these bind to the TiO2 with an affinity
between that of acidic and phosphate groups (Fig 1.18C)238–240. Secondly, TiO2 has such a high
affinity of phosphate groups, multiply phosphorylated peptides are often very difficult to elute once
bound, resulting in a bias towards the recovery of singly phosphorylated species; however, sev-
eral studies have shown the effectiveness of multiple elutions from the TiO2 in order to recover
as many phosphopeptides as possible238,239. Finally, non-phosphorylated peptides bind to TiO2
through mechanisms other than the interaction between oxygen atoms and the titanium. For ex-
ample, recent data have demonstrated that peptides bind in HILIC mode, and thus extra washes
are necessary to remove these interfering peptides241.
Similar to MOAC, IMAC employs the use of metals to bind to phosphate groups; however,
unlike MOAC, it is based on the use of complexed metal ions as opposed to their oxides. Common
transition metal ions that are used for this purpose include: Zn2+, Co2+, Al3+, Ga2+, Fe3+, Cu2+,
Ni2+, and more recently Ti4+. When passed across the sorbent the negatively charged phosphate
groups form complexes with the positively charged metal ions, and can then be eluted through
modification of the pH or with a binding competitor. Fe3+ ions have been used most frequently
for phosphopeptide enrichment, as they have been shown to possess high affinity for phosphate
groups (Fig 1.18D)242,243; however, recent data from the Heck lab has demonstrated the superior
efficacy of Ti4+-based IMAC244. Similar to MOAC, IMAC suffers from a lack of specificity due to
the concomitant binding of acidic peptides (Fig 1.18E). Moreover, the transition metal ions used
possess affinity for sulphur and nitrogen-containing moieties (e.g. Cys residues), further reducing
the phospho-specificity. The specificity of IMAC enrichment methods has however been improved
through the optimisation of the loading and washing conditions. For example, it has been shown
that an acidic pH, addition of formic acid, and presence of a high proportion of organic solvent
(e.g. ACN) each act to improve phosphopeptide binding and reduce non-phospho interactions
with the sorbent245,246.
Alongside their use in isolation, both MOAC and IMAC methods have been employed in com-
bination with each other and with other chromatographic technologies in an effort to produce a
comprehensive phospho-enrichment method. Examples of such techniques include SIMAC (se-
quential elution from IMAC) and TiSH (TiO2, SIMAC and HILIC), both developed by the Larsen
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lab247,241. SIMAC involves the sequential elution of phosphopeptides from the IMAC sorbent
with solvents of different pH and subsequent TiO2 enrichment of these fractions in order to gain
greater coverage of the phosphoproteome and to resolve mono- and multiply-phosphorylated pep-
tides. Similarly, TiSH involves the initial enrichment of phosphopeptides using TiO2, followed by
SIMAC, and subsequent HILIC fractionation of the mono-phosphorylated peptides produced from
the SIMAC separation. Both of these methods have been demonstrated to be highly sensitive and
produce excellent coverage of the phosphoproteome; however, the resources and time required
to carry out the sample processing steps reduce the method’s applicability to large-scale studies.
MOAC and IMAC technologies have revolutionised the study of the phosphoproteome by mass
spectrometry; however, the technique of choice with regards to single-shot enrichment of indi-
vidual samples has been demonstrated to be TiO2-based MOAC, due to its simplicity, speed,
specificity and sensitivity. Consequently, the Cutillas lab has developed a TiO2-based enrichment
method for use in single-shot, label-free, quantitative phosphoproteomics experiments141.
1.6.3 MS2 ion activation methods for phosphopeptide ions
Concurrent with the technical challenge of enriching phosphopeptides/proteins from complex bio-
logical matrices, phosphopeptides also present a significant challenge with regards to their MS2-
based fragmentation and therefore identification. This manifests itself in the physicochemical
properties of the phosphopeptides themselves, as they possess a lower positive charge than their
non-phosphorylated counterparts (due to the negative charge(s) on the phosphate) and thus frag-
ment less efficiently when subjected to CID. Furthermore, due to the relatively labile nature of the
phosphoester bond, when subjected to CID, pSer/pThr phosphopeptides often undergo neutral
loss, whereby uncharged phosphoric acid (H3PO4) is lost from the peptide and dehydroalanine
or dehydroaminobutyric acid are produced. The resulting MS2 spectra contain a very intense
peak corresponding to the peptide minus the neutral loss of H3PO4 and comparatively sparse
sequence information, rendering phosphopeptide identification challenging (Fig 1.19). Alongside
the sometimes poor fragmentation of phosphopeptide ions in the gas phase, it is often difficult to
accurately localise the phosphorylation site in the peptide sequence, particularly when multiple
phosphorylation sites are present. As a result of these limitations, numerous ion fragmentation
methods and computational approaches have been developed to improve the sequencing and
accurate site localisation of phosphopeptides by MS.
In order to combat the prevalence of neutral loss in phosphopeptide MS2 spectra, an extension
of CID fragmentation was developed, termed CID-MSA (multi-stage activation). In this pseudo-
MS3 method, the phosphopeptide undergoes normal CID fragmentation; however, the theoretical
m/z values corresponding to a potential neutral loss are automatically fragmented and the result-
ing spectra combined (Fig 1.19). Another fragmentation method, HCD, has also been employed
for the sequencing of phosphopeptide ions in the gas phase, and due to the ions being measured
at higher mass accuracy and resolution in an orbitrap mass analyser, the data provide more ac-
curate sequence and site localisation information than normal CID. On the contrary, however, due
to the slower speed of HCD fragmentation in most instruments, CID still provides richer datasets
with regards to LTQ-Orbitrap instruments248. Alongside the traditional CID-based fragmentation
methods, ETD has also been used for phosphopeptide identification. ETD works on the principle
of the transfer of electrons from a donor molecule (often fluoranthene) to the substrate peptide
in the gas phase, therefore resulting in its dissociation. ETD presents with the advantage that
it provides comprehensive sequence information alongside the preservation of post-translational
modifications and has been used successfully in multiple proteomics studies. It is, however, most
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Figure 1.19: MS2 fragmentation methods for phosphopeptide ions. Following data-dependent selection of a phos-
phopeptide precursor ion, a number of fragmentation methods can be used to confirm its sequence. CID-MSA (left) allows
the activation of a an unfragmented phosphopeptide ion in a pseudo-MS3 reaction, following neutral loss of H3PO4. These
reactions primarily produce b- and y -ions. HCD (middle-left) produces data of higher mass accuracy and higher resolu-
tion compared to CID-MSA, as the precursor ion is fragmented in a separate octopole and measured in the orbitrap mass
analyser, predominantly producing y -ions. ETD (middle-right) involves the reaction of the precursor ion with an electron
donor (fluoranthene pictured), allowing fragmentation through electron transfer. ETD produces both c- and z-ions. EThcD
(right), a hybrid between ETD and HCD involves the initial reaction of the precursor ion with an electron donor, and sub-
sequent HCD fragmentation of the remaining ions. In this scenario, b-, y-, c-, and z-ions are producing, providing optimal
sequence coverage.
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effective when used with highly charged peptides ( 3+); a feature largely incompatible with tryptic
peptides, as these are commonly  3+. To circumvent this, it is possible to “super-charge” pep-
tides within a sample through the addition of m-nitrobenzyl alcohol (m-NBA) to the mobile-phases
of the LC system128, thus making ETD more suitable for tryptic digests.
Analogous to the aforementioned phospho-enrichment methodologies, a combination of ion
activation methods produces the best fragmentation of phosphopeptide ions. To this end, several
methods have been developed which combine fragmentation technologies, either physically or
computationally, to produce the most efficient sequencing of peptides. Firstly, EThcD, a physical
hybrid of ETD and HCD technologies, allows the initial reaction of the precursor ion with fluo-
ranthene to produce c- and z-ions, and subsequent HCD fragmentation of the remaining ions to
produce further b- and y -ions249. Therefore, any intact precursor ion that persists following ineffi-
cient ETD fragmentation (perhaps due to the peptide possessing a low charge) will still produce
fragments from the HCD stage and vice versa. Thus, the method compounds the advantages
of both fragmentation methods and produces data-rich MS2 spectra that allow accurate peptide
sequencing, high peptide coverage, and high confidence PTM localisation249,250. Based upon a
similar notion, other methods have sought to allow on-the-fly decision tree-driven fragmentation
methods, whereby the instrument, based on the empirically determined parameters of the pre-
cursor ion (m/z, z, etc.), decides which fragmentation method to use on an ion-by-ion basis. For
example, large ions possessing a high charge will be subjected to ETD, whereas smaller ions of
lower charge will be subjected to HCD/CID251. Therefore, as each ion is subjected to the theoret-
ically optimal fragmentation method, the best possible sequence information can be obtained in
order to allow accurate peptide identification.
1.6.4 Bioinformatic considerations for the sequencing of phosphopeptide ions
In parallel with the improvements in ion activation technologies, there has been continued de-
velopment of the search algorithms required to analyse the resulting datasets. The sequencing
of phosphopeptide ions is a distinct computational challenge, primarily due to the prevalence of
neutral loss events and the combinatorial complexity of the number of possible isomeric forms
of any particular phosphopeptide (increasing exponentially with an increasing number of phos-
phorylation sites). These issues are compounded by the distinct peptide fragmentation patterns
and probabilities between different ion activation methods. Thus, phosphopeptide search engines
are required to produce an estimate of the error inherent in sequencing the amide backbone of
the peptide itself (often referred to in the form of an FDR), whilst also provide an estimate of
the error inherent in phosphosite localisation (or false localisation rate [FLR]). Several algorithms
have been developed for these purposes, both proprietary and academic, including: Mascot Delta
Score, PhosphoRS, and LuciPHOr. These algorithms, whilst differing in the exact method they
use, each produce an objective assessment of the accuracy of the phosphosite localisation, and
each has demonstrated its utility for phosphoproteomics experiments252–254.
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Materials and Methods
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2.1 Antibodies
Primary Target Manufacturer Product
number
Specification Concentration
(v:v)
GADPH Abcam ab9485 Rabbit pAb 1:2000
Phospho-Akt (Ser473) Cell Signaling 9271 Rabbit pAb 1:500
Phospho-ERK1/2 (Thr202; Tyr204) Cell Signaling 4370 Rabbit mAb 1:1000
EGFR Cell Signaling 2232 Rabbit pAb 1:500
Phospho-MARCKS (Ser152=156) Cell Signaling 2741 Rabbit pAb 1:1000
Phospho-RPS6 (Ser235=236) Cell Signaling 2211 Rabbit pAb 1:1000
Phospho-S6K (Thr389) Cell Signaling 9202 Rabbit pAb 1:1000
-tubulin Cell Signaling 2144 Rabbit pAb 1:1000
Vinculin Sigma Aldrich V9131 Mouse mAb 1:2000
Table 2.1: A summary of primary antibodies used for western blotting. pAb, polyclonal antibody; mAb, monoclonal
antibody.
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2.2 Miscellaneous reagents and materials
Reagent/material Manufacturer Product num-
ber
Supplementary information
Acclaim R© PepMap RLSC C18 Analytical
Column (75 m x 25 cm, 2 m, 100A˚)
Thermo Scientific 164536 Analytical column used for Velos LC
separations
Acclaim R© PepMap 100 C18 Trap Col-
umn (100 m x 2 cm, 5 m, 100A˚)
Thermo Scientific 164564 Trap column used for Velos LC sepa-
rations
BEH C18 nanoACQUITY column (75 m
x 15 cm, 1.7 m, 130A˚)
Waters Corp. 186003543 Analytical column used for XL LC
separations
Bradford assay reagent Sigma-Aldrich B6916 Protein concentration estimation
Bicinchoninic acid (BCA/Smith) assay
reagent
Thermo Scientific
Pierce
23227 Protein concentration estimation
CellTiter R© 96 AQueous non-radioactive
cell proliferation assay
Promega G5421 Cell viability assay platform
C18 micro-spin columns Protea Biosciences SP-150-96 Phosphopeptide enrichment platform
C18 micro-spin columns Glygen TT2C18.96 Phosphopeptide enrichment platform
C18/graphitic carbon TopTip micro-spin
columns
Glygen TT2MC18.96 Phosphopeptide enrichment platform
Dulbecco’s Modified Eagle’s Medium
(DMEM)
PAA/Sigma Aldrich E15-843/D6429 MCF7 culture medium
Dulbecco’s Phosphate-Buffered Saline
(PBS)
PAA/Sigma Aldrich H12-002/D8537 Used for all cell culture and lysate
preparation
ECL HRP-linked anti-rabbit antibody GE Life Sciences NA934 Western blotting reagent
ECL HRP-linked anti-mouse antibody Dako P0260 Western blotting reagent
EDTA-trypsin (0.05%/0.02%) PAA/Sigma Aldrich L11-004/T4299 MCF7 culture reagent
Empty TopTip micro-spin columns (PE-
filtered)
Glygen TF2EMT Phosphopeptide enrichment platform
Eppendorf LoBind micro-centrifuge tubes Sigma-Aldrich Z666505 Used for all sample preparation
Eppendorf LoRetention pipette tips Fisher Scientific Ltd PMP-907-040W Used for all [phospho-]peptide sam-
ple handling were available
Foetal Bovine Serum (FBS) PAA/Gibco A15-
104/10500-064
MCF7 culture medium supplement
Immobilon R©-P PVDF membrane Millipore IPVH00010 Western blotting membrane
mini-PROTEAN R© 12% PA-gels Biorad 456-1044 PAGE reagent
mini-PROTEAN R© 4-15% PA-gels Biorad 456-1084 PAGE reagent
OASIS R© HLB 1 cc (30/10 mg) cartridges Waters Corp. WAT094225 Reversed-phase solid-phase extrac-
tion cartridges
Penicillin/streptomycin PAA/Sigma Aldrich P11-010/P4333 MCF7 culture medium supplement
Phosphatase inhibitor cocktail I Sigma Aldrich P8340 Western blot lysis buffer supplement
PMSF Sigma Aldrich 93482 Western blot lysis buffer supplement
PVDF membrane Millipore IPVH00010 Western blot component
Recombinant EGF (human) Peprotech AF-100-15 Cell culture medium additive
Recombinant IGF-1 (human) Peprotech AF-100-11 Cell culture medium additive
SuperSignal West Pico ECL substrate Thermo Scientific
Pierce
34080 Western blotting reagent
Symmetry C18 nanoACQUITY trap col-
umn (180 m x 2 cm, 5 m, 100A˚)
Waters Corp. 186006527 Trap column used for XL LC separa-
tions
Titansphere TiO2 beads (10 m) GL Sciences Inc. 5020-75010 TiO2 chromatographic media
TPCK-trypsin (immobilised) Thermo Scientific 20230 In-solution protein digestion reagent
Table 2.2: A summary of all miscellaneous materials and reagents used.
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2.3 Kinase/phosphatase inhibitors
Compound Manufacturer Product
number
Primary target Concentration
(M)
Akt inhibitor VIII Chemdea CD0223 Akt/PKB 1
Bisindolylmaleimide-1 Calbiochem 203290 PKC 1
Cantharidic acid Calbiochem 210150 PP2A 10
DG2 Calbiochem 559274 p70S6K 5
ERK inhibitor Calbiochem 328006 ERK 40
ERK inhibitor II Calbiochem 328007 ERK 30
GDC-0941 Chemdea CD0245 PI3K (pan) 1
Go¨-6976 Calbiochem 365250 PKC 1
GSK-1120212 Selleckchem S2673 MEK 0.5
H-1152 Calbiochem 555550 ROCK 5
KN-93 Calbiochem 422708 CAMK2 5
KN-62 Calbiochem 422706 CAMK2 10
KU-0063794 Chemdea CD0274 mTORC1/2 1
MK-2206 Selleckchem S1078 Akt/PKB 1
Okadaic acid Calbiochem 495604 PP2A 1
PD-153035 Calbiochem 234490 EGFR 1
PD-168393 Calbiochem 513033 EGFR 10
PF-4708671 Calbiochem 559273 p70S6K 20
PI-103 Chemdea CD0113 PI3K (pan) 1
Torin-1 AxonMedchem 1833 mTORC1/2 1
U0126 Calbiochem 625005 MEK 10
Y-27632 Chemdea CD0141 ROCK 10
Table 2.3: A summary of all kinase and phosphatase inhibitors used.
2.4 Cell culture – MCF7
All cell handling procedures, including lysis, were performed under an appropriate laminar flow
hood using sterile materials. Parental MCF7 cells were routinely cultured using DMEM (10%
FBS; 1% penicillin/streptomycin, unless otherwise stated), at 37 oC, in a humidified atmosphere
containing 5% CO2. The identity of the MCF7 cell-line was confirmed using short tandem repeat
genotyping (AmpFlSTR R© Identifiler R© panel).
2.4.1 Cell seeding for experimentation
MCF7 cells were washed twice with PBS and subsequently detached through incubation at 37
oC (5 min) with 0.05% EDTA-trypsin. Inactivation of the trypsin was achieved through addition of
1:1 DMEM. The suspension was then centrifuged at 1,300 rpm for 5 min (18 oC) and the cells
resuspended in fresh DMEM and counted using a haemocytometer or Beckman Coulter ViCell
XR instrument. Cells were seeded 3 days before each experiment in the appropriate size tissue-
culture treated plates, at approximately 7–9 x 103 cellscm 2. Each plate was washed once
with PBS and fresh DMEM added approximately 24 hours before each experiment. For those
experiments involving serum starvation, cells were washed twice with PBS and an appropriate
volume of fresh serum-free DMEM (0% FBS; 1% penicillin/streptomycin) added 24 hours prior to
the relevant experiment.
2.4.2 Cryopreservation
Cells were washed and detached from the relevant flask (as in Section 2.4.1), collected by cen-
trifugation at 1,300 rpm for 5 min (18 oC), and resuspended in the appropriate volume of 10%
DMSO; 90% FBS. The cells were then transferred to 1.8 mL cryovials, placed in isopropanol
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tanks and transferred to -80 oC. After 24 hours, the cryovials were transferred to liquid nitrogen
storage tanks (approximately -178 oC) for long-term preservation. When required, cells were
removed from liquid nitrogen, thawed at room temperature and immediately transferred to fresh
DMEM. The suspension was then centrifuged and resuspended in fresh DMEM.
2.4.3 Treatment with kinase/phosphatase inhibitors
Each compound was diluted to 1000 times the desired concentration for treatment (as Table 2.3),
using dimethyl sulphoxide (DMSO). Each compound was then added to the relevant cell popula-
tion at a 1:1000 dilution in the media. Cells were incubated with the appropriate concentration of
the relevant compound for the indicated time prior to lysis.
2.4.4 Creation and maintenance of resistant cell-lines
Parental MCF7 cells were split into six identical populations of cells. Three cultures began GDC-
0941 treatment, and three began KU-0063794 treatment at 100 nM. At each passaging of the
individual cultures (when they reached approximately 80-90% confluency), the concentration of
relevant drug was increased by 100 nM. This drug concentration was increased in this manner
until a maximum of 1 M of the relevant drug in the media was reached. Once at this point,
the resistant cell-lines were maintained in 1 M of the relevant compound at all times unless
otherwise stated. The cell-lines resistant to each drug were maintained at the same passage
number throughout.
2.4.5 MTS proliferation assays
The relevant cell-lines were seeded in 96-well plates (clear, flat-bottomed) at approximately 3,000
or 5,000 cellswell 1 (as indicated) in triplicate or quadruplicate. After 24 hours, the cells were
then treated with the indicated concentrations of the specified drugs or vehicle (DMSO). Follow-
ing a 48 hour treatment with the compounds, cell viability was determined with the MTS assay
reagent (Promega, WI, USA), as per the manufacturer’s instructions. The absorbance (490 nm)
of each well was determined using a spectrophotometer – this measurement being acquired in
duplicate. The ratio of absorbance of each concentration data-point versus the absorbance of ve-
hicle treated cells was then calculated. Third-order polynomials were fitted to the data using the
ggplot2 package within the R statistical computing environment. IC50 values were then estimated
by solving the respective fitted equations.
2.4.6 Crystal violet assays
The relevant cell-lines were seeded in 96-well plates at approximately 5,000 cellswell 1, in trip-
licate. After 24 hours, cells were treated with the indicated concentrations of drugs or vehicle
(DMSO). Following a 48 hour treatment with the relevant compounds, cells were fixed with 100
Lwell 1 PFA (4% w/v, PBS) for 30 min on ice. Following removal of the PFA, cells were stained
with 100 Lwell 1 crystal violet (0.5% w/v, 20% MeOH; 80% ddH2O) for 10 min at room temper-
ature. Plates were then washed with water until no soluble dye remained. The crystal violet stain
was then re-solubilised with 100 Lwell 1 Sorenson’s buffer (0.1M Na3C6H5O7, 50% EtOH; 50%
ddH2O) and mixed on a plate shaker at room temperature for 30 min at 300 rpm. The absorbance
(540 nm) of each well was determined using a spectrophotometer, in duplicate.
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2.5 Cell lysis
Experimental use Lysis buffer components
LC-MS phosphoproteomics/proteomics 8M Urea in 20 mM HEPES (pH 8.0)
(supplemented with 1 mM Na3VO4, 1 mM NaF, 1 mM -
glycerol phosphate, and 2.5 mM Na2H2P2O7)
Western blotting 50 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, and 1%
Triton X-100 (pH 7.4)
(supplemented with 1 mM Na3VO4, 1 mM NaF, 1 mM -
glycerol phosphate, 2.5 mM Na2H2P2O7, 1 M okadaic
acid, 1X Sigma protease inhibitor cocktail and 1 mM
phenylmethylsulphonyl fluoride [PMSF])
Table 2.4: A summary of lysis buffers used and their constituents.
Cells were washed with ice-cold PBS (supplemented with 1 mM Na3VO4 and 1 mM NaF). An
appropriate volume of lysis buffer was added to each plate, the cells scraped, and the resulting
lysate collected. Each lysate was then briefly sonicated, centrifuged at 20,000 x g for 10 minutes
(5oC) and the resulting supernatant kept for further analysis. The approximate protein concen-
tration of each lysate was then determined using a standard Bradford or bicinchoninic acid assay
(BCA) (utilising BSA to construct a standard curve – correlating absorbance at 595 (Bradford)/562
(BCA) nm with protein concentration).
2.6 SDS-PAGE
Lysates prepared for Western blotting analysis were normalised to an appropriate concentration
using lysis buffer and an equal volume 4X Laemmli buffer (240 mM Tris-HCl pH 6.8; 40% glycerol,
0.02% bromophenol blue, 0.1 M DTT, 12.5% SDS). Samples were then heated at 95oC for 5 min.
Samples were loaded into 12% or 4-15% precast SDS-PA gels, the gels assembled into Biorad gel
tanks, submerged in running buffer (25 mM Tris; 192 mM glycine; 0.1% SDS), and electrophoresis
performed at 70 V for approximately 15 min and 100 V for 1 hour.
2.6.1 Western blotting
Following SDS-PAGE, proteins were transferred to polyvinylidene fluoride (PVDF) membranes
(as Table 2.2) using the BioRad Trans-Blot R© Turbo system as per the manufacturer’s instructions.
Transfers were performed at 25 V/1.0 A for 30 min. Once transferred, the membranes were
blocked through incubation with blocking buffer (5% w/v skimmed milk powder in Tris-buffered
saline with Tween (TBS-T: 0.15 M NaCl; 0.05 M Tris-HCl; pH 7.6; 0.1% Tween-20) for  1 hour.
The membranes were then incubated at 4oC with the relevant primary antibody (diluted in 5% w/v
BSA; TBS-T – concentrations as Table 2.1) overnight. Prior to incubation with secondary antibody,
each membrane was washed with TBS-T for 5 min (in triplicate). Membranes were incubated with
secondary antibody (anti-rabbit/anti-mouse Ig conjugate diluted in 2.5% w/v skimmed milk powder
in TBS-T) at room temperature for 1 hour. Following this incubation, membranes were washed
with TBS-T for 5 min (in triplicate), excess solution removed, and incubated with 1X SuperSignal
West Pico ECL solution (2 mLmembrane 1) for 1 min. Antibody affinity was then visualised using
X-ray film.
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2.7 LC-MS sample preparation
2.7.1 Tryptic digestion
Prior to digestion, all lysates (normalised to 500 or 250 g using lysis buffer) were reduced (10
mM DTT for 30 min at room temperature in the dark) and alkylated (16.6 mM iodoacetamide for 30
min at room temperature in the dark). On completion of the alkylation, each sample was diluted
1:4 with 20 mM HEPES (pH 8.0). To prepare the trypsin beads for addition to the sample, an
appropriate volume of beads was taken from the stock and centrifuged at 2,000 x g for 5 min (5oC).
The resulting supernatant was discarded, and an equal volume of 20 mM HEPES (pH 8.0) added
to create a 50% slurry. This process was repeated three times to ensure adequate conditioning of
the beads. 50% trypsin bead slurry was added to each sample to a final concentration of 4% (v/v)
( 32 TAME units) and the samples then incubated at 37oC, with constant agitation, overnight.
2.7.2 Peptide desalting by solid-phase extraction
Peptide solutions (resulting from the overnight tryptic digestion – Section 2.7.1) were desalted
by means of reversed-phase solid-phase extraction (utilising OASIS R© HLB cartridges). The car-
tridges, held in a vacuum manifold (P = 5.0 inHg  0.5), were conditioned with LC-MS grade
acetonitrile (ACN) and subsequently equilibrated with 99% H2O (1% ACN; 0.1% TFA). Samples
were loaded into individual cartridges and washed with 99% H2O (1% ACN; 0.1% TFA) to remove
residual salts. The bound peptides were then eluted with 0.5 mL 1M glycolic acid (50% ACN; 5%
TFA – for phosphoproteomics) or 70% ACN (30% H2O – for proteomics). Desalted peptide sam-
ples for phosphoproteomics analysis were then normalised to 1 mL through addition of 0.5 mL 1M
glycolic acid (80% ACN; 5% TFA), and subsequently stored on ice prior to phospho-enrichment.
Desalted peptide samples for proteomics analysis were vacuum dried immediately following the
desalting. All solutions for use in either desalting or phospho-enrichment protocols were prepared
with LC-MS grade solvents.
2.7.3 TiO2-Metal Oxide Affinity Chromatography (MOAC) – on-line method
Following digestion and desalting, peptide samples were incubated with TiO2 beads (25 g TiO2
beadsg protein 1) at room temperature for 5 min, with constant agitation. The samples were
then centrifuged at 500 x g for 30s and 0.8 mL of the remaining supernatant removed and dis-
carded. The remaining volume was subsequently used to resuspend the beads. The resus-
pended beads were then loaded into Protea C18 micro-spin columns (pre-cleaned with LC-MS
grade ACN) and centrifuged at 4,000 x g for 3 min. Any residual beads in the incubation tubes
were resuspended in 0.2 mL 1M glycolic acid (80% ACN; 5% TFA) and loaded into the columns
as before. The columns were then washed sequentially with 0.2 mL 1M glycolic acid (80% ACN;
5% TFA), 98% H2O (2% ACN), and 100 mM NH4CH3COO  (75% H2O; 25% ACN) – centrifuging
at 4,000 x g for 3 min between each wash. The phosphopeptides were then transferred from
the TiO2 layer to the reversed-phase sorbent by means of a wash with 0.2 mL 5% (v/v) NH4OH
(98% H2O; 2% ACN), and then washed twice with 0.2 mL 98% H2O (2% ACN; 0.1% FA). The
phosphopeptides were then eluted from the C18 layer with two washes of 0.1 mL 40% H2O (60%
ACN; 0.1% FA). Samples were then vacuum-dried overnight and stored at -80 oC.
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2.7.4 TIO2-MOAC – off-line method
Digested, desalted peptide samples were incubated with TiO2 beads (25/50 g TiO2 beadsg
protein 1) at room temperature for 5 min, with constant agitation. The samples were then cen-
trifuged at 500 x g for 30s and 0.8 mL of the remaining supernatant removed and stored on ice.
The remaining volume was subsequently used to resuspend the beads which were then packed
into pre-cleaned Glygen empty TopTips and centrifuged at 1,500 x g for 3 min. The stored 0.8 mL
of each sample was then washed over the packed beads (four washes of 0.2 mL), centrifuging at
1,500 x g for 3 min between loading of each aliquot. Each micro-spin column was then washed
sequentially with 0.2 mL 1M glycolic acid (80% ACN; 5% TFA), 0.2 mL 100 mM NH4CH3COO 
(75% H2O; 25% ACN), and 0.1 mL 98% H2O (2% ACN) – centrifuging at 1,500 x g for 3 min
between each wash. The bound phosphopeptides were then eluted with four 50 L washes with
5% (v/v) NH4OH (98% H2O; 2% ACN) – centrifuging at 1,500 x g for 2 min and collecting the
eluate of each wash. The resulting phosphopeptide solution was then acidifed to 10% TFA on ice.
For the following desalting stage, C18 or C18+GC micro-spin columns were conditioned and
equilibrated with two aliquots of 0.2 mL 50% H2O (50% ACN; 0.1% FA) and 0.2 mL 99% H2O (1%
ACN; 0.1% FA), respectively – centrifuging at 1,500 x g for 2 min between each wash. Each sam-
ple was then removed from ice and the 0.2 mL phosphopeptide eluate loaded into the columns.
Each column was then washed with 99% H2O (1% ACN; 0.1% FA) in duplicate and the peptides
eluted by means of four, 50 L washes with 50% H2O (50% ACN; 0.1% FA). The resulting eluates
were vacuum-dried overnight and stored at -80 oC.
2.7.5 TiO2-MOAC – final enrichment method
Each desalted peptide sample was incubated with 50 g TiO2 beadsg protein 1 (50% slurry in
1% TFA) at room temperature for 5 min, with constant agitation. The samples were centrifuged at
500 x g for 30 s, 0.8 mL of the supernatant transferred to a fresh tube on ice, and the remaining
0.2 mL used to re-suspend the beads. The remaining 0.2 mL of each sample (containing the
beads) was then loaded into pre-washed Glygen empty TopTips and centrifuged at 1,500 x g for 3
min. Any residual beads were resuspended with 0.2 mL 1M glycolic acid (80% ACN; 5% TFA) and
loaded into the columns as before. The remaining 0.8 mL of each sample was then washed over
the beads (four washes of 0.2 mL), centrifuging at 1,500 x g for 3 min between loading of each
aliquot. Each micro-spin column was then washed sequentially with 0.2 mL 1M glycolic acid (80%
ACN; 5% TFA), 0.2 mL 100 mM NH4CH3COO  (75% H2O; 25% ACN), and 0.6 mL 90% H2O
(10% ACN – three washes of 0.2 mL) – centrifuging at 1,500 x g for 3 min between each wash.
The bound phosphopeptides were then eluted with four 50 L washes with 5% (v/v) NH4OH (90%
H2O; 10% ACN) – centrifuging at 1,500 x g for 2 min and collecting the eluent of each wash. The
resulting phosphopeptide solution was then snap-frozen on dry-ice for 15 min and vacuum dried
until no solvent remained.
2.8 Liquid Chromatography-Mass Spectrometry (LC-MS)
2.8.1 Sample reconstitution and LC separations
Immediately prior to LC-MS analysis, the samples were reconstituted with 20 L (Velos) or 14
L (XL) of 50 fmolL 1 enolase peptide digest (dissolved in 95% H2O; 5% ACN; 0.1% TFA),
bath sonicated for 5 min at room temperature, centrifuged at 16,000 x g for 5 min (5 oC), and the
resulting supernatant recovered for LC-MS analysis.
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Peptide and phosphopeptide LC separations – unless stated otherwise – were carried out on-
line on Dionex Ultimate 3000 nRSLC (Velos) and Waters NanoACQUITY UPLC systems (XL).
Separations on the Dionex system were performed using an Acclaim R© PepMap RLSC C18 Ana-
lytical Column (75 m x 25 mm, 3 m, 100A˚) and an Acclaim R© PepMap 100 C18 Trap Column
(100 m x 2 cm, 5 m, 100A˚). Solvent A and B were 98% H2O (2% ACN; 0.1% FA) and 20% H2O
(80% ACN; 0.1% FA) respectively. All sample injections were equal to 3.0 L; being loaded onto
the trap column at a flow rate of 8 Lmin 1 for 5 min. Once loaded, the samples were eluted over
an 85 min gradient from 6.3 to 43.8% solvent A. Following elution, the column was cleaned with
90% solvent B for 10 min, and subsequently equilibrated with 6.3% solvent A for 10 min.
Separations on the Waters system were performed using a Waters BEH130 (ethylene bridged
hybrid) C18 analytical column (75 m x 150 mm, 1.7 m, 300A˚) and a Waters UPLC 2G trap
column (180 m x 20 mm, 5 m, 100 A˚). Solvent A and B were 100% H2O (0.1% FA) and 100%
ACN (0.1% FA) respectively. Samples were injected at a volume of 3.0 L and were loaded on
to the trap column at a flow rate of 2 Lmin 1 for 8 min. Elution was performed over an 100
min gradient from 5 to 35% solvent A. Following the gradient, the column was cleaned with 90%
solvent B for 10 min, and then equilibrated to 99% A; 1% B for 5 min.
2.8.2 Mass spectrometric analysis
Analyses were performed on Thermo Scientific LTQ Orbitrap-Velos and LTQ Orbitrap-XL hybrid
instruments (as indicated), operated in data-dependent acquisition (DDA) mode. In the DDA
method used – unless stated otherwise – a full MS1 survey scan (m/z 350-1500) was performed
at a resolution of 30,000 FWHM (at m/z 400); the ions being analysed in the Orbitrap. The top 7
(Velos) or top 5 (XL) most intense multiply charged precursor ions present in the MS1 scan were
automatically mass-selected and fragmented by collision-induced dissociation (CID – normalised
collision energy = 35%) with multi-stage activation enabled, and analysed in the LTQ-Velos/XL
linear ion trap (m/z 190-2000). Neutral losses of 98, 49, 32.7, and 24.5 were accounted for and
dynamic exclusion was enabled (avoiding repeat analysis of identical precursor ions within a 60 s
window).
2.8.3 Thermo LTQ-Orbitrap-Velos and -XL mass spectrometers
The Thermo LTQ-Orbitrap-Velos and -XL instruments both consist of a combination of orbitrap
and linear quadrupole ion trap mass analysers (Fig 2.1); however, the instruments differ in the
composition of the ion optics prior to the ion trap. The overall schematics of both mass spectrom-
eters are shown in Fig 2.1. Peptide ions, separated on the nano-LC system connected online to
the mass spectrometer, are introduced to the instrument via the electrospray ionisation process
(Chapter 1; Fig 1.5). The ions are then focused by the ion optics and guided into the linear ion
trap.
The XL ion optics are based on a high-pressure, skimmer-based design, whereas the Velos
employs a stacked-ring ion guide (S-lens). The S-lens greatly improves the efficiency of the
transfer of ions from the ion source to the ion trap, thus improving the sensitivity and limit of
quantification (LOQ) of the instrument.
Once in the ion trap, the ions are trapped radially and axially through the application of an elec-
trical field to the hyperbolic rod quadrupoles that constitute the ion trap. This creates a potential
well, where the ions are unable to exit the trap. The ions, now confined within the trap, proceed
to orbit at a frequency directly related to their m/z, as described by the Mathieu equation. Once
collected, a packet of the ions is ejected and passed through to the C-trap, where they are then
65
Figure 2.1: Schematics of the orbitrap-XL and -Velos mass spectrometers. The major components of the orbitrap-XL
(A) and orbitrap-Velos (B) are shown (not to scale). The main differences between the instruments are highlighted with
red boxes. Diagrams adapted from: planetorbitrap.com
tangentially injected into the orbitrap mass analyser for high resolution and high mass accuracy
MS1 analysis. Fig 2.2A shows an example MS2 spectrum produced in an ion trap.
The orbitrap consists of two electrodes: the outer, barrel-like electrode and the inner, spindle-
like electrode. Due to the RF and DC fields applied to the electrodes, ions orbit around the inner
electrode on helical trajectories at a frequency determined by the ions’ m/z ratios. The mass
spectrum of the ions present within the orbitrap is obtained from a Fourier transform of the image
current produced from the trapped ions. Fig 2.2B shows an example MS1 spectrum measured in
an orbitrap.
In DDA methods, the n most intense, multiply charged ions (i.e. those likely to represent
tryptic peptides) are then sequentially selected by the ion trap, fragmented, and the m/z ratios of
the resulting fragment ions measured by electron multipliers adjacent to the ion trap. This process
is referred to as MS2 analysis and the overall time taken to measure one MS1 scan and n x MS2
scans is referred to as a duty cycle. The duty cycle of an instrument is related to its sensitivity (i.e.
how quickly/efficiently it can fill the ion trap), scan speed of both analysers, the number of ions
chosen to be selected for MS2 (n), and the fragmentation method used. Alongside the impact on
the number of peptide identifications can be made, the duty cycle also directly impacts the quality
of MS1-based quantitative data, as a shorter duty cycle allows for more quantitative (MS1) data-
points per peak, and thus a more accurate peak shape. In this respect, a distinct advantage of the
Velos instrument is that, due to its increased sensitivity, its duty cycle is much shorter than that
of the XL and thus a greater number of peptides can be identified in the same chromatographic
separation time. Moreover, this allows for shorter overall separation times (therefore increasing
throughput), without sacrificing the number of identifications and quantitative data quality.
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Figure 2.2: Example spectra produced in ion trap and orbitrap mass analysers. (A) An MS2 spectrum produced in
an ion trap instrument. (B) An MS1 spectrum produced in an orbitrap instrument. The zoomed area shows the isolated
spectrum of a specimen precursor ion, demonstrating the resolution of the orbitrap mass analysis (at 30,000 FWHM).
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2.9 Data analysis
2.9.1 Mascot database searches
Mascot Daemon and Distiller (v2.3.0.0 and v2.4.2.0 respectively – Matrix Science, London, UK)
were used in conjuction to automate the conversion of Thermo Scientific .raw files to MS2 smoothed
and centroided peak lists (.mgf files), and to search the peak lists against the Uniprot/Swissprot
human database (downloaded on 03/10/2012). LTQ Orbitrap-Velos and-XL data were searched
using the following criteria: 10 ppm precursor and 600 mmu fragment ion m/z tolerances;
enyzme = trypsin (2 missed cleavages tolerated); fixed modification: carbamidomethyl (C); vari-
able modifications: gln!pyro-glu (N-term Q), oxidation (M), phospho (ST), and phospho (Y).
Phosphopeptide identification data produced by Mascot search engine results were collated
using a combination of a Perl script and Peptide ANalysis and Database Assembly (PANDA) soft-
ware (v1.1) – both developed in-house. The data were algorithmically curated to only include
unique phosphopeptide ions (accurate to 10 ppm) with a q-value  0.05 (calculated via com-
parison to searches against a randomised database). All phosphopeptides with a Mascot delta
score < 10 were reported as ”Protein (residues); charge; modification(s)”. All those with a score
 10 were reported as the specific phosphorylation site (e.g. MAPK3 p-T202 p-Y204). Protein
identity was inferred from peptides identified from the aforementioned Mascot search engine re-
sults (excluding phospho (ST) and (Y) variable modifications). Identified proteins were required to
meet the following thresholds to be included in further analyses: minimum peptide score  20; 
2 unique peptides; minimum protein score  60.
2.9.2 Phosphopeptide quantification
Phosphopeptides and peptides were quantified using the in-house developed PESCAL (Peak
Statistic Calculator) software (written in Python v2.7); automatically generating XICs for the first
three isotopes of each peptide ion within the created database (7 ppm m/z tolerance; 1.5 min
retention time tolerance; isotope correlation > 0.8), subsequently calculating the peak heights
of each constructed XIC. A specimen XIC is presented in Fig 2.3. Data were then processed
further and analysed within Microsoft Excel (2007/2010), R (v3.0.0 – reshape2, ggplot2, plot3D,
XMLRPC, RCytoscape, igraph, limma, and gplots packages)255–263 and Cytoscape (v.2.8.3)264.
Proteomics data were processed as above; however, the abundance of each protein was inferred
by computing the sum of the intensities of all the peptides in the database corresponding to
the relevant protein. Where applicable, stoichiometry ratios were calculated by subtracting the
log2 fold-ratio (vs control) of the total protein from the log2 fold-ratio (vs control) of the individual
phosphopeptide. Phosphopeptides not possessing protein data in this context were removed from
downstream analyses.
2.9.3 Quantitative data: pre-processing and differential abundance analysis
Phosphopeptide ion intensities were log2 transformed, resulting in intensities symmetrically dis-
tributed about the mean (approximating normal distributions). The values were then between-
sample quantile normalised to produce statistically identical distributions across the sample ar-
ray265.
Differential abundance analysis was conducted using the limma package within the R statisti-
cal computing environment. This involved the fitting of a linear model to the quantitative data for
each phosphopeptide ion within the dataset (Fig 2.4; equation 2.1). Briefly, a design matrix (X –
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Figure 2.3: A specimen XIC produced by PESCAL. (A) An XIC representing an ion of m/z = 698.3588 and tR  80
min under control conditions. (B) An XIC representing the same ion as in (A), under drug treated conditions. Blue line, 1st
isotope; red line, 2nd isotope; green line, third isotope. Dashed, grey line represents the predicted retention time in each
case.
specific to each experiment) was created, which served to define the linear relationships between
individual treatments and observed values (phosphopeptide peak heights) – Fig 2.4; equation 2.2.
A linear model was then fitted to each phosphopeptide ion in the dataset, and the coefficients ()
calculated – this approximately representing the arithmetic mean of technical and/or biological
replicates for each condition within the experiment design. The biological comparisons of inter-
est were then specified in a contrast matrix (), which described the linear relationships between
the individual coefficients previously calculated (Fig 2.4; equations 2.3 and 2.4). This calculation
produced log2 ratios for each of the comparisons specified (log2(drug)  log2(control), for exam-
ple). An overall, generalised form of the linear model equation summarising the aforementioned
processes is shown in Fig 2.4; equation 2.5. Statistical significance of differential expression was
then determined by means of empirical Bayes shrinkage of standard deviations262,266. The gen-
erated P-values were then adjusted for multiple testing using the Benjamini-Hochberg procedure
to control the type I error rate267.
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E[yj ] = X:j (2.1)
X =
Sample Drug Control
drug rep1 1 0
drug rep2 1 0
control rep1 0 1
control rep2 0 1
=

1 0
1 0
0 1
0 1
 (2.2)
CT =
Sample Drug –
Control
drug rep1 1
drug rep2 1
control rep1 -1
control rep2 -1
=

1
1
 1
 1
 (2.3)
j = C
T :j (2.4)
E[yi ] = X:j +  (2.5)
Figure 2.4: Linear models for differential expression analysis. Equation 2.1: the linear model fitted to each phos-
phopeptide ion, where yj = the quantitative data for the phosphopeptide ion j, X = the specified design matrix, and j =
the vector of coefficients to be calculated. Equation 2.2: constructing the design matrix specific to the experiment. In this
case, the replicates representing drug and control treated samples are assigned 1 or 0 according to which coefficient ()
they represent (Drug or Control). Equation 2.3: defining the biological comparisons to be computed. CT = the contrast
matrix representing the linear relationships between the drug and control treated samples in order to produce the contrast
of interest: Drug – Control. Equation 2.4: j = the contrasts to be calculated, CT = the contrast matrix, and j = the
vector of previously calculated coefficients. Equation 2.5: the summarised, general equation for the linear models fitted
to the data; yj = the quantitative data for the phosphopeptide ion j, X = the specified design matrix, j = contrasts to be
calculated, and  = the error associated with the model.
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Chapter 3
Enhancement of “single-shot” phospho-enrichment
and mass spectrometric methodologies to
maximise phosphoproteome coverage
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3.1 Introduction and aims of the study
The enrichment of phosphopeptides from complex biological matrices is key to the success of
phosphoproteomics experiments. As outlined in Section 1.6, this is necessary as a result of
the substoichiometric levels of phosphorylation sites in biological systems. As such, enrichment
methods bring phosphorylated peptides within the dynamic range of modern mass spectrom-
eters. TiO2-based enrichment methods have been developed extensively in recent years and
have proved to be superior to Fe3+-IMAC and antibody-based approaches with respect to the
enrichment of pSer and pThr peptides in terms of a number of factors, including: the number
of phosphopeptides detected, the specificity of the enrichment, and the simplicity and speed of
the method190,237,239,268. Due to their relative simplicity, TiO2-based methods are particularly well
suited to label-free phosphoproteomics analyses. This is because, as large two-dimensional sep-
arations are generally incompatible with label-free analyses, “single-shot” enrichments (i.e. one
enrichment per sample) are necessary. As a result, such single-shot enrichments must be op-
timised to be as specific and sensitive as possible in order to provide maximal coverage of the
phosphoproteome from a single extraction.
The utility of single-shot enrichment methods, both in terms of qualitative and quantitative
data has been previously demonstrated244. Work from the Cutillas lab has also characterised a
single-step TiO2-based enrichment method (Fig 3.1A), primarily for label-free analyses, that has
been shown to be both quantitatively reproducible and accurate (mean CV post-normalisation
= 23.8% and error  30% for the majority of peptides), alongside being qualitatively efficacious
(approximately 500 phosphopeptides per sample at 90% enrichment)141. Despite this method’s
utility, a number of issues were present with the protocol; namely, a lack of reversed-phase me-
chanical robustness, relatively low recovery compared to two-dimensional methods, and most
pertinently, N-formylation of phosphopeptides during vacuum drying (Fig 3.1B). N-formylation of
amino groups present within the phosphopeptides occurred in this context due to the heating of
the sample in the presence of 10% formic acid – utilised to neutralise the NH4OH necessary to
elute the phosphopeptides from the TiO2 – while drying. This unexpected modification result-
ing in a lower number of phosphopeptide identifications (as this modification was not included in
the database searches), whilst concomitantly convoluting the quantitative analysis, as the rate of
N-formylation for each peptide is unknown, resulting in unknown ratios of N-formylated vs unmod-
ified phosphopeptide ions.
The aim of the experiments presented in this Chapter was to optimise and enhance the orig-
inal phospho-enrichment method as presented in Montoya et al.141; in terms of absolute recov-
ery of phosphopeptides, a reduction in the N-formylation rate of said peptides, and an improve-
ment of the protocol’s robustness and efficiency. In order to achieve this, several iterations of the
phospho-enrichment method were devised and tested to provide a single, efficient method that
would provide adequate depth of analysis for future experiments. Furthermore, mass spectromet-
ric parameters, such as the precursor ion selection and fragmentation methods used to sequence
the recovered phosphopeptides, were also tested.
72
Figure 3.1: The original phospho-enrichment methodology as presented in Montoya et al. (A) Following desalting,
the purified peptide mixture is mixed and incubated with TiO2 beads. This mixture is then loaded onto the C18 sorbent
(packed in a micro-spin column format) in the presence of a high percentage of ACN (to prevent C18 binding), 5% TFA and
1M glycolic acid (to prevent non-phosphopeptide binding to the TiO2). (B) Following washing steps to improve specificity of
phosphopeptide binding, the phosphopeptides are eluted with 5% NH4OH in the presence of a high percentage of ACN.
The resulting phosphopeptide mixture is acidified with formic acid (10% final concentration) and vacuum-dried. Blue,
non-phosphopeptides; red, phosphopeptides. (C) In the presence of formic acid and vacuum-drying at relatively high
temperatures (30-40 oC), free amino groups (e.g. N-termini, Arg, and Lys residues) can become formylated, adding 31
Da to the peptide.
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3.2 Optimisation of phospho-enrichment conditions
3.2.1 Effects of on-line desalting on phosphopeptide recovery
In order to circumvent the issue of N-formylation and therefore improve phosphopeptide recovery,
it was hypothesised that an on-line enrichment method may be more effective. Such a method
would involve the elution of the phosphopeptides from the TiO2 layer and immediate recaptured
on a reversed-phase (C18) layer coupled on-line in a micro-spin column (Fig 3.2A-B). The C18
layer could then be washed to remove the remaining NH4OH, formic acid, and ammonium formate
salt (Fig 3.2B), thereby removing the acidification step. The remaining peptides could then easily
be eluted from the C18 layer with a high concentration of ACN (Fig. 3.2C). To test this hypothesis,
an experiment was designed to compare the two enrichment methods. To achieve this, a pooled
MCF7 lysate was separated into eight 500 g aliquots. Following reduction, alkylation, and an
overnight tryptic digestion (at 37 oC), these eight samples were desalted via solid-phase extraction
using OASIS R© HLB cartridges (1 cc; 30 mg) and the phosphopeptides extracted via TiO2-MOAC
– four extractions utilising the published method141 and four using the on-line method (Fig 3.2A-C).
Once vacuum-dried, these extractions were analysed on a Thermo LTQ-Orbitrap-XL instrument
after having been separated on a 45 min linear gradient (5-35% ACN) on a Waters nanoACQUITY
UPLC system. In each case the ions were fragmented by CID-MSA (top 5). The results of this
comparison are shown in Fig 3.2D.
Figure 3.2: An “on-line” desalting phospho-enrichment methodology improves phosphopeptide recovery (A) Fol-
lowing desalting, the purified peptide mixture is mixed and incubated with TiO2 beads. This mixture is then loaded onto
the C18 sorbent in the presence of a high percentage of ACN (to prevent C18 binding), 5% TFA and 1M glycolic acid
(to prevent non-phosphopeptide binding to the TiO2). (B) Following washing steps, the phosphopeptides are eluted with
5% NH4OH in the presence of a low percentage of ACN. The phosphopeptides are therefore removed from the TiO2, but
retained by the C18 layer. The C18 is then washed with a low percentage of ACN containing 1% formic acid in order to
neutralise any remaining NH4OH. (C) The remaining phosphopeptide ions are then eluted from the C18 layer with a high
percentage of ACN and vacuum-dried for further analysis. (D) Qualitative comparison of the Montoya et al. method and
the on-line method. (E) Comparison of the number of N-formylated peptides identified using both methods. Error bars
represent SEM (n = 4). P-values were determined via a two-tailed Student’s t-test.
As Fig 3.2D demonstrates, and as anticipated, the on-line method was able to substantially
increase the recovery of unique phosphopeptide ions from single-step TiO2 enrichments (580
vs 898; P = 0.009). Moreover, the number of N-formylated peptides was significantly reduced
(Fig 3.2D – 112 vs 14; P = 9.2 x 10 8). Despite these clear improvements, the efficiency of
enrichment, defined as the ratio between identified phosphopeptides and non-phosphopeptides,
was significantly poorer (76.0% vs 63.6%; P = 0.029).
In an effort to improve the enrichment efficiency, an experiment was designed to compare
the newer on-line method with the same method with an additional 200 L 100 mM ammonium
acetate (25% ACN) wash prior to transfer of the phosphopeptides from the TiO2 layer to the
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C18. It was hypothesised that, as high salt concentrations aid peptide binding to C18269 and
that ammonium acetate has previously been shown to improve the specificity of phosphopeptide
binding to TiO2 141, this extra wash would improve both the yield and specificity of the enrichment.
As with the data shown in Fig 3.2, this experiment involved the comparison of four individual
TiO2 extractions (from 500 g digests derived from a pooled MCF7 lysate) for each method.
The data presented in Fig 3.3 demonstrate that the extra salt wash did not affect the number of
phosphopeptides recovered and did not have a significant impact on the enrichment efficiency
(70.3% and 70.6% first iteration and extra wash, respectively).
Figure 3.3: An additional salt wash does not improve phosphopeptide enrichment. Qualitative comparison of the first
iteration of the “on-line” method as in Fig 3.2, and the identical method with an additional 100 mM ammonium acetate (25%
ACN) wash prior to TiO2 elution. Error bars represent SEM (n = 4). Blue, non-phosphopeptides; red, phosphopeptides.
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3.2.2 Effects of “off-line” desalting
Despite the effectiveness of the on-line method, the specificity of enrichment was poorer than
the original method. The source of this lack of specificity was posited to be due to high reten-
tion of non-phosphorylated peptides on the C18 layer. To combat this, it was hypothesised that,
concurrent with the unforeseen availability of empty micro-spin columns that could be packed
in-house, the enrichment and desalting stages could be separated. This presented several ad-
vantages. Firstly, unwanted (non-phosphopeptides) would not have the opportunity to bind to the
reversed-phase and thus contaminate the enrichment. Secondly, the volume remaining following
the incubation with the TiO2 beads could be washed over the packed TiO2 to encourage further
phosphopeptide binding. Finally, the TiO2 could be washed multiple times with high pH NH4OH
elution buffer, as concerns over the pH stability of the C18 layer were rendered irrelevant. This
latter factor was of particular importance, as several groups have noted the efficacy of eluting off
the TiO2 multiple times141,240. A schematic of this off-line methodology is shown in Fig 3.4A-D.
To further investigate conditions that might enhance phosphopeptide recovery, two different
reversed-phase sorbents were compared: C18 and C18 combined with graphitic carbon (GC).
Graphitic carbon has been explored as an alternative to C18 due to its superior chemical and
physical stability (particularly with regards to pH extremes). GC retains compounds via a mixed-
mode mechanism, involving both charge-dependent/ion-exchange alongside C18-like hydropho-
bic interactions270. It was reasoned that, as phosphopeptides are generally more hydrophilic, this
sorbent (in combination with C18) may improve phosphopeptide retention in the desalting stage.
To test these two hypotheses, twelve independent TiO2 independent extractions (from 500 g di-
gests derived from a pooled MCF7 lysate) were performed. Four extractions were performed using
the on-line methodology, four using the off-line method with C18 only, and four using the off-line
method with C18 and GC. In order to prevent N-formylation in these samples between enrich-
ment and desalting, the samples were acidifed with 10% TFA – this also acting as an ion-pairing
agent in the subsequent desalting stage, therefore aiding the binding of hydrophilic peptides to
the reversed-phase – and were kept at 0 oC. The results of this experiment are presented in Fig
3.4E.
The results shown in Fig 3.4E show that the off-line methodology drastically improved the
specificity of the enrichment (85%, 96%, and 95% for the on-line, off-line (C18), and off-line
(C18+GC) methods respectively). More importantly, as predicted, the C18+GC reversed-phase
sorbent facilitated the recovery of a significantly greater number (approximately 1.6-fold) of unique
phosphopeptide ions than either the on-line or C18-based off-line method, whilst maintaining
specificity. As a result, this method was taken forward for further development.
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Figure 3.4: Decoupling enrichment and desalting improves phosphopeptide recovery. Qualitative comparison of
the “on-line” method as in Fig 3.3, and the newly devised ‘off-line” method. (A) Phosphopeptides are incubated with TiO2
beads and loaded into empty micro-spin columns. (B) The remaining phosphopeptides are eluted from the TiO2 layer using
5% NH4OH, acidified (to a final concentration 10% TFA), and kept at 0 oC. (C-D) Post-acidification, the phosphopeptides
are loaded into a conditioned reversed-phase-containing micro-spin column and desalted (to remove the remaining TFA
and ammonium salts thereof). Error bars represent SEM (n = 4). P-values were determined via a two-tailed Student’s
t-test.
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3.2.3 Optimisation of off-line desalting conditions
Having demonstrated that the off-line desalting method, combined with the C18-+GC sorbent,
improved the yield of phosphopeptides from single extractions, a number of further enrichment
conditions were adjusted in an effort to improve recovery. To this end, the amount of TiO2 added
to the reaction, C18+GC elution conditions, and TiO2 incubation conditions were tested. The
TiO2 and elution conditions were tested at two different concentrations: 25 and 50 g TiO2  g
protein 1 (Fig 3.5A) and 50 and 60% ACN (Fig 3.5B) – both of these comparisons were performed
in quadruplicate. In order to test the loading/incubation conditions for the TiO2, four different
buffers were used: 1M glycolic acid (80% ACN; 5% TFA), 1M glycolic acid (80% ACN; 0%TFA),
2M glycolic acid (80% ACN; 0%TFA), and 2M lactic acid (80% ACN; 0%TFA), as proposed by
Kettenbach and Gerber240 – these comparisons were performed in triplicate.
Figure 3.5: Optimisation of off-line desalting conditions for maximal phosphopeptide recovery. (A) Optimisation of
TiO2 concentration (n = 4). (B) Optimisation of ACN concentration for the elution of phosphopeptides from the C18+GC
layer (n = 4). (C) Optimisation of TiO2 loading buffer conditions (n = 3). Error bars represent SEM. P-values were
determined via a two-tailed Student’s t-test.
The results presented in Fig 3.5A demonstrate that a doubling of the concentration of TiO2
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present in the initial incubation did not result in a doubling of the number of identified phospho-
peptides; however, the number of recovered phosphopeptides did increase significantly (853 vs
1102; P = 0.001). Moreover, this increase did not correspond with a significant increase in non-
phosphopeptides (144 vs 167; P = 0.124), therefore resulting in a slight increase in specificity. As
with the increase in TiO2 concentration, increasing the proportion of ACN in the C18+GC elution
buffer also significantly increased the number of phosphopeptides recovered (Fig 3.5B – 1028 vs
1151; P = 0.0002). Fig 3.5C shows the results from the comparison between TiO2 loading buffers.
These data demonstrate that there was no significant difference between the buffers in terms of
absolute phosphopeptide recovery; however, the number of non-phosphopeptides, and therefore
the specificity of enrichment, was poorer for those samples enriched in 1M glycolic acid without
the presence of TFA. The specificity of enrichment was restored however, when a higher concen-
tration of glycolic acid or lactic acid were used. Alongside these findings, it was observed that the
variability in phosphopeptide recovery was higher for those samples enriched in the presence of
2M lactic acid.
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3.2.4 Effects of removing phosphopeptide acidification
As previously discussed, the purpose of the acidification of the phosphopeptides is to neutralise
the NH4OH used to elute them from the TiO2 beads, so as to prevent the loss of phosphate groups
through -elimination (i.e. base hydrolysis). Following discussions with Dr N. Morrice (University
of Dundee)271 however, it was postulated that the rate of -elimination of phosphopeptides is
only significant in the presence of high pH (> 12) and a strong base (e.g. Ba(OH)2 [pKb  -
2.0], compared to pKb  4.8 for NH4OH), and at temperatures greater than those experienced
by the phosphopeptides at any stage during the enrichment process. Moreover, snap-freezing
(on CO2(s)) prior to vacuum drying, further prevents any potential base hydrolysis of phosphate
groups and encourages sublimation of the volatile ammonium compound.
As a result of these discussions, it was hypothesised that the acidification step, and therefore
the desalting of the peptides via C18+GC, was both unnecessary and may result in the loss of
acidic phosphopeptides. This loss of acidic phosphopeptides occurs as, at low pH, acidic groups
shift towards a state of higher protonation and are therefore less hydrophilic271. Alongside the loss
of acidic phosphopeptides, the desalting step may result in loss of peptides both from increased
contact of the peptides with plastics, and from those that bind and cannot be eluted from the
C18+GC layer. To explore this hypothesis, an experiment was designed to compare the off-line
desalt method (as in Fig 3.4) with one devoid of acidification and the consequential desalting
step. To this end, triplicate 500 g digests prepared from a single pooled MCF7 lysate were
either enriched as per the off-line desalt method, or by means of an identical TiO2 enrichment
immediately followed by vacuum drying, with or without snap-freezing (Fig 3.6A-B). The results of
this comparison are shown in Fig 3.6C.
Fig 3.6C demonstrates that the removal of the acidification steps in the protocol had no de-
tectable effect on the absolute number of phosphopeptides recovered; however, the data showed
a trend towards a decrease in phosphopeptide identifications when the samples were not snap-
frozen immediately prior to vacuum-drying (1636 vs 1541, snap-frozen vs non-snap-frozen; P =
0.075). Despite no discernible difference in phosphopeptide identifications, the size of the peptide
pellet recovered post-vacuum drying was much larger for those samples that were not acidified
compared to those processed using off-line desalt method (data not shown). Moreover, a compar-
ison of the chromatograms produced from off-line and no acidification (with snap-freezing) method
demonstrated that, although both samples were similarly complex in the hydrophilic region (5-30
min), the latter showed much more complexity in the hydrophobic region of the chromatogram
(Fig 3.6D, red box). To further investigate the effect of the off-line and new method (no acidifi-
cation with snap-freezing), two phosphopeptide databases were created; one representing the
combined database from the samples processed with the off-line and one representing the com-
bined database for the samples processed with the new method. The peptide length, number of
ionisable residues (to estimate hydrophilicity), and peptide charge were then computed and the
number of common peptide identifications compared – this analysis is shown in Fig 3.7.
The analysis presented in Fig 3.7 demonstrates that removal of the acidification and desalting
steps in the phospho-enrichment resulted in the recovery of significantly longer phosphopeptides
(Fig 3.7A) and those that contained a greater proportion of ionisable residues (Fig 3.7B). The
quantile-quantile plots presented in Fig 3.7C-D provide further evidence to suggest that these
data are indeed from different distributions (as they do not conform to y = x [red line]). Fur-
thermore, the extent of overlap in peptide identifications between the two methods was approxi-
mately 43%, suggesting that they enrich for subtly different populations of phosphopeptides (Fig
3.7E). In concordance with these observations and as hypothesised, the removal of acidification
80
Figure 3.6: Removal of phosphopeptide acidification has no impact of phosphopeptide recovery, therefore
streamlining the method. (A) Following incubation of the total peptide mixture with TiO2, the beads are loaded into empty
micro-spin columns and washed with phosphopeptide excluders. (B) The remaining phosphopeptides are then sequen-
tially eluted with NH4OH and immediately vacuum-dried (with or without prior snap-freezing on CO2(s)). (C) Comparison of
the number of phosphopeptides recovered via the off-line desalt method and methods involving the direct vacuum-drying
of the unacidified phosphopeptide eluate snap-freezing. Red, phosphopeptides; blue, non-phosphopeptides. Error bars
represent SEM (n = 3). P-values were determined via a two-tailed Student’s t-test. (D) Representative chromatograms
(normalised to the base peak) of a sample enriched using the off-line method (upper panel) and one enriched without
acidification, with snap-freezing (lower panel). BPI, base peak intensity.
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Figure 3.7: Removal of phosphopeptide acidification results in the recovery of longer and more highly charged
phosphopeptides. (A) Probability density function of peptide length for combined databases of the samples processed
using the off-line method (red) or those processed using the no acidification and snap-freeze method (blue). (B) Probability
density function of the number of ionisable residues within each phosphopeptide for the samples as in (A). (C) Quantile-
quantile plot for the peptide length distributions as in (A). Red line(s) represents y = x. (D) Quantile-quantile plot for the
proportion of ionisable residue distributions as in (B) P-values were determined via a two-sample Mann-Whitney test. (E)
Venn diagram showing the overlap in phosphopeptide identifications between the off-line and no acidification methods. (F)
Distribution of charge states for the identified phosphopeptides, expressed relative to the total number of identifications.
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steps/desalting resulted in the recovered phosphopeptides possessing higher charge states (Fig
3.7F). Taken together, these data suggest that the removal of acidification and desalting, whilst
drastically streamlining the protocol (reducing potential sources of error/peptide loss) and reduc-
ing the material cost per enrichment, has no effect on the net recovery of phosphopeptides.
3.3 Comparison of mass spectrometric methods for phosphoproteomics
Alongside the importance of sample processing methods, the optimisation of mass spectrometric
methods used for phosphoproteomics experiments is also key to the optimal detection and se-
quencing of phosphopeptide ions. As discussed in Chapter 1, such methods include altering the
fragmentation technique at the MS2 level (e.g. CID-MSA, ECD, HCD, EThcD, etc.) or altering the
data-dependent selection of precursor ions (e.g. DIA or exclusion lists). The impact of these on
phosphopeptide identifications will be discussed in the following sections.
3.3.1 Effects of gas-phase fractionation on precursor ion selection
Data-dependent acquisition methods are, despite ever-faster duty cycles, notorious for under-
sampling. A number of techniques have been developed to circumvent this issue, e.g. DIA163,164,
exclusion and inclusion lists272, and gas-phase fractionation273. Gas-phase fractionation (GPF)
relies on the sampling of different m/z windows for MS2-selection in separate injections of the
same sample. Therefore, alongside being selected based upon their intensities, precursor ions
are only accepted between pre-programmed m/z ranges in each run (Fig 3.8A). Theoretically
then, deeper phosphoproteome coverage is obtained as different populations of precursor ions
are fragmented in each injection, thus reducing redundancy in the MS2 spectra produced273.
This method is particularly attractive with respect to MS1-based quantification methods such as
PESCAL, as the MS1 data produced from each injection are identical (thus forming the routine
quantitative technical replicates), yet phosphoproteome depth and coverage is theoretically in-
creased with no additional analysis time.
In order to assess the impact of GPF on the number of phosphopeptide identifications, an
experiment was designed whereby a single preparation of phosphopeptides was subjected to
six LC-MS/MS injections on the LTQ-Orbitrap-XL mass spectrometer – three operating with full-
scan MS2 selection and three operating with GPF (window 1: m/z 375-625; window 2: m/z 625-
805; and window 3: m/z 805-1800). These m/z windows were chosen on the basis that they
contained equal numbers of ions based upon previously acquired MS2 data generated from MCF7
cells. In each case, the samples were first separated on a 45 min gradient (5-35% ACN) and the
ions fragmented by CID-MSA (top 3). This experiment was then repeated to produce technical
duplicates. The results of this experiment are presented in Fig 3.8.
To confirm that the mass spectrometer was indeed only selecting precursor ions for fragmen-
tation within certain m/z windows, the m/z distributions of the phosphopeptide ions identified in
each injection were analysed. These data demonstrate that the instrument was indeed effective
at fractionating the precursor ions selected for fragmentation, as only precursors between the
specified ranges were identified in each injection when operated in GPF mode (Fig 3.8B). On the
contrary, the injections operated in full-scan mode identified phosphopeptide ions across the full
m/z range (Fig 3.8C). Despite the ability of the instrument to effectively fractionate peptide ions
selected for MS2 in the gas-phase, significantly fewer identifications were made in those samples
that were run in GPF mode compared to three identical injections operating with full-scan MS2
selection (Fig 3.8D; P = 0.021). Although fewer identifications were made, it was hypothesised
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Figure 3.8: Gas-phase fractionation results in fewer phosphopeptide identifications. (A) Schematic of the principles
of GPF. The sample is injected n times (in this case three). In each injection, identical MS1 data are obtained (m/z a-d);
however, different windows of precursor ion m/z-ratios are selected for MS2 fragmentation in each injection (e.g. only
precursor ions between m/z a-b are accepted for MS2 in injection 1). (B) The distribution of identified precursor ion
m/z-ratios in each injection when operated in GPF mode. (C) The precursor ion m/z distribution for each injection when
operated in full-scan mode. (D) The mean number of unique phosphopeptide ions identified in combined databases of all
three technical replicates for full-scan and GPF-based MS2 precursor selection (n = 2). Error bars represent the maximum
and minimum value. (E) Venn diagram illustrating the overlap between phosphopeptide identifications made in each set
of three injections. Each circle represents a combined database of the three injections performed for each scan mode
(with two replicates per scan mode). (F) and (G) Top N spacing distributions for the samples run with GPF and full-scan
precursor selection respectively. Window 1, m/z 375-625; window 2, m/z 625-805; window 3, m/z 805-1800.
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that in GPF mode, the instrument samples a different population of phosphopeptides, as low in-
tensity peptides that may be ignored in full-scan mode, are selected for fragmentation. Therefore,
if the instrument was indeed sampling different populations to those ions observed in full-scan
mode, the overlap in identifications between the two modes would be minimal. To assess this, the
overlap in phosphopeptide identifications between combined databases of the three injections for
each scan mode were compared (Fig 3.8E). These data show that, as expected for technical
replicates274, the overlap in identifications between replicates in full-scan mode was 69% (Fig
3.8E, purple circles) and 75% in GPF mode (Fig 3.8E, orange circles). The overall overlap be-
tween the identifications made between GPF and full-scan mode was 74%, suggesting that the
unique identifications observed in GPF mode (a total of 799 between GPF 1 and 2) were more
likely to be as a result of under-sampling, as opposed to the sampling of a unique population of
ions. Further analysis of the top N spacing distributions of samples run with GPF and full-scan
precursor selection revealed that the GPF precursor ion MS1 scans rarely triggered the maximum
of three MS2 scans, as the distribution was shifted towards only one MS2 scan (Fig 3.8F). This
was most prominent for the third m/z window, suggesting that this was the least populated with
multiply charged peptide ions amenable for selection for fragmentation. Conversely, the majority
of the full-scan injections triggered the maximum of three MS2 scans between each MS1 scan
(Fig 3.8G).
3.3.2 Comparison of CID-MSA and HCD for phosphopeptide fragmentation
Several studies have investigated the utility of different fragmentation methods for phosphopro-
teomics experiments248–250,275. In order to optimise the fragmentation methods with those avail-
able to the Cutillas lab however, the utility of HCD and CID-MSA for single-shot, global phospho-
proteomics experiments was assessed. To this end, four TiO2 extractions (from four independent
500 g digests derived from a pooled MCF7 lysate) were run on an LTQ-Orbitrap-Velos instru-
ment connected on-line to a Thermo EASY-nLC. Each sample was injected four times, separated
over a three hour gradient (5-35% ACN), and each injection subjected to a different ion activation
method: CID-MSA (top 10), CID-MSA (top 15), HCD (top 7), and HCD (top 10). The resulting
CID-MSA and HCD data were searched against the Uniprot/Swissprot human database as per
previous experiments (10 ppm precursor ion tolerance); however, the HCD data were searched
with a fragment ion tolerance of 50 mmu, as opposed to 600 mmu for the CID-MSA data. The
results of this comparison are presented in Fig 3.9.
The data shown in Fig 3.9A demonstrate that a significantly greater number of phosphopep-
tides were identified in those samples sequenced using CID-MSA compared to those sequenced
using HCD, regardless of top N spacing (P = 0.001 [CID10 vs HCD7]; P = 0.001 [CID10 vs
HCD10]; P = 0.0006 [CID15 vs HCD7]; P = 0.0005 [CID15 vs HCD10]). Interestingly, although
the data show a slight trend towards an increase, the number of identifications did not increase
significantly with an increase in the maximum number of MS2 scans permitted between each
MS1 scan (Fig 3.9A). Despite the lower total number of phosphopeptides identified using HCD,
a comparison of the distributions of Mascot delta scores (; the higher the score, the greater the
confidence in phosphosite localisation) revealed that a greater proportion of the identified phos-
phopeptides possessed a more confident assignment of the phosphosite location – 44.1% and
53.5% possessing a  > 10 with CID-MSA and HCD respectively (Fig 3.9B). In-line with this ob-
servation, analysis of the Mascot peptide score distributions revealed that HCD produced peptides
with higher average Mascot scores (1=2 = 37.82) compared to those sequenced using CID-MSA
(1=2 = 30.09), therefore providing greater confidence in the assigned peptide identities (Fig 3.9C).
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Figure 3.9: HCD ion activation identifies fewer phosphopeptides than CID-MSA. (A) The mean number of unique
phosphopeptide ions identified using each ion activation method. Error bars represent SEM (n = 4). P-values were
determined via a two-tailed Student’s t-test. (B) and (C) Relative frequency distributions of Mascot delta and peptide
scores in combined phosphopeptide databases from all the samples run in either CID-MSA or HCD mode, respectively.
(D) Venn diagram illustrating the overlap in identifications made using the two fragmentation modes.
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Finally, a comparison of the unique phosphopeptide ion identifications made using each method
demonstrated that the large majority of those identified in HCD mode were also identified using
CID-MSA (Fig 3.9D), suggesting that the differences observed were more likely to have been as
a result of under-sampling in the CID-MSA runs.
3.4 Conclusions
Several modifications to the original phosphopeptide enrichment protocol were proposed and
experiments designed to test their efficacy (Figs 3.1-3.7). Furthermore, several mass spectromet-
ric methods for phosphopeptide precursor ion selection and fragmentation were compared (Figs
3.8 and 3.9). The overall aim of these investigations was to increase the depth of phosphopro-
teome coverage in single-shot enrichments of whole-cell lysates, increase the robustness and
efficiency of the enrichment protocol, and to reduce the frequency of unwanted modifications (i.e.
N-formylation).
Initially, a series of experiments were performed to determine the effect of an on-line desalting
method on phosphopeptide recovery and subsequent modifications to this method. These data
demonstrated that the on-line method resulted in the recovery a significantly larger amount of
phosphopeptides and dramatically reduced the frequency of N-formylation (Fig 3.2). The speci-
ficity of the enrichment, however, was significantly poorer than the original method, as there
was a concomitant increase in non-phosphopeptide identifications. It was subsequently hypoth-
esised that an additional salt wash (100 mM ammonium acetate; 25% ACN) might result in an
increased specificity of phosphopeptide enrichment. An experiment comparing the first iteration
of the on-line method and that with an additional wash demonstrated no significant difference in
the specificity of the enrichment (Fig 3.3). This, however, may have been a result of the non-
phosphopeptides being removed from the TiO2, but subsequently binding to the C18 layer due
to the concentration of ACN not being sufficient to exclude this. To this end, and based on prior
findings141, the ammonium acetate wash was kept in the protocol for the later modifications.
To further investigate protocol modifications that may increase specificity whilst not reducing
yield, an off-line desalting method was proposed, whereby the TiO2 enrichment and subsequent
desalting steps were decoupled. Alongside this, the effect of a more retentive sorbent (C18+GC)
on phosphopeptide yield was also tested (Fig 3.4). These data demonstrated that the off-line
method, combined with the C18+GC sorbent for subsequent desalting, drastically improved both
the specificity of the enrichment alongside increasing the yield of phosphopeptides by approx-
imately 1.6-fold. As a result of these data, the off-line method was taken forward for further
testing.
After having demonstrated the success of the off-line method in improving both specificity and
yield of single-shot phosphopeptide enrichments, a number of parameters were adjusted and their
effect on the enrichment assessed. To this end, the concentration of TiO2 in the initial incubation,
the concentration of ACN in the elution buffer, and the several different TiO2 loading buffers were
optimised (Fig 3.5). These experiments showed that doubling the concentration of TiO2 in the ini-
tial incubation, whilst not doubling the identifications that could be made, did significantly increase
the number of identified phosphopeptides (Fig 3.5A). Furthermore, it was observed that a 10%
increase in the proportion of ACN in the C18+GC elution buffer also significantly increased the
number of identifications (Fig 3.5B). Contrary to the data published by Kettenbach and Gerber240,
the presence of TFA (5%) in the loading buffer had a positive effect on the number of recovered
phosphopeptides, although an increase the concentration of the relevant -hydroxy acid rescued
this effect (Fig 3.5C). Taken together, out of the conditions tested, these data suggested that 50
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g TiO2 g protein 1, 60% ACN, and 1M glycolic acid (80%; 5% TFA) were the optimal conditions
for maximal phosphopeptide recovery.
Despite the optimisation and success of the off-line method, a more time-efficient and ro-
bust protocol with less reliance on multiple sorbents (therefore increasing the chances of peptide
loss/sorbent failure and introducing potential sources of error) remained desirable. Indeed, in or-
der to remove the reliance on the desalting step, the acidification of the phosphopeptide eluents
from the TiO2 would have to be removed (to avoid N-formylation). It was hypothesised, however,
that due to the lack of a strong base (e.g. Ba(OH)2) and lack of high temperatures experienced by
the phosphopeptides at any stage of the protocol, the rate of -elimination of phosphate groups in
the NH4OH elution buffer would be insignificant. In order to test this, an experiment was designed
to compare the off-line method with a method devoid of acidification (and therefore the desalting
step), with or without snap-freezing prior to vacuum drying (Fig 3.6). These data demonstrated
that the number of recovered phosphopeptides was not affected (Fig 3.6C), despite there being
a visibly larger phosphopeptide pellet following vacuum drying with the new method. This new
method, however, resulted in the enrichment of a different subset of the phosphoproteome – this
manifesting itself in the greater proportion of longer and more highly charged phosphopeptides
(Fig 1.7). Due to its increased robustness, lower material cost, and more time-efficient nature,
this method was taken forward for all future experiments.
Having optimised the method by which phosphopeptides can be enriched for the phosphopro-
teomics experiments described in this work, the efficacy of various mass spectrometric methods
for the sequencing of these peptides were investigated. Firstly, the effectiveness of gas-phase
fractionation was assessed. These experiments demonstrated that gas-phase fractionation, de-
spite being applied successfully, was not as efficacious as full-scan MS2 precursor selection for
the identification of phosphopeptides (Fig 3.8). As a result, full-scan MS2 precursor ion selection
was the method employed for future work. Alongside alternative precursor ion selection modes,
the methods by which precursor ions were fragmented, namely CID-MSA and HCD, were also
compared. This experiment demonstrated that a greater number of identifications were made
using CID-MSA; however, HCD data provided a slight increase in the proportion of identifica-
tions with high confidence phosphosite localisations (i.e.  > 10) and peptide identifications (Fig
3.9). Taken together, in order to increase the depth of single-shot analyses, CID-MSA was the
fragmentation method taken forward for future experiments.
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Chapter 4
Empirical determination of a kinase signalling
network
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4.1 Introduction and aims of the study
The results presented in Chapter 3 outlined the improvement and development of a robust and effi-
cacious protocol for the enrichment of phosphopeptides from complex biological matrices, along-
side the optimisation of mass spectrometric methods for the identification of phosphopeptides.
Having finalised these methods and increased the depth of coverage of the phosphoproteome
analysed in each experiment as a result, it was then possible to proceed with the empirical deter-
mination of the topology a kinase signalling network in an untargeted manner.
Kinase signalling networks, through the orchestrated flux of phosphorylation events, regulate a
plethora of core biological processes (e.g. protein synthesis and responses to external stimuli)276
and the translation of cell-cell interactions into functional outcomes (e.g. immunological and neu-
rological signalling)277,278. Disruption of these networks has been shown to be implicated in the
pathogenesis of several diseases. The pathways that lie within these signalling networks are often
conceptualised as being linear and mono-directional. Concurrent with advances in the theoretical
understanding of networks, and the technologies that allow their interrogation, however, these
pathways have been better placed in the contexts in which they operate. Consequently, it has be-
come increasingly appreciated that signalling pathways do not signal in isolation, but rather form
compact, functional modules of large and highly inter-connected networks123,279.
Two key properties of kinase signalling networks that facilitate their functional output are: their
topology (i.e. how nodes are connected) and their plasticity (i.e. how the nodes can alter their
interactions in response to perturbations). The highly evolved and complex topology of signalling
networks confers them with the ability to change their output signals in response to changes in
their environment. This phenomenon, often referred to as plasticity, has clear implications in the
pathogenesis of multiple diseases (e.g. cancers and metabolic disorders), whereby cells have
been shown to alter which stimuli they respond to and their signalling output (e.g. in a hypoxic
environment at the core of a tumour, or in response to targeted kinase inhibition)124.
Several methods have been developed to allow the investigation of network topology in bio-
logical systems. The majority of these involve the measurement of protein kinase/phosphatase
signalling outputs and the inference of the network’s topology from these data, on both small and
large scales280–282. Mass spectrometry-based phosphoproteomics, and developments thereof,
have been instrumental in increasing the tractability of such experiments, particularly label-free
methods that facilitate the comparison of the large numbers of experimental conditions required.
The aim of the work presented in this Chapter was to empirically define the topology a kinase
signalling network in MCF7 cells without any preconceptions of how the kinases interacted with
one another. The definition of this network’s topology would then allow unbiased investigation of
its plasticity in these cells under different environmental conditions in an untargeted manner. To
achieve this, a panel of structurally distinct, small-molecule kinase and phosphatase inhibitors was
selected. The kinases targeted in the experiment were based on their known importance in cellu-
lar signalling and current clinical relevance. Critically, two inhibitors were selected for each kinase,
so as to allow an estimation and reduction of the impact of the off-target effects of the compounds.
Two inhibitors against the Ser/Thr phosphatase PP2A were included to provide a positive control,
as the phosphopeptides reduced in abundance by the kinase inhibitors should demonstrate an
increase in abundance upon treatment with inhibitors of PP2A. The global phosphoproteomes of
MCF7 cells treated with these inhibitors were then quantitatively analysed by means of a label-
free mass spectrometry-based phosphoproteomics strategy on an LTQ-Orbitrap-Velos instrument
(Fig 4.1).
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Figure 4.1: The experimental design used to empirically define the topology of a kinase signalling network. MCF7
cells were cultured and treated with one of the twenty-two inhibitors (Table 2.3) or DMSO control. The cells were then lysed,
proteins digested, and phosphopeptides enriched using TiO2 beads. Each sample was then subjected to nLC-MS/MS in
triplicate. This experiment was repeated in its entirety to provide two biological replicates. The MS data were searched
against the Uniprot/Swissprot database using Mascot and the resulting data combined into a single phosphopeptide
database. Each phosphopeptide in the database was then quantified in each sample using PESCAL and the quantitative
data analysed using limma (within the R statistical computing environment).
4.2 Qualitative data analysis and quality controls
Before proceeding to the quantitative analysis of the dataset produced from the experiment out-
lined in Fig 4.1, qualitative and quality control analyses were performed. The results of these are
shown in Fig 4.2.
Combining the identifications made from each of the 144 nLC-MS/MS runs performed for this
experiment produced a database of 13,405 unique phosphopeptide ions (FDR < 5%). Fig 4.2A
shows the distribution of q-values for these 13,405 phosphopeptides – this demonstrating that
95% of the phosphopeptides possessed a q-value < 0.01, providing high confidence in their
assigned identity. Out of these 13,405 identifications, 11,129 and 8,397 possessed  > 5 and >
10, respectively, thus providing high confidence in their assigned phosphosite localisation.
Prior to label-free quantification using PESCAL, the sample specific retention times of each
phosphopeptide ion present within the database were predicted through the use of linear models
formed by pairwise alignment of spiked enolase peptide internal standard retention times. Fig
4.2B demonstrates the strongly linear relationship observed between these peptides’ retention
times between two independent samples. This highlighted that a linear model adequately de-
scribed the relationship between two samples’ enolase peptide retention times and that these
peptides maintain the same relative elution order despite small retention time shifts. Assessing
the strength of linear alignments between each pair of samples by means of a correlation matrix
showed that this was a robust phenomenon (Fig 4.2C).
Following retention time prediction and subsequent label-free quantification of each phospho-
peptide ion present within this database, the data were log2-transformed (Fig 4.2D, upper panel)
and quantile normalised (Fig 4.2D, lower panel). This analysis demonstrated that the phospho-
peptide intensities were approximately normally distributed (in log-space), thus lending them-
selves to the subsequent parametric statistical analyses. Moreover, these visualisations showed
that quantile normalisation adequately normalised the intensity distributions between nLC-MS/MS
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runs and conditions, thereby aiding in the removal of the majority of technical variability265. Finally,
analysing the variability of enolase peptide retention times over the course of the 144 nLC-MS/MS
runs (Fig 4.2E) revealed that, even following many sequential injections, the peptides maintained
very similar retention times and identical relative elution orders. This served to provide signifi-
cant confidence in the reliability of the quantitative data, as label-free methods are dependent on
robust LC separations.
Figure 4.2: Quality control analyses of the network determination MS data. (A) Distribution of q-values for the
identified phosphopeptides contained within the combined database created from the 144 MS runs. (B) Representative
pairwise alignment of enolase ion retention times used to predict phosphopeptide retention times in samples where the
phosphopeptide was not identified. (C) Distribution of Pearson’s r values for each pairwise enolase ion retention align-
ment. (D) Upper panel: box plots demonstrating the distribution of log2-transformed phosphopeptide peak intensities
pre-normalisation. Lower panel: log2 phosphopeptide peak intensities distributions post-quantile normalisation. (E) Eno-
lase ion retention time vs sample (in chronological order of nLC-MS/MS run). Each line represents an individual enolase
ion.
4.3 Quantitative data analysis
4.3.1 Differential abundance
Following the log2-transformation and quantile normalisation of the phosphopeptide peak inten-
sities, the magnitude and statistical significance of changes in individual phosphopeptides’ abun-
dances were assessed using a linear modelling strategy and empirical Baye’s shrinkage of stan-
dard deviations262,266. Multiple designs for the linear model applied to the data were tested;
however, the final design (selected based on Akaike’s Information Criterion) included a single
DMSO control factor, a factor for each inhibitor treatment, and a factor for the biological replicates
present in the experiment. The correlations between the technical triplicates were also included in
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the model. Table 4.1 shows the results of this analysis, displaying the number of phosphopeptides
found to be significantly up-regulated (log2 fold-ratio > 0; adjusted P  0.05) and down-regulated
(log2 fold-ratio < 0; adjusted P  0.05). These data highlighted the large discrepancy between the
proportion of the measured phosphoproteome affected by each compound, particularly regarding
inhibitors targeting the same kinase (e.g. Akt inhibitor VIII and MK-2206).
Compound/inhibitor Reference FR< 0; adjusted P
 0.05
FR> 0; adjusted P
 0.05
Akt VIII Akt1 1784 245
MK-2206 Akt2 684 228
KN-93 CAMK21 348 101
KN-62 CAMK22 211 152
PD-168393 EGFR1 370 36
PD-153035 EGFR2 162 30
ERK I ERK1 319 73
ERK II ERK2 263 37
GSK-1120212 MEK1 68 12
U0126 MEK2 33 15
KU-0063794 mTOR1 295 58
Torin-1 mTOR2 339 117
PF-4708671 p70S6K1 373 109
DG2 p70S6K2 343 163
GDC-0941 PI3K1 304 137
PI-103 PI3K2 404 175
Go¨-6796 PKC1 249 65
BIM-1 PKC2 219 52
Okadaic acid PP2A1 2447 1477
Cantharidic acid PP2A2 457 247
H-1152 ROCK1 267 27
Y-27632 ROCK2 111 28
Table 4.1: The results of differential abundance analysis using limma. The number of phosphopeptides either signifi-
cantly increased or decreased in abundance compared to DMSO are shown (ntotal = 10,596). FR, log2 fold-ratio vs DMSO
control; adjusted P, Benjamini-Hochberg multiple testing corrected P-value derived from a moderated t-test.
To confirm that the inhibitors were having the expected effects on the kinases they targeted,
Western blots were performed for phosphorylation sites on known substrates of the target ki-
nases/phosphatase (where reliable reagents were available). MCF7 cells were first starved for
24h in serum-free medium. The cells were then either stimulated for 1 hour with FBS, with or
without the compound of interest, or left in starvation medium. The resulting data, shown in Fig
4.3, demonstrated that the inhibitors of the indicated kinases/phosphatase were having the de-
sired effect on their downstream substrates. For example, the two mTOR inhibitors abrogated the
phosphorylation of p70S6K (Thr389) and the two PI3K inhibitors prevented the phosphorylation of
Akt (Ser473). Consistent with the greater effect on the phosphoproteome observed in quantitative
MS data (Table 4.1), PP2A1 (okadaic acid) had a more substantial effect on the phosphorylation
of Akt (Ser473) than PP2A2 (cantharidic acid). These data served to highlight that these inhibitors
were indeed inhibiting their target kinases in the concentrations used in the experiment, therefore
providing further confidence in validity of the MS data.
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Figure 4.3: Inhibition of the target kinases/phosphatase reduces the abundance of their known downstream tar-
gets. Western blots for known downstream substrates of the indicated kinases. The loading control is total glyceraldehyde-
3-phosphate dehydrogenase (GADPH) in each case. The inhibitor reference names are as shown in Table 4.1.
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4.3.2 Examination of kinase inhibitor relationships
In order to determine the relationships between the kinase and phosphatase inhibitors with re-
spects to their inhibitory effects on the MCF7 phosphoproteome, the dataset was filtered to only
include phosphopeptides that demonstrated a significant (adjusted P  0.05) decrease in abun-
dance upon treatment with at least one inhibitor. This process resulted in a refined dataset of
4,651 phosphopeptides (out of the total 10,596 with reliable quantification data).
To analyse the relationships between the effects of each inhibitor treatment on the phospho-
proteome, principal component (PC), correlation matrix, and hierarchical clustering analyses were
performed (Fig 4.4). The principal component analysis of the log2 fold-ratios for the filtered 4,651
phosphopeptides revealed that, as expected, the PP2A inhibitors separated well from the kinase
inhibitors in three-dimensional PC-space (Fig 4.4A). Moreover, this showed that inhibitors directed
against the same kinase were closer to each other in PC-space than to the rest of the inhibitors –
the only exception being the ERK inhibitors. Whilst kinase inhibitors related to the MAPK cascade
(ERK, MEK, and EGFR) separated from those related to the PI3K/mTOR signalling axis (p70S6K,
mTOR, and PI3K), inhibitors of Akt associated more closely in PC-space to ERK, MEK and EGFR,
than to inhibitors against its well-known upstream activator, PI3K. The correlation matrix analysis
reinforced the relationships observed between the Akt, mTOR, and PI3K inhibitors and between
ERK, MEK, and EGFR inhibitor pairs in the PCA (Fig 4.4B; lower triangle, white boxes), as these
alignments demonstrated a robust and statistically significant correlation (Fig 4.4C).
Further analysis of the mean log2 fold-ratios of the consensus phosphorylation motifs repre-
sented in the 4,651 phosphopeptides (using kinase-substrate enrichment analysis [KSEA]97) and
hierarchical clustering of the resulting data also revealed the patterns observed using PCA and
correlation matrices. As such, inhibitors against the same kinase clustered more closely to one
another than to the other inhibitors, and kinases of similar canonical function (e.g. p70S6K, PI3K
and mTOR) clustered together. As with the other analyses, ERK inhibitors were the only excep-
tion to this observation and PP2A inhibitors clustered away from the kinase inhibitors (Fig 4.4D).
Interestingly, this analysis, as observed in Fig 4.4A, demonstrated that Akt had a more similar
impact on these significantly changing phosphopeptides to MAPK-associated kinases than to its
canonical signalling partners mTOR and PI3K.
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Figure 4.4: Analysis of the relationships between the effects of kinase and phosphatase inhibitors on the MCF7
phosphoproteome. (A) Principal component analysis (PCA) of the 4,651 phosphorylation sites whose abundance was
significantly reduced by at least one compound/inhibitor treatment. PC, principal component. (B) Lower triangle: heatmap
representing the Pearson correlation coefficients (r ) between each pairwise alignment of log2 fold-ratios for each inhibitor
treatment. Well-known kinase-kinase relationships are highlighted with white, dashed squares. Upper triangle: scat-
ter plots showing the pairwise alignments between each inhibitor treatment. Red lines indicate the linear model formed
between each treatment (from which the Pearson’s coefficients were derived, as in the lower triangle). Grey ellipses rep-
resent one standard deviation from the mean in both dimensions. (C) Heatmap showing the significance (Holm-adjusted
P-values) of each of the correlation coefficients shown in (B). (D) Hierarchical, unsupervised clustering (Pearson corre-
lation distance metric) of the mean log2 fold-ratios for phosphopeptides containing common consensus phosphorylation
motifs represented in the filtered 4,651 phosphorylation sites.
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4.4 Derivation of compound-target activity markers (CTAMs) from phos-
phoproteomics data
In an effort to to provide an additional level of classification to the dataset, the phosphopeptides
were further grouped according to their quantitative behaviour under treatment with inhibitors tar-
geting the same kinase. To this end, it was hypothesised that phosphopeptides whose abundance
was significantly reduced under treatment with both inhibitors against the same kinase (e.g. Akt1
and Akt2), would represent a subset of phosphorylation sites – enriched for on-target effects of the
inhibitors – which could be conceptualised as markers of both the kinase’s and the compounds’
activities. The identified phosphorylation sites, although not necessarily phosphorylated directly
by the targeted kinase (as they could potentially be substrates of closely related kinase or those
acting downstream) would be readouts of the actual kinases affected by the compound/inhibitor.
These markers were therefore termed compound-target activity markers (CTAMs). Several CTAM
identification criteria were tested, and the number of identified CTAMs for a least one kinase was
affected as a function of these (Fig 4.5).
Figure 4.5: Increasingly stringent criteria reduce the number of CTAMs identified. The number CTAMs identified
under each set of selection criteria. In each case the phosphopeptide in question was required to pass the thresholds in
both inhibitor treatments against the same kinase. FR, log2 fold-ratio; P, Benjamini-Hochberg adjusted P-value; , Mascot
Delta score.
As Fig 4.5 demonstrates, the number of phosphopeptides identified as being CTAMs for at
least one kinase inhibitor pair decreased as the criteria were rendered more stringent (both in
terms of magnitude change and statistical significance). The final thresholds were arrived at
through a number of logical deductions. First, It was reasoned that, in order to reduce the number
of false positive CTAMs (in terms of phosphorylation site localisation) it was deemed reasonable,
despite the resulting loss of identified CTAMs, to impose a -score threshold. A threshold of   5
reduced the number of identified CTAMs by approximately 13-15%, but increased the confidence
in the phosphorylation site localisation in the remaining peptides. Second, it was postulated that
true CTAMs of the kinases targeted in the experiment would represent those that underwent sub-
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stantial and robust decreases in their abundance. Therefore, phosphopeptides that possessed a
log2 fold-ratio -1 and an adjusted P  0.1, alongside those with a smaller (log2 fold-ratio -0.75)
but more robust change (adjusted P  0.05), were selected. The introduction of these extra fold-
ratio thresholds reduced the number of identified CTAMs by approximately 8-10%, but increased
the likelihood that the remaining CTAMs truly represented the targeted kinases’/compounds’ ac-
tivities. A schematic and a graphical representation of the final algorithm used to select CTAMs
based on these criteria are shown in Fig 4.6A and B respectively. The data shown in Fig 4.6B
demonstrate the strength of correlation between the log2 fold-ratios for the two Akt inhibitors,
MK-2206 and Akt inhibitor VIII (as shown in Fig 4.4B-C). These data also illustrate, however, the
number of phosphopeptides detected as being reduced in abundance by one or the other inhibitor
only, suggesting that these are off-target effects of the compounds (purple boxes). In conjunction
with this, these data show the different thresholds for marker selection, highlighting the necessity
for the thresholds to be met for both inhibitor treatments for the phosphopeptide to be classed as
a CTAM.
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Figure 4.6: Schematic and graphical representation of the CTAM selection algorithm. (A) Schematic representation
of the algorithm used for CTAM selection. Phosphopeptides (from the 13,405 identified) were serially selected. The log2
fold-ratios and adjusted P-values for each inhibitor pair were then used as the input. Firstly, each phosphopeptide was
required to have a   5. Secondly, the log2 fold-ratios and adjusted P-values were assessed at several thresholds of
magnitude and statistical significance. Finally, only if the phosphopeptide satisfied these criteria for both inhibitors was it
defined as a CTAM. (B) Graphical representation of the algorithm described in (A). Each point represents a phosphopep-
tide under treatment with the two Akt inhibitors, MK-2206 and Akt inhibitor VIII. Grey, not identified as a CTAM; blue, FR
 -0.75 and adjusted P  0.05 for both inhibitors; green, FR  -0.75 and adjusted P  0.05 with one inhibitor and FR 
-1 and adjusted P  0.1 with the other; red, FR  -1 and adjusted P  0.1 with both inhibitors. Purple boxes represent
phosphopeptides whose abundance was only reduced under treatment with one of the two inhibitors.
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4.5 Inference of a kinase signalling network from phosphoproteomics data
The CTAM selection algorithm was applied to each drug pair against each kinase, resulting in
the identification of 610 unique CTAMs (Appendix 1). As previously mentioned, the selection of
inhibited phosphopeptides by structurally distinct compounds targeting the same kinase should
have resulted in CTAM populations enriched in phosphopeptides specific to the intended kinase.
Visualisation of the 610 CTAMs simultaneously, revealed that a large number of these phos-
phopeptides were identified as activity markers of more than one compound-target pair. More-
over, some common patterns of CTAM identity emerged from the dataset (Fig 4.7A). This analysis
demonstrated that the dataset could be utilised in this way to recapitulate known interactions be-
tween kinases (e.g. those phosphopeptides that were identified as markers of Akt, mTOR, and
PI3K) alongside uncovering those that were previously uncharacterised (e.g. Akt-CAMK2). Impor-
tantly, these data could then be used to infer the topology of a kinase signalling network. To this
end, the CTAMs were further classified into CTAM groups, based on the compounds/targets for
which they were found to be activity markers (Appendix 2). A number of known phosphorylation
site substrates of various signalling pathways emerged from this analysis and served as positive
controls (Fig 4.7B). For example, 41 phosphopeptides were identified as CTAMs for Akt, mTOR,
p70S6K, and PI3K. Consistent with previous knowledge, these sites included those on RICTOR
(Thr1135) and KS6B1 (Ser427)43,61. Similarly, sites modulated by Akt, PI3K and mTOR inhibitor
pairs, independent from the p70S6K inhibitor pair, were also identified. These included sites on
GSK3 (Ser9), AKT1S (PRAS40 – Ser183), and Myc (Ser62). Furthermore, phosphorylation sites
on the well-known EGFR and MEK substrates ERK1/2 (MAPK1 Thr185/Tyr187 and MAPK3 Tyr204)
emerged as CTAMs of EGFR and MEK.
In addition to the recapitulation of these well-known kinase signalling cascades, evidence for
the existence of uncharacterised relationships between kinases targeted by the inhibitors, and/or
the inhibitors themselves were also identified. Examples of these include Akt-CAMK2 and mTOR-
PI3K (independent from Akt or p70S6K) as shown Fig 4.8A-B. This analysis also provided ev-
idence for sites that, although being identified as CTAMs of Akt, were unaffected by PI3K and
other inhibitors. Alongside these, PI3K CTAMs independent of Akt and mTOR were also identi-
fied. In total, the 610 CTAMs were further grouped into 55 CTAM groups (Appendix 2).
To assess the relationships between the kinases based on their CTAMs, a PCA was performed
on the log2 fold-ratios for the 610 CTAMs (Fig 4.7C). This analysis, as with those presented in Fig
4.4, showed that inhibitors against the same kinase were closer in PC-space to one another
than to the other compounds and that the PP2A inhibitors (particularly the more potent PP2A1,
okadaic acid) separated clearly from the kinase inhibitors. This analysis also demonstrated that
inhibitors against mTOR-PI3K related kinases and those against MAPK kinases separated in all
three dimensions. Interestingly, the two Akt inhibitors were positioned more closely to the MAPK-
associated kinases (e.g. EGFR and CAMK2) in the first and second PC dimensions (Fig 4.7C,
upper panel); however, inhibitors of Akt were more similar to its canonical activators PI3K and
mTOR in the third PC dimension (Fig 4.7C, lower panel).
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Figure 4.7: Analysis of the relationships between CTAMs and their upstream kinases. (A) Heatmap of the log2
fold-ratios for each of the 610 identified CTAMs under each inhibitor/compound treatment. The dendrogram represents
the unsupervised, hierarchical clustering of the phosphopeptides according to their behaviour under each treatment (Eu-
clidean distance metric). (B) Heatmap of selected phosphopeptides from the 610 CTAMs. Red squares highlight whether
the phosphopeptide was identified as a CTAM for each specific kinase inhibitor pair. The CTAM groups each phosphopep-
tide was identifed as belonging to are shown (* adjusted P  0.05, FR  -0.75; ** adjusted P  0.1, FR  -1; *** adjusted
P  0.01, FR  -1). (C) PCA of the log2 fold-ratios for the 610 CTAMs. Upper panel, PC2 vs PC1; lower panel, PC3 vs
PC1.
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Having defined the CTAMs and the groups of compound-target activities they represent, a
kinase signalling network was then inferred from these data. To achieve this, a binary adjacency
matrix was constructed. This involved the conversion of the quantitative data into a binary format,
whereby an edge between each kinase node and its corresponding CTAM nodes was denoted as
a “1” and those with no association as a “0”. A simplified version of such a matrix is shown in Fig
4.8A. Visualisation of this adjacency matrix as an undirected, bipartite network graph allowed a
further assessment of the way in which the investigated kinases interacted with one another (Fig
4.8B).
Concordant with published data and their canonical associations, Akt, PI3K, mTOR, and
p70S6K inhibitor pairs shared a large number of common CTAMs, and hence grouped together
in two-dimensional space. Similarly, kinases associated with MAPK signalling (EGFR, MEK, and
ERK) also grouped together in the network, alongside the related CAMK2. Most interestingly,
Akt shared a large number of activity markers with both its canonical activators PI3K and mTOR,
and with the MAPK-related kinases. This was observed alongside Akt possessing many activity
markers that were unconnected to any of the other nodes present in the network.
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Figure 4.8: Inference of a kinase signalling network from phosphoproteomics data. Undirected, bipartite network
graph representing the identified CTAMs. Large nodes represent the kinases targeted in the experiment (green, mTOR-
PI3K associated; orange, MAPK-associated; blue, mixed association). Small nodes represent individual phosphopeptides,
coloured according to the CTAM group they belong to. Edges between large and small nodes denote whether the phos-
phopeptide was identified as a CTAM for that kinase.
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4.6 Conclusions
The initial objective of the experiments presented in this Chapter was to utilise the increased
depth of analysis described in Chapter 3 to characterise a kinase signalling network with no prior
knowledge of its topology, whilst simultaneously examining the relationships between previously
well-characterised kinases in an untargeted manner. This was achieved through the use of mass
spectrometry-based phosphoproteomic profiling of MCF7 cells under treatment with a panel of
twenty-two structurally distinct kinase/phosphatase inhibitors (Fig 4.1).
Firstly, through a thorough quality control analysis of the dataset, it was determined that the
data were of high qualitative and quantitative quality (Fig 4.2), both in terms of the identification of
phosphopeptides and the subsequent prediction of their retention times and label-free quantifica-
tion. Based upon previous publications advocating the efficacy of linear models for the analysis of
such datasets283,284, linear models were then fitted to the quantitative data and differential abun-
dance of phosphopeptides (vs DMSO control) assessed by means of empirical Baye’s shrinkage
of standard deviations266 (Table 4.1). This analysis showed that the magnitude in the effects of
each compound on the MCF7 phosphoproteome were highly variable, as some inhibitors caused
statistically significant (adjusted P  0.05) decreases or increases in abundances of large num-
bers of phosphopeptides (e.g. Akt1 and PP2A2) and others had comparatively smaller effects
(e.g. MEK1 and MEK2).
The effects of the inhibitors on their target enzyme was assessed by Western blot (Fig 4.3).
These data showed that, of the inhibitors tested, they each demonstrated a reduction (or increase
in the case of the inhibitors of PP2A) in the abundance of their known downstream substrates’
phosphorylation. This suggested that the inhibitors were efficacious at inhibiting their target ki-
nase/phosphatase, thus providing evidence to support the validity of the MS data generated using
these compounds.
To further assess the relationships between the effects of each inhibitor on the phosphopro-
teome, the data were filtered to only include those phosphopeptides that were significantly re-
duced in abundance by at least one treatment. The similarity between the log2 fold-ratios of the
remaining 4,651 phosphopeptides were then assessed using PC, motif, and correlation matrix
analyses (Fig 4.4). These revealed that, as expected, inhibitors against the same kinase had
more similar quantitative effects on the phosphoproteome than those against other kinases, sug-
gesting that the inhibitors were indeed inhibiting the same kinases. Also, as was hypothesised,
the phosphatase inhibitors had distinctly dissimilar effects from the kinase inhibitors (Fig 4.5A-
D). These methods showed that inhibitors against PI3K, mTOR, and p70S6K had more similar
impacts on the phosphoproteome than the MAPK-associated kinases (CAMK2, ERK, MEK, and
EGFR) as these clustered separately (Fig 4.5D). Interestingly, the Akt inhibitors correlated signif-
icantly with the PI3K and mTOR inhibitors (Fig 4.5B-C); however, they clustered differently and
separated in PC-space (Fig 4.5A and D).
Having analysed the relationships between different kinase inhibitors, the phosphoproteomics
data were classified further in order to characterise compound-target activity markers (CTAMs) of
the kinases targeted in the experiment. These CTAMs were conceptualised to represent activity
markers of both the intended target kinase (both direct and indirect) and the kinases that the com-
pounds actually inhibited. In an effort to deconvolute the off-target effects of the compounds, an
algorithm was designed to select markers based upon their quantitative behaviour with respects to
both inhibitors targeting the same kinase (Figs 4.5 and 4.6A). To this end, filters on the accuracy of
phosphorylation site localisation, statistical significance and magnitude of inhibition were applied
to reduce the presence of false positive identifications (Fig 4.5). This algorithm was assessed
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graphically (Fig 4.6B) and, when applied to each kinase inhibitor pair, led to the identification of
610 CTAMs for at least one kinase/compound pair.
It was observed that a number of the identified CTAMs were identified as markers of more
than one kinase/inhibitor pair (Fig 4.7A). Therefore, in order to infer signalling network circuitry
from these data, these CTAMs were grouped into 55 distinct CTAM groups (e.g. phosphopeptides
that were simultaneously identified as CTAMs of Akt, mTOR, and PI3K, were classified into the
Akt-mTOR-PI3K CTAM group). A number of well-known pathways could be recapitulated from this
analysis, such as the Akt-mTOR-PI3K and EGFR-MEK pathways (Fig 4.7B). Alongside these well-
known signalling routes, a number of novel associations were also identified (e.g. Akt-CAMK2,
and mTOR-PI3K bereft of Akt). PCA of the log2 fold-ratios of the 610 markers revealed similar
separation of the kinases in PC-space as those observed in Fig 4.4A.
Following the identification of these markers and the groups they were classified into, the topol-
ogy of the kinase signalling network they represented in MCF7 cells was inferred. The network
was constructed by conversion of the CTAM membership data into a binary adjacency matrix (Fig
4.8A) and subsequent drawing of this in two-dimensional space as an undirected, force-directed,
bipartite network graph (Fig 4.8B). Visualisation of the data in this manner revealed that as would
be expected from their canonical association with one another, mTOR, PI3K, and p70S6K shared
a large number of CTAMs. Furthermore, the MAPK-associated kinases also shared a number
of CTAMs with each other and thus formed a cluster in two-dimensional space. As would be
expected from canonical knowledge, Akt shared a large number of markers with its well-known
upstream activators mTOR and PI3K; however, it also shared a large number with the MAPK-
associated kinases and CAMK2. Moreover, Akt possessed a large number of CTAMs that were
not shared with any of the other kinases targeted in the experiment, perhaps suggesting a more
substantial role outside of PI3K/mTOR and MAPK signalling than has previously been appreci-
ated.
In summary, mass spectrometry-based phosphoproteomics data was used to define a kinase
network signalling topology in MCF7 cells. These experiments were able to recapitulate both
known interactions between well-known kinases and signalling pathways, whilst also uncovering
novel relationships between these. It remained to be proven, however, whether this network
was biologically relevant and whether it would provide a meaningful output when its activity was
assessed under functional activation of the kinases that it represented.
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Chapter 5
Analysis of signalling network plasticity in
response to network perturbation
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5.1 Introduction and aims of the study
Chapter 4 outlined the derivation of compound-target activity markers, and the subsequent defini-
tion of a kinase signalling network based upon their interactions with one another, in MCF7 cells.
Having finalised the topology of the network, it was then hypothesised that it could be used to as-
sess the global signalling activity of MCF7 cells under any given treatment, without bias towards
which kinases and pathways would be be activated/deactivated. Theoretically then, the cells could
be treated with a stimulus, subjected to nLC-MS/MS-based phosphoproteomics and the activity
of the kinases/pathways within the network determined computationally (as shown in Fig 5.1).
This approach could then be used to monitor changes in the activity the defined kinase signalling
network (i.e. its plasticity) upon acquisition of resistance to chronic treatment with targeted kinase
inhibitors.
Figure 5.1: Untargeted assessment of network activity through the quantitative monitoring of CTAM groups. (A)
A selected portion of the defined CTAM network as shown in Fig 4.7B. (B) In a separate experiment, MCF7 cells are
subjected to an arbitrary treatment and their phosphoproteomes analysed by nLC-MS/MS. The number of CTAMs from
each group identified in this experiment is then determined (m, red). The mean log2 fold-ratio (vs control) of these is then
computed (Sm). The enrichment/activity of each CTAM group is calculated by means of a Z -score (t = mean abundance
of all phosphopeptides in the experiment; t = standard deviation of all phosphopeptides). The statistical significance
of this enrichment is then calculated by computing the probability that a random variable drawn from a standard normal
distribution will be less than or equal to Z (as in refs 97,285)
Epidermal growth factor (EGF) and insulin-like growth factor-1 (IGF-1) are important molecules
in the control of cell growth, metabolism, and proliferation. EGF binds to its cognate receptor
EGFR, which, as discussed in Section 1.1.4, causes EGFR’s autophosphorylation and subse-
quent acute activation of several downstream intracellular signalling pathways (e.g. PI3K/Akt
and MAPKs)286. In contrast, IGF-1 binds to IGF-1R and the insulin receptor (InsR), although
with significantly lower affinity for the latter. IGF-1 is one of the most potent activators of the
PI3K/Akt/mTOR signalling axis and as such, serves to promote growth in a diverse array of cell-
types287. In both cases, once bound to their ligand, the receptors undergo clathrin-mediated
endocytosis, are trafficked through the cell, and are eventually degraded or recycled back to the
plasma membrane288. Consequently, the activation kinetics of the signalling pathways down-
stream of these receptors follow distinct temporal patterns; MAPK signalling showing an acute
increase upon stimulation and Akt signalling demonstrating a slower activation with regards to
EGF, for example286. Due to their roles in cell growth and proliferation, both of these growth fac-
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tors (and their receptors) have been implicated in the development and maintenance of cancers
and other metabolic diseases289,290.
To test whether the network was indeed biologically relevant and could be used to assess net-
work plasticity systematically, an experiment was designed whereby MCF7 cells were starved (0%
FBS DMEM) and then treated with 100 ngmL 1 of either recombinant human epidermal growth
factor (EGF) or insulin-like growth factor-1 (IGF-1), for 0, 5, 10, 30, or 60 minutes. The resulting
lysates were then processed, phospho-enriched and analysed by nLC-MS/MS in triplicate. The
experiment was repeated to produce biological duplicate measurements.
It was postulated that, if the network embodied a true representation of signalling within these
cells, functional activation of the kinases within the network (with growth factors) would result in
measurable and biologically meaningful pertubations within this network. Thus, the aim of the
work shown in this Chapter was to determine whether the output from the CTAM network analysis
recapitulated what is known about the functional activation of these kinase/pathways upon growth
factor stimulation. A quality control analysis for the resulting dataset is shown in Appendix 3.
5.2 Quantitative data analysis
5.2.1 Differential abundance of phosphopeptides over the growth factor time-courses
The quantitative data resulting from the experiment were processed as outlined in Chapters 2 and
4. The final linear model design (selected based on Akaike’s Information Criterion) included a
single t = 0 min control factor, a factor for each time-point, and a factor for the biological replicates
in the experiment. The correlations between the technical triplicates were also included in the
model. Table 5.1 shows the results of this differential abundance analysis, displaying the number
of statistically significant increases and decreases in phosphopeptide abundances. These data
highlighted the differential effects of EGF and IGF-1 on the phosphoproteome at a global level.
The number of significantly decreased phosphopeptides was much greater for those time-points
under IGF-1 treatment compared to those under EGF treatment. Moreover, the difference in the
kinetics of responses was evidenced in the greater number of significantly changing phosphopep-
tides at longer time-points under IGF-1 treatment.
Condition/time-point FR< 0; adjusted P
 0.05
FR> 0; adjusted P
 0.05
EGF (t = 5 min) 260 741
EGF (t = 10 min) 245 862
EGF (t = 30 min) 77 423
EGF (t = 60 min) 42 348
IGF (t = 5 min) 349 792
IGF (t = 10 min) 481 779
IGF (t = 30 min) 1014 796
IGF (t = 60 min) 708 621
Table 5.1: The results of differential abundance analysis using limma. The number of phosphopeptides either sig-
nificantly increased or decreased in abundance compared to t = 0 min are shown (ntotal = 11,029). FR, log2 fold-ratio vs
DMSO control; adjusted P, Benjamini-Hochberg multiple testing corrected P-value derived from a moderated t-test.
5.2.2 Examination of positive controls and validation of MS data
To ensure the mass spectrometry data were of good quality and to provide confidence in the
downstream analyses, a number of positive control phosphorylation sites were extracted from the
data and their temporal profiles analysed (Fig 5.2). As expected, the MS data showed that upon
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EGF stimulation, the MAPK signalling axis underwent substantial increases in phosphorylation
of its members on phosphorylation sites responsible for their activation – the upstream members
RAF1 (Thr641) and SOS1 (Ser1134) and downstream members MEK2 (MAP2K2 Ser226), ERK1/2
(MAPK1 Tyr187/MAPK3 Tyr204), and p90RSK (RPS6KA1 Ser380), for example. Similarly, members
of the PI3K/Akt/mTOR signalling axis also demonstrated the expected temporal kinetics upon both
EGF and IGF-1 stimulation. For example, a phosphorylation site (most probably Ser263) on the
p85 PI3K regulatory subunit (PIK3R2) demonstrated an increase in abundance under both EGF
and IGF-1 stimulation. Interestingly, a phosphorylation site on the closely related p150 regula-
tory subunit (PIK3R4), which interacts with Vps34, also increased in abundance, although this
was restricted to IGF-1 stimulation. Consistent with an activation of PI3K, a phosphorylation site
within the activation loop of Akt1 (residues 466-480) demonstrated a sharp, significant increase
in abundance following 5 min of EGF treatment; however, consistent with IGF-1 being a more
potent activator of this pathway, this increase showed more sustained kinetics with IGF-1 stimu-
lation. In-line with these observations, the abundance of Ser9 on GSK3 (a direct Akt substrate)
also increased under both treatments, although with different kinetics between the two. Further
downstream from Akt, phosphorylation sites on mTOR substrates also increased in abundance,
demonstrating an increase in mTOR activity that would be expected under growth stimulatory
conditions (e.g. RICTOR, p70S6K [RPS6KB1], and eIF4-binding proteins).
To validate the activation of MAPK and PI3K/Akt/mTOR signalling observed in the MS data
generated from this experiment, Western blots were performed for well-known activatory phos-
phorylation sites on both Akt and ERK1/2. The results of this analysis are shown in Fig 5.3.
These data, as with those presented in Fig 5.2, showed that EGF and IGF-1 stimulation resulted
in acute increases in the phosphorylation of Akt and ERK1/2 within 5 minutes of treatment. More-
over, in agreement with the MS data, the increase in the phosphorylation of Akt in its activation
loop was sustained for a longer time period under IGF-1 stimulation. Taken together, these analy-
ses provide evidence to support the notion that the MS data were representative of the canonical
effects of both EGF and IGF-1 in these cells.
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Figure 5.2: Analysis of known downstream phosphorylation sites reveals the expected effects on core signalling
axes upon EGF/IGF-1 stimulation. Heatmap of the log2 fold-ratios (vs t = 0 min) for phosphorylation sites known to be
downstream of the PI3K/Akt/mTOR and MAPK signalling axes. Uniprot protein ID (gene name), phosphorylation sites,
peptide charge, and other peptide modifications are shown. If the -score for the peptide is < 10, the peptide is shown in
the following format: ”protein gene name (sequence residues); charge; modification”.
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Figure 5.3: Validation of known downstream phosphorylation sites by Western blot confirms the MS data obser-
vations. Western blots for activatory phosphorylation sites on Akt and ERK1/2, as indicated. Quantity of the unmodified
proteins and loading control are also shown.
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5.3 Analysis of network plasticity
5.3.1 Temporal behaviour of CTAM groups
Having established that the dataset provided a veritable representation of the EGF and IGF-1-
stimulated signalling in these cells, it was then sought whether the CTAM group network could
be used to measure the biochemical activation of signalling pathways within the network, in an
untargeted manner. It was hypothesised that, should this network provide a reliable readout of
signalling activity, this analysis would show the expected signalling changes when the network was
perturbed under these well-characterised experimental conditions. The CTAM network analysis
was therefore performed on this dataset and the results of this are presented in Fig 5.4.
It was observed that the temporal dynamics of CTAM groups commonly associated with IGF-
1R and EGFR signalling were consistent with previously reported effects of IGF-1 and EGF on
kinase signalling (Fig 5.4A-B)286. For example, in-line with the known activation dynamics of
the MAPK signalling axis and the Western blot analyses (Fig 5.2-5.3), the EGFR-MEK and MEK
CTAM groups underwent acute and significant up-regulation with both EGF and IGF-1 stimulation.
As Fig 5.4 shows, these groups peaked in intensity at 5 min before beginning to return to base-
line after 60 min. Alongside these groups, those characterising PI3K/Akt/mTOR signalling also
demonstrated the expected dynamics. The Akt-PI3K, Akt-mTOR-PI3K, and Akt-mTOR-p70S6K-
PI3K CTAM groups demonstrated a steady increase in activity over the period of stimulation,
peaking in signal at 60 min. Despite both growth factors having a stimulatory impact on these
groups, consistent with the notion that IGF-1 is a more potent activator of these network branches
than EGF, several CTAM groups demonstrated a greater intensity of activation under IGF-1 treat-
ment (e.g. Akt-mTOR, PI3K, Akt-PI3K, and p70S6K-PI3K).
Visualisation of these data in the form of a dotplot more efficiently showed how they could be
used to provide a snapshot of the network’s activity under any given condition. Hierarchical clus-
tering of the time-dependent behaviour of each CTAM group revealed which network branches
signalled in a similar manner to one another in the network (Fig 5.5), and as observed in Figs 5.2-
4, this demonstrated that the core MAPK signalling axis demonstrated similar behaviour between
EGF and IGF-1 (EGFR-MEK and MEK groups). In addition, visualising the data in this way facil-
itated an easier comparison of the differences between the two growth factors; several network
branches showing different temporal behaviours (e.g. Akt-CAMK2-EGFR-p70S6K and p70S6K-
PI3K-PKC-ROCK). To determine more objectively whether the CTAM network model was able
to resolve the differences between the two growth factors, a principal component analysis was
performed on the data shown in Figs 5.4 and 5.5 (Fig 5.6).
The PCA presented in Fig 5.6 shows that the behaviour of the network as a whole was very
similar between EGF and IGF-1 at 5 minutes following stimulation, and this was the time-point at
which the network was most different from 0 minutes (as both points are the furthest from t = 0 min,
yet very similar to one another in PC-space). The state of the network at 10 minutes then began
to highlight the differences between IGF-1 and EGF regarding their effects on the cells’ signalling
(as these began to separate in the second PC dimension). The plot then demonstrates that the
network began to relax towards its basal state (i.e. returning towards 0 in both dimensions);
however, the way in which it proceeded to do this was different between the two growth factors.
In this regard, the network state under EGF stimulation at 60 minutes appeared to be closer to
0 minutes in PC-space than at 60 minutes with IGF-1, suggesting that the activity of the network
returned towards its basal state more rapidly than under treatment with the latter. This was again
consistent with the prior notion, and evidence observed in the other analyses, that IGF-1 has a
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Figure 5.4: Branches of the defined network show substantial plasticity with EGF and IGF-1 stimulation. (A)
Lineplots showing the temporal profiles of the CTAM groups with EGF stimulation (with m  2). (B) Temporal profiles of
CTAM group activities with IGF-1 stimulation (with m  2). Data points represent the mean  SD. * P < 0.05; ** P < 0.01;
*** P < 0.001. P-values determined from a Z -test as outlined in Fig 5.1.
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Figure 5.5: CTAM group profiling allows the capture of network activity at each time-point. Dotplot representing
the temporal profiles of CTAM groups upon EGF and IGF-1 stimulation, as indicated. Each dot represents the mean log2
fold-ratio (vs t = 0 min) for the relevant CTAM group’s constituent phosphopeptides, for each condition. The colour of each
point represents the statistical significance associated with the change in abundance. The dendrogram represents the
unsupervised, hierarchical clustering of the log2 fold-ratios for each CTAM group (Euclidean distance metric). P-values
determined from a Z -test as outlined in Fig 5.1.
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more sustained impact on PI3K/Akt signalling (Fig 5.2-5.4).
Figure 5.6: Principal component analysis of the CTAM network data resolves the late time-point differences in
signalling between EGF and IGF-1. PCA of the time-course data as shown in Fig 5.5. Each point summarises the
behaviour of each of the CTAM groups at the relevant time-point. Points are coloured according to the relevant growth
factor (EGF, green; IGF-1, purple).
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5.3.2 Intra-CTAM group homogeneity
Alongside the observation that the CTAM groups accurately represent the signalling within a sys-
tem under well-known conditions, it was hypothesised that if CTAM groups truly represented the
functional activation of the kinases and pathways they represent, the individual members of each
group should demonstrate similar time-dependent behaviour. Although the error associated with
each calculated mean is displayed in Fig 5.4 (one standard deviation), to assess each CTAM
group’s variability in a systematic manner, the coefficient of variations (CVs) for each CTAM group,
at each time-point, and for each growth factor, were calculated. Plotting the distributions of the re-
sulting values (Fig 5.7) revealed that the median of the aggregated CVs within each CTAM group,
at each time-point, was 0.454 (45%) and 0.518 (52%) for EGF and IGF-1 respectively. These
values, alongside the fact that the majority of the data-points were distributed between 0-1.0 (0-
100%) suggested that the individual phosphopeptides within each CTAM group did indeed follow
similar patterns of abundance as a function of time.
Figure 5.7: Analysis of the variability in CTAM group behaviour reveals intra-group homogeneity in responses.
Histograms representing the distribution of coefficient of variations for each CTAM group under stimulation with each
growth-factor. Red lines represent the median (1=2) in each case. The histograms are coloured according to which
growth factor they represent (EGF, green; IGF-1, purple).
This homogeneity of response is visualised for two CTAM groups, one with a large number
of members (Akt-mTOR-PI3K) and one with fewer (EGFR-MEK), in Fig 5.8. These data lend
support to the notion that the branches of the defined network did in fact represent the functional
activation of the kinases they represent, as the substrates – albeit with a degree of variability –
showed the same trends upon growth factor stimulation. This observation held true in both a
highly and sparsely populated CTAM group (Fig 5.8A and B respectively).
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Figure 5.8: Examples of homogeneity in CTAM response to EGF and IGF-1. (A) Lineplots showing the temporal
profiles of the individual CTAMs within the Akt-mTOR-PI3K group (m = 46) with EGF (green) and IGF-1 stimulation (purple).
(B) Temporal profiles of individual CTAMs within the EGFR-MEK group (m = 4) with EGF and IGF-1 treatment. Red data
points represent the mean of the green/purple data-points at each time-point.
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5.4 Conclusions
A strategy was designed to test the functional relevance of the CTAM groups (and the network
they form) defined in Chapter 4, and to test whether it was possible to assess network activity in
an untargeted and global manner (Fig 5.1). Accordingly, the quantitative dynamics and plasticity
of this network under EGF and IGF-1 stimulation were assessed through the use of label-free
phosphoproteomics.
MCF7 cells were serum-starved and treated with 100 ngmL 1 of either EGF or IGF-1 at five
different time-points. The phosphoproteome of these cells was then analysed by nLC-MS/MS.
Applying a robust statistical framework to the resulting data allowed the extraction of the mag-
nitude and significance of changes in phosphopeptide abundance compared to the cells in a
starved state (Table 5.1). Analysis of known downstream markers of EGFR and IGF-1R ligand
stimulation within the MS dataset revealed that the MS data were able to recapitulate the known
effects of these growth factors on the phosphoproteome (Fig 5.2). Western blots for canonical
activatory phosphorylation sites on Akt and ERK1/2 served to validate that the MS data provided
a faithful representation of the signalling events occurring in these cells upon stimulation (Fig 5.3).
These data also confirmed the differential effects of EGF and IGF-1 on Akt phosphorylation (and
therefore potential activation) observed in the MS data (Figs 5.2 and 5.3).
Following this validation, the quantitative dynamics of the defined CTAM grou-ps were as-
sessed systematically with in-house developed scripts (as outlined in Fig 5.1). Firstly, the CTAMs
identified in the experiment were extracted from the data. CTAM groups with  2 CTAMs iden-
tified (i.e. m) were then taken forward for further analysis. The mean log2 fold-ratio of each
CTAM group (and associated error) was then calculated for each time-point. The statisical sig-
nificance of changes in these CTAM groups was assessed by means of a modified Z -test (Fig
5.1 and ref16). This analysis revealed that many branches of the network exhibited plasticity un-
der stimulatory conditions (Fig 5.4). Consistent with previous studies, this analysis showed that
the network underwent acute and short-lived increases in MAPK-related kinase activities (EGFR-
MEK and MEK). Furthermore, these data showed that the network underwent smaller but more
sustained increases in Akt-mTOR-PI3K pathway activities. Clustering of these data revealed the
network branches that showed similar kinetics of activation/inhibition over the time-course, whilst
also revealing the differences between the responses to the two growth factors (Fig 5.5). In-line
with the data shown in Figs 5.2 and 5.3, IGF-1 appeared to have a larger and more sustained
impact on Akt-mTOR-PI3K signalling than EGF.
The difference in response of the cells to the two growth factors was assessed further using
a principal component analysis. This showed that, alongside the patterns observed in Figs 5.2-
5.5, IGF-1 had a more sustained impact on the phosphoproteome, as the state of the network at
60 minutes after IGF-1 stimulation was further away from the basal state (in PC-space) than the
same time-point with respects to EGF. This revealed that this method of CTAM/network analysis
was not only able to recapitulate the known effects of the growth factors on the phosphoproteome
of MCF7 cells, but also resolve differences between them and provide insight into both EGF and
IGF-1 signalling.
It was postulated that, should the CTAM groups/network branches represent functionally rele-
vant signalling pathways then, alongside their accurate representation of signalling, the individual
members within these groups should demonstrate similar temporal behaviour. To assess this,
the CVs for each of the CTAM groups at each time-point were calculated and their distributions
under both EGF and IGF-1 stimulation analysed (Fig 5.7). This analysis showed that the medians
of these distributions were 45% and 52% for EGF and IGF-1 respectively, suggesting that the
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individual CTAMs did indeed demonstrate intra-group homogeneity in their responses. This was
assessed visually for two CTAM groups; one with a large number of members (Akt-mTOR-PI3K,
m = 46), and one more sparsely populated (EGFR-MEK, m = 4) (Fig 5.8). This demonstrated
the level of homogeneity in response of the individual CTAMs, as the vast majority in both the
Akt-mTOR-PI3K and EGFR-MEK groups followed similar temporal profiles.
Collectively, these data suggested that the defined network, and the conceptual methodol-
ogy by which its activity was measured, allowed the reconstruction of the effects on signalling
caused by EGF and IGF-1 that was consistent with both previous studies and validation with an
orthogonal method. Theoretically then, the defined network could be utilised to accurately assess
kinase signalling in MCF7 cells, without prior knowledge as to the expected effects of the relevant
treatment(s).
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Chapter 6
Signalling network plasticity in models of acquired
resistance to chronic PI3K or mTORC1/2 inhibition
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6.1 Introduction and aims of the study
The results presented in Chapter 5 detailed the utility of the defined network, alongside a com-
putational method, for the accurate assessment of the activity of the kinases within the network
(and the connections between them) in an unbiased manner. It was then reasoned that, to in-
vestigate the effects of chronic inhibition of PI3K and mTORC1/2 and the subsequent acquisition
of resistance, this method would reveal how the network is remodelled under these conditions.
Importantly, this method would be without bias towards a particular signalling node.
The acquisition of resistance to targeted therapies, as discussed in Chapter 1, can occur
through numerous mechanisms. These often include point-mutations on the target kinase(s), re-
sulting in an abrogation of drug affinity whilst maintaining kinase activity. In recent years, however,
numerous studies have demonstrated the ability of the targeted signalling pathway to compensate
for the chronic inhibition of a particular signalling node by up-regulating or modifying downstream
or upstream pathway members106–108,110,112. Alongside these phenomena, it has also been shown
that pathways parallel to that being targeted can also compensate for the loss its activity; often
through the up-regulation of an alternate RTK or cytoplasmic kinase113,119. Despite the uncov-
ering of these mechanisms, it has become increasingly clear that signalling pathways are not as
linear and monodirectional as they are often conceptualised to be. As a result, kinase signalling
has become increasingly appreciated to involve large, highly interconnected networks of kinases
and their substrates, which act in a concerted manner to translate extracellular stimuli into ap-
propriate responses. The remodelling and plasticity of these networks in the context of chronic
kinase inhibition and acquired resistance has not been studied in depth; however, mass spectro-
metric technology has rendered questions of this nature more tractable and less biased towards
particularly well-characterised signalling nodes.
The objective of the experiments presented in this Chapter was to investigate the plasticity of
the signalling network in models of acquired resistance to inhibitors of both PI3K and mTORC1/2.
The ultimate aim of this was to increase our understanding of how kinase signalling changes in
response to chronic inhibition of particular network nodes. To achieve this, a single MCF7 culture
(at low passage number) was homogenised and split into six identical populations of cells. Three
of these new cultures were treated with a gradually increasing concentration of GDC-0941 (pan-
class I PI3K inhibitor) and three with KU-0063794 (mTORC1/2 inhibitor). The initial concentration
of each drug was 100 nM and this was raised by 100 nMpassage 1 to a maximum of 1 M (Fig
6.1).
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Figure 6.1: Generation of models of acquired resistance through the chronic treatment of identical MCF7 cultures
with either GDC-0941 or KU-0063794. Parental MCF7 cells (MCF7-P) were split into six identical cultures. Three
were treated with 100 nM GDC-0941 (MCF7-G1:3, blue) and three with 100 nM KU-0063794 (MCF7-K1:3, green). The
concentration of the drug was increased by 100 nM at each passage of the cells, until a final concentration of 1 M. Each
cell-line was treated identically throughout and the three cultures treated with each drug were maintained at the same
passage number throughout the treatments and subsequent experiments.
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6.2 Defining the sensitivity of parental cells
Prior to the creation of the resistant cell-lines, the sensitivity of the MCF7-P (parental) cells to
the two compounds was determined through the use of an 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The cells were treated with
either compound on a log10 scale between 0.001 and 10 M for 48 hours. The reduction of the
MTS compound through mitochondrial action was then used a proxy for cell viability. The experi-
ment was performed in quadruplicate (Fig 6.2).
The data shown in Fig 6.2 demonstrate that the parental cells were initially sensitive to both
compounds. Fitting third-order polynomial models to the data and solving the relevant equations,
however, showed that the parental cells were more sensitive to GDC-0941 (IC50  162 nM) than
to KU-0063794 (IC50  503 nM).
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Figure 6.2: The parental cells are sensitive to the compound at nM concentrations. (A) Viability of the parental
cells under treatment with GDC-0941. (B) Viability of the parental cells under treatment with KU-0063794. Data-points
represent the mean  SEM (n = 4) relative to DMSO control. Solid lines represent third-order polynomials fitted to the
data. Dashed lines represent the computed IC50 of the relevant compound.
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6.3 Profiling of the resistant cell-lines
6.3.1 Determination of acquired resistance
After having grown the six cell-lines up to a maximum of 1 M of the relevant compound, an exper-
iment was designed to determine whether the cells were indeed resistant to the anti-proliferative
effects of the drugs. To this end, the proliferation in the presence of each drug was compared
between the resistant and parental cell-lines (Fig 6.3). Cells were treated with 1 M of the rele-
vant inhibitor and cultured for 0, 1, 3, or 5 days. The number of viable cells at each time-point
was then measured by means of a Beckman Coulter ViCELL counter as per the manufacturer’s
instructions.
These data served to demonstrate that the resistant cell-lines were indeed resistant to the
compounds they had been treated with, as they were able to proliferate in the presence of drug
where the parental cells were unable to do so (Fig 6.3A-B). Of note, however, the rates of prolifer-
ation were not identical for each cell-line resistant to same drug. For example, MCF7-K1 and K3,
despite still being able to proliferate in the presence of KU-0063794, grew much more slowly than
MCF7-K2 (Fig 6.3B).
The resistance of each of the cell-lines was also assessed by means of the MTS and crystal
violet (CV) cell viability assays (Fig 6.3C-D). These experiments, although performed after only
2 days of treatment, also demonstrated that the cells were able to proliferate in the presence of
the relevant compound where the parental cells were not. The differences in proliferation rates
between the resistant cells were also observed with these techniques, providing further evidence
to suggest that these differences were robust.
Overall, these data showed that the resistant cell-lines were resistant to their respective com-
pounds; however, the cells treated with GDC-0941 were comparatively more resistant than those
treated with KU-0063794 – this being in-line with the observation that the parental cells were
initially less sensitive to treatment with KU-0063794 (Fig 6.2).
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Figure 6.3: The resistant cell-lines are able to proliferate in the presence of their respective inhibitors. (A) Prolif-
eration of the parental and GDC-0941-resistant MCF7 cells in the presence of 1 M GDC-0941. (B) Proliferation of the
parental and KU-0063794-resistant MCF7 cells in the presence of 1 M KU-0063794. Data-points represent the mean 
SD (n = 3). Solid lines represent second order polynomials fitted to the data and are coloured according to the cell-line
they represent. (C) MTS and CV cell viability assays for the parental and GDC-0941-resistant MCF7 cells treated with 1
M GDC-0941 for 48 hours. (D) MTS and CV cell viability assays for the parental and KU-0063794-resistant MCF7 cells
treated with 1 M KU-0063794 for 48 hours. Bars represent the mean  SD (n = 3). Long-dashed and short-dashed lines
represent the parental cell-line’s proliferation as determined by the MTS and CV assays respectively.
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6.3.2 Phosphoproteomic and proteomic profiling of the resistant and pare-ntal models
Having established that the resistant cell-lines were resistant to the anti-proliferative effects of the
two compounds, the changes in the signalling network between the parental and resistant lines
could be compared. To accomplish this, each of the cell-lines was grown in duplicate and their
phosphoproteomes analysed by nLC-MS/MS. For the purposes of this experiment, the parental
cells were grown in 0.1% DMSO and the resistant cell-lines maintained in 1 M of the relevant
inhibitor. Due to the disparate rates of the growth of the resistant cell-lines, the MCF7-G and
MCF7-K cells were processed separately, both with a duplicate MCF7-P control. To control for
changes in expression of the unmodified proteins represented by the identified phosphorylation
sites, the total proteome of these cells was also analysed. These measurements were then used
to normalise the phosphoproteomics data and thus calculate stoichiometry for each phosphopep-
tide (where these data were available). A quality control assessment of these data is shown in
Appendix 4.
The quantitative data, as with the experiments presented in Chapters 4 and 5, were analysed
using limma. The linear model designs for the phosphoproteomics and proteomics data included
a single MCF7-P control factor, a factor for each resistant cell-line, and a factor for the different
experiments. The correlations between the technical triplicates (phosphoproteomics) and dupli-
cates (proteomics) were accounted for in the design. The results of this differential abundance
analysis are shown in Tables 6.1 and 6.2.
Cell-line FR< 0; adjusted P
 0.05
FR> 0; adjusted P
 0.05
MCF7-G1 1558 1486
MCF7-G2 1087 1151
MCF7-G3 1040 1070
MCF7-K1 2084 1318
MCF7-K2 1887 1511
MCF7-K3 2146 1750
Table 6.1: Differential abundance analysis of the phosphoproteomics data using limma. The number of phospho-
peptides either significantly increased or decreased in abundance compared to parental cells are shown (ntotal = 11,307).
FR, log2 fold-ratio vs DMSO control; adjusted P, Benjamini-Hochberg multiple testing corrected P-value derived from a
moderated t-test.
Cell-line FR< 0; adjusted P
 0.05
FR> 0; adjusted P
 0.05
MCF7-G1 24 49
MCF7-G2 185 82
MCF7-G3 195 323
MCF7-K1 18 25
MCF7-K2 73 90
MCF7-K3 40 61
Table 6.2: Differential abundance analysis of the proteomics data using limma. The number of proteins either
significantly increased or decreased in abundance compared to parental cells are shown (ntotal = 2,593). FR, log2 fold-
ratio vs DMSO control; adjusted P, Benjamini-Hochberg multiple testing corrected P-value derived from a moderated
t-test.
The results shown in Tables 6.1 and 6.2 highlight that a large number of significant differ-
ences, at both the phosphopeptide and protein levels, existed between the resistant and parental
cells. Interestingly, the number of differentially regulated phosphopeptides and proteins was het-
erogeneous between each of the resistant cell-lines, suggesting that their phosphoproteome and
proteome had been remodelled differently.
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6.3.3 CTAM network analysis of the resistant cell-lines
Following on from the differential abundance analysis that demonstrated clear quantitative differ-
ences in phosphopeptide and protein abundances between the parental and resistant cell-lines,
the quantitative data – in the form of computed stoichiometry ratios – were used to profile the
CTAM network as discussed in Chapters 4 and 5 (Fig 5.1). The results of this analysis are shown
in Fig 6.4.
Figure 6.4: CTAM analysis of the resistant cell-lines reveals substantial remodelling of the signalling network.
CTAM group/network branch profiles for each of the resistant cell-lines compared to the parental cells. The size of each
dot represents the mean log2 fold-ratio of each CTAM group’s constituent phosphopeptides relative to the parental cell-
line, where each individual phosphopeptides abundance is normalised to the relative abundance of the unmodified protein.
Colours represent the statistical significance of enrichment, as determined by a modified Z -test. The dendrogram repre-
sents the hierarchical clustering of the mean log2 fold-ratios (Euclidean distance metric).
Analysing the data in this manner revealed that the activity of the different branches (i.e. CTAM
groups) of the defined signalling network were substantially altered in activity when compared to
the parental cells. Importantly, as previously alluded to, these differences were independent of
changes at the protein level. Hierarchical clustering of these data revealed the CTAM groups
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which displayed similar quantitative behaviour across the cell-lines. This clustering showed that
the majority of CTAM groups representing PI3K and mTOR were reduced in abundance in both
the MCF7-G (Fig 6.4, green arrows) and MCF7-K (Fig 6.4, green and orange arrows) compared
to the parental cells. This suggested that these kinases remained inhibited by each compound
and that instead, compensatory mechanisms were allowing continued proliferation. In agreement
with this hypothesis, a number of other CTAM groups were increased in abundance compared to
the parental levels.
This analysis also highlighted that the responses of the network evolved in response to GDC-
0941 (left, blue) were distinct to those for KU-0063794 (right, green). Moreover, a degree of
heterogeneity between the individual cell-lines within each drug group was also observed. To
assess the differences between this inter- and intra-group heterogeneity between the two groups
of cell-lines more objectively, a principal component analysis was performed on these data (Fig
6.5).
Figure 6.5: The resistant cell network profiles are distinct between MCF7-G and -K cells. Scatter plot representing
the first three principal components of the network data shown in Fig 6.4. GDC-0941-resistant cells, blue; KU-0063794-
resistant cells, green; parental cells, black; PC, principal component.
The analysis shown in Fig 6.5 reinforced the idea that the activity of the network within the
resistant cells had evolved to become substantially different to the parental cells, as the MCF7-
G and -K cells separated from MCF7-P cells in PC-space. This analysis also showed that the
responses evolved in the MCF7-G cells were distinct to those in the MCF7-K cells, as these
also separated well. Most strikingly, a degree of separation was observed between the individual
cell-lines within each group (e.g. MCF7-G1, -G2 and -G3), mirroring the heterogeneity of CTAM
group activation noted in Fig 6.4 and suggesting that even cells resistant to the same compound
remodelled their network in subtly different manners.
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6.3.4 Validation of the MS and CTAM analyses
To provide further evidence for the maintained reduction of PI3K and mTOR signalling in the resis-
tant cells, a number of known downstream phosphorylation sites of these kinases were extracted
from the data (Fig 6.6A). In addition, Western blots were performed for known activatory phospho-
rylation sites on kinases downstream of PI3K and mTOR (Fig 6.6B). Consistent with the CTAM
analysis shown in Fig 6.5, a number of known mTOR substrates were significantly reduced in
abundance in both the MCF7-G and -K cells. In-line with the patterns observed in these data
and those shown in Figs 6.4 and 6.5, Western blots against Akt Ser473 and p70S6K (RPS6KB1)
Thr389 demonstrated a substantial reduction of Akt and p70S6K phosphorylation in these cells,
suggesting that the signalling of these kinases was indeed reduced. These data also mirrored the
patterns observed in the MS data (Fig 6.6A) as the down-regulation of mTOR signalling (based
on the phosphorylation of p70S6K) was more substantially reduced in the MCF7-K than MCF7-G
cells.
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Figure 6.6: PI3K and mTOR signalling is reduced in the resistant cell-lines. (A) Heat map of selected phosphorylation
sites representing the activity of PI3K and mTOR signalling in the resistant cells (where proteomics data was available
to provide stoichiometry). Uniprot protein ID (gene name), phosphorylation sites, peptide charge, and other peptide
modifications are shown. If the -score for the peptide is < 10, the peptide is shown in the following format: ”protein gene
name (sequence residues); charge; modification”. (B) Westerns blots for known markers of PI3K/mTOR signalling activity
in the resistant and parental cells. Abundance of the unmodified protein is shown in each case.
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6.4 Linking network activities to phenotypic outputs
6.4.1 Responses of resistant and parental cells to a panel of kinase inhibitors
To investigate whether remodelling of the network had functional consequences for the resistant
cells, and that the observed intra- and inter-group heterogeneity could be recapitulated with an or-
thogonal method, the responses of the cells to a panel of small-molecule inhibitors was assessed
using both the MTS and CV assays. It was hypothesised that, as the response to kinase inhibitors
is a function of signalling network activity, the resistant cells should respond differently to both
parental cells and one another. An unbiased, multivariate analysis (PCA) should then be able
to resolve these differences and reaffirm the observations made in Figs 6.4 and 6.5. For these
experiments, each of the cell-lines was plated in triplicate and treated with inhibitors of Akt, MEK,
EGFR and CAMK2, both alone and in combination with GDC-0941 or KU-0063794. The resulting
viability data from these experiments (normalised to DMSO control) is shown in Fig 6.7.
These experiments clearly demonstrated that, based on the differences between parental and
resistant cells (dashed and coloured bars), the network remodelling observed in the phospho-
proteomics and network analyses did indeed have an effect on the way in which these cells
responded to other small-molecule kinase inhibitors. Moreover, these data recaptured the dif-
ferences observed in the network between the MCF7-G and -K cells, as these responded dif-
ferently to a number of different drug combinations. The MCF7-G cells, for example, although
clearly resistant to GDC-0941, remained as sensitive to mTOR inhibition as the parental cells. On
the contrary, the MCF7-K cells, alongside being more resistant to KU-0063794 than the parental
cells, were also able to proliferate in the presence of 1 M GDC-0941 (Fig 6.7). In-line with the
observation that the network remodelling was heterogeneous between cells resistant to the same
inhibitor, Fig 6.7 shows that the responses to the inhibitor panel were also subtly heterogeneous
between individual cell-lines. MCF7-K1 and K3 cells were sensitive to the combined inhibition of
PI3K/CAMK2 and PI3K/MEK, whereas the MCF7-K2 cells were able to proliferate more success-
fully in the presence of these drugs, for example (Fig 6.7).
To examine the relationships between each of the cell-lines based on the viability data pre-
sented in Fig 6.7, a principal component analysis was performed on this dataset (Fig 6.8). This
analysis showed that the two sets of viability data, alongside the CTAM network analysis, were
able to separate the MCF7-G and -K cells from the parental cell-line, providing further evidence
to suggest that the network had been remodelled upon acquisition of resistance. The analyses
were also able to discriminate between the MCF7-K and -G cells, further suggesting that the
evolved responses to the two drugs were distinct. Alongside these observations – reflecting what
was observed in the MS data – these analyses separated cell-lines resistant to the same drug,
thus lending support to the notion that cells treated with the same compound, under the same
conditions, remodelled their network in different ways to overcome chronic inhibition.
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Figure 6.7: Network remodelling in resistant cells results in differential responses to small-molecule kinase in-
hibitors. (A) MTS cell viability data for the resistant and parental cell-lines treated with a panel of small-molecule kinase
inhibitors (normalised to DMSO control). (B) CV cell viability for the identical experiment as in (A). Data points represent
the mean  SD (n = 3). Dotted lines represent the responses of the parental cells in each case. Akt-i, MK-2206 (1 M);
CAMK2-i, KN-93 (5 M); EGFR-i, PD-153035 (1 M); MEK-i, GSK-1120212 (0.5 M); mTOR-i, KU-0063794 (1 M);
PI3K-i, GDC-0941 (1 M).
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Figure 6.8: Multivariate analysis of the cell viability data separates the MCF7-G and -K cells. (A) Scatter plot of the
first three principal components of the MTS cell viability data as in Fig 6.6A. (B) PCA of the CV cell viability data as in Fig
6.6B. GDC-0941-resistant cells, blue; KU-0063794-resistant cells, green; PC, principal component.
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6.5 Rewiring of the signalling network in MCF7-G cells
The previous experiments provided evidence to suggest that: (i) the network was remodelled
following chronic kinase inhibition; (ii) this remodelling was different for cells treated with GDC-
0941 and KU-0063794 and; (iii) this remodelling was subtly different between cells resistant to
the same compound. Despite this, these data were unable to distinguish if this was merely due to
differences in the extents of signalling pathway activation between the resistant and parental cell-
lines or whether the network was indeed rewired, with signals being redirected through different
paths in the network. To distinguish between these two possibilities, it was hypothesised that if the
network was indeed rewired, differences should be observed between the growth-factor induced
phosphorylation kinetics in the resistant and parental cell-lines. To test this, an experiment was
designed whereby the three MCF7-G cell-lines and the parental cells were starved for 24h (in
FBS and DMSO/drug-free DMEM) and subsequently treated with 100 ngmL 1 EGF for 0, 30, 60,
or 120 minutes. The phosphoproteome of these cells at each time-point was then analysed by
nLC-MS/MS in triplicate and the experiment was repeated to produce biological duplicates, thus
resulting in a total of six analytical replicates. A quality control analysis of this dataset is shown in
Appendix 5.
The quantitative data were normalised to, and statistical significance computed against, the 0
minute time-point for each respective cell-line. The results of the differential abundance analysis
using limma are shown in Table 6.3. As an overview, these data provided preliminary evidence
for a difference in the way in which the GDC-0941-resistant cells responded to EGF compared
to the parental cells. These data showed that a large number of phosphopeptides significantly
increase in abundance following EGF stimulation of the parental cells. In contrast, much fewer
changes were observed following EGF stimulation of the resistant cell-lines. In comparison to the
parental and MCF7-G1 and -G2 cells, the G3 cell-line appeared to be the least responsive to EGF
treatment.
Cell-line/time-point FR< 0; adjusted P
 0.05
FR> 0; adjusted P
 0.05
MCF7-P (t = 30 min) 589 336
MCF7-P (t = 60 min) 457 621
MCF7-P (t = 120 min) 224 488
MCF7-G1 (t = 30 min) 159 272
MCF7-G1 (t = 60 min) 169 226
MCF7-G1 (t = 120 min) 121 186
MCF7-G2 (t = 30 min) 228 233
MCF7-G2 (t = 60 min) 178 182
MCF7-G2 (t = 120 min) 246 190
MCF7-G3 (t = 30 min) 46 150
MCF7-G3 (t = 60 min) 10 83
MCF7-G3 (t = 120 min) 64 31
Table 6.3: Differential abundance analysis of the resistant cell growth factor time-course phosphoproteomics
data using limma. The number of phosphopeptides either significantly increased or decreased in abundance compared
to parental cells are shown (ntotal = 4,228). FR, log2 fold-ratio vs DMSO control; adjusted P, Benjamini-Hochberg multiple
testing corrected P-value derived from a moderated t-test.
6.5.1 Differences in EGF-induced phosphorylation kinetics between MCF7-G and -P cells
To assess the differences in EGF-responsive phosphorylation site kinetics between the resistant
and parental cells in more depth, the dataset was filtered to only include those sites that demon-
strated a statistically significant change compared to t = 0 minutes, in at least one condition.
The log2 fold-ratios of the resulting 2,322 phosphopeptides were then hierarchically clustered and
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visualised (Fig 6.9A).
Figure 6.9: EGF-induced phosphorylation kinetics are distinct between MCF7-G and -P cells. (A) Heat map of the
2,322 significantly changing (adjusted P  0.05) phosphopeptides for both the MCF7-G and -P cells treated with EGF
for 0, 30, 60, and 120 minutes. The dendrogram represents the hierarchical clustering of each phosphopeptide based on
their temporal behaviour (Euclidean distance metric). (B) Heat map of selected phosphorylation sites from the original
2,322, highlighting similarity in MAPK signalling (black arrows) and differences in signalling (orange arrows) between the
parental and resistant cells. Uniprot protein ID (gene name), phosphorylation sites, peptide charge, and other peptide
modifications are shown. If the -score for the peptide was < 10, the peptide is shown in the following format: ”protein
gene name (sequence residues); charge; modification”.
The data shown in Fig 6.9A demonstrated that a core set of phosphorylation sites followed the
same activation kinetics in the three resistant cell-lines and the parental cells (black arrow). Fur-
ther analysis of this group revealed that these sites were closely associated with MAPK signalling
(Fig 6.9B). The data also showed, however, that a large proportion of the assayed phosphopep-
tides demonstrated different kinetics between the resistant and parental cells and between the
three resistant cell-lines (Fig 6.9B, orange arrows). This suggested that EGF-induced signals
were flowing through different routes of the signalling network and therefore reinforced the view
that the network was indeed rewired in these cells.
Analysing the CTAM signalling network in these cells also revealed similarities and differences
in the way in which they responded to EGF (Fig 6.10). For example, as with the analysis shown in
Fig 6.9, the resistant cells shared a marked activation of MAPK signalling upon EGF stimulation
(Fig 6.10, black arrows). In addition, these cells appeared to still activate the Akt-mTOR-p70S6K-
PI3K axis, alongside the parental cells (FIg 6.10, green arrow). In contrast to these observed
similarities, several groups, although responsive in the parental cells, were non-responsive or
even decreased in activity in the resistant cells (e.g. the Akt-CAMK2-EGFR and Akt-CAMK2-
EGFR-ERK-MEK groups – Fig 6.10, orange arrows). To further distinguish between the response
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of the phosphoproteome to EGF stimulation in these cells, multivariate analyses were performed
on both the filtered phosphoproteomics data shown in Fig 6.9 and the CTAM network analysis of
these data shown in Fig 6.10.
Figure 6.10: CTAM analysis further show that EGF-induced phosphorylation kinetics are distinct between MCF7-
G and -P cells. CTAM network analysis of the resistant cell-line time-course experiment. The dendrogram represents the
hierarchical clustering of each CTAM group based on their temporal behaviour (Euclidean distance metric).
The PCAs presented in Fig 6.11A and B demonstrate how the phosphoproteome/network
was most different from the 0 minute time-point (i.e. a greater distance from these points in PC-
space) at 30 minutes. This was a robust phenomenon, as it was observed in the responses of
each of the cell-lines. These analyses also showed, however, that each of the resistant cell-lines’
phosphoproteome 30 minutes following EGF stimulation, separated in PC-space from the parental
cells and from one another (Fig 6.11A and B). Furthermore, the routes in PC-space by which
the phosphoproteome/network relaxed back towards its basal state (0 minutes) were distinct for
each of the cell-lines – this being observed with respect to both the filtered phosphoproteomics
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Figure 6.11: Multivariate analyses of the time-course and associate CTAM datasets highlight the separate EGF-
induced phosphorylation kinetics between MCF7-G and -P cells. (A) PCA of the phosphopeptides demonstrating a
statistically significant change in abundance in at least one condition (as shown in Fig 6.9). (B) PCA of the CTAM analysis
of the time-course dataset (as shown in Fig 6.10).
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data and CTAM network analysis. The data shown in Fig 6.11 also suggested that, as seen in
Table 6.3, MCF7-G3 responded the least to EGF stimulation. Taken together, these analyses
suggested that the EGF-induced signalling responses, and the routes through which the EGF-
induced signals were propagated in the resistant cells, were different to the parental cells, whilst
also being different to each of the other resistant cell-lines. These observations further supported
the hypothesis that the network was rewired in these cells and the heterogeneity of this rewiring
and phenotypes observed in Fig 6.3-6.8.
6.5.2 Degradation and recycling of EGFR in GDC-0941-resistant cells
Due to the differences observed in the EGF-induced changes in signalling between the parental
and resistant cells, it was hypothesised that this may be as a result of impaired EGFR degradation
and recycling (and the equilibrium that exists between these two processes). This is because the
rate at which EGFR is retrieved from the membrane and is trafficked through endosomes deter-
mines its signalling kinetics. Recent data has outlined the importance of Akt in these processes,
and as PI3K activates Akt in response to growth factor stimulation, it was not unreasonable to
hypothesise that chronic inhibition of PI3K may have an effect on EGFR trafficking291. To test the
degradation kinetics of EGFR in the resistant and parental cells, Western blots were performed
for EGFR under the same conditions as the experiment presented and discussed in Figs 6.9-6.11
(Fig 6.12).
Figure 6.12: MCF7-G cells have impaired EGFR degradation and recycling kinetics and signal in an Akt-
independent manner. Western blots for total EGFR (A) and activatory phosphorylation sites on ERK1/2 and Akt (B).
Loading controls and blots for the total protein are shown in each case.
The data shown in Fig 6.12A demonstrated that the parental cells had a higher basal amount
of EGFR under starvation conditions (t = 0 minutes), and upon stimulation with EGF, degraded
EGFR to undetectable levels at 120 minutes. The resistant cells showed very different kinetics
of EGFR degradation however: MCF7-G1 degrading EGFR more quickly, and MCF7-G2 and -
G3 demonstrating an accumulation of EGFR. As observed in the MS data, the phosphorylation
of ERK1/2 was stimulated in all four cell-lines and followed similar kinetics. As expected, and
concordant with the data presented in Chapter 5, the phosphorylation of Akt was responsive to
EGF stimulation in the parental cells. Consistent with the observations made in Fig 6.6, how-
ever, Akt phosphorylation (on Ser473) was undetectable in each of the resistant cell-lines and did
not respond to EGF stimulation. This suggested that the activation of downstream substrates
of Akt-mTOR-PI3K seen in the CTAM network analysis (Fig 6.10) was independent of Akt phos-
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phorylation and that the network had been rewired to facilitate phosphorylation of downstream
substrates without the need for canonical Akt activation.
6.6 Conclusions
The experiments described in this Chapter aimed to utilise the previously defined kinase signalling
network to investigate the changes in kinase signalling and the plasticity of this network in cells
that had acquired resistance to the targeted inhibition of PI3K and mTORC1/2.
Firstly, it was determined whether the parental MCF7 cells (MCF7-P) were sensitive to the
two compounds with which models of acquired resistance would be generated (GDC-0941 and
KU-0063794). Cell viability (MTS) assay data for the parental cells treated with either GDC-0941
or KU-0063794 over a range of concentrations demonstrated that the parental cells were indeed
sensitive to both compounds, although they were initially more sensitive to the former (Fig 6.2).
Treating six identical populations of the parental MCF7 cells with an increasing concentration of
each drug – three with GDC-0941 and three with KU-0063794 – led to the development of six
cell-line models of acquired resistance (MCF7-G1:3 and MCF7-K1:3). Cell viability assays of
the resistant cell-lines and the parental cells in the presence of 1 M of the relevant compound
revealed that these models were indeed resistant to the drugs with which they had been treated
chronically (Fig 6.3). Consistent with the observation that the parental cells were less sensitive
to KU-0063794 treatment, the cells resistant to this compound (MCF7-K1:3) were comparatively
less so compared to the GDC-0941-resistant cells. These data also showed that there was a
degree of heterogeneity in the relative resistance of each of the cell-lines resistant to the same
compound.
The phosphoproteome of the six resistant cell-lines was then profiled by nLC-MS/MS and com-
pared to that of the parental cells. To ensure the data were not confounded by acquired differences
in the abundance of the unmodified proteins on which the measured phosphorylation sites were
present, the total proteome of these cells was also compared and the phosphoproteomics data
normalised to these differences. This comparison revealed that, on the whole, many statistically
significant differences in the abundance of phosphopeptides and proteins between the resistant
and parental cells existed (Tables 6.1 and 6.2). CTAM network analysis using these data showed
that many branches of the defined network had altered activites in the resistant cells (Fig 6.4), and
highlighted that the signalling pathways containing the targeted kinases (e.g. Akt-mTOR-PI3K and
Akt-mTOR-p70S6K-PI3K) remained inhibited in the resistant cells. Accordant with other studies,
this suggested that other signalling pathways were compensating for the lack of the activity of the
inhibited kinases.
The patterns of the differences between the resistant and parental cells observed in the CTAM
network analysis were distinct between the MCF7-G and -K cells. This was assessed objectively
using multivariate analysis and this was able to separate the MCF7-G and -K cells both from the
parental cells and from one another (Fig 6.5). This suggested that the evolved differences in the
network’s activity were distinct for cells treated with an mTORC1/2 or PI3K inhibitor. Moreover,
this analysis showed a degree of separation between the three cell-lines resistant to same com-
pound, in-line with the heterogeneity in proliferation rates observed in Fig 6.3, and suggestive of
differences in the network’s remodelling between cells treated with the same inhibitor.
The observation that the targeted kinases remained inhibited in these cells was validated by
extracting some of their known substrates from the MS data and by Western blots for these (Fig
6.6). These experiments provided further evidence to support the observed maintained inhibition
of PI3K and mTORC1/2 in the resistant cells, as the levels of Akt and p70S6K phosphorylation
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were substantially reduced when compared to parental cells.
To investigate whether the changes in signalling network activity seen in the CTAM analysis
had an impact of the phenotypes of the resistant cells, and to determine whether the heterogeneity
observed in the remodelling of the network could be recapitulated based on these phenotypes, the
resistant and parental cells’ viability was assayed under treatment with a panel of small-molecule
kinase inhibitors (Fig 6.7). These experiments revealed that the resistant cells had different re-
sponses to the drug combinations when compared to the parental cells; this being in-line with the
idea that their signalling network had been remodelled. Multivariate analyses of these data, mir-
roring that seen in the CTAM data, were able to robustly separate the MCF7-G and -K cells from
their parental counterparts and one another, whilst also separating individual cell-lines resistant
to the same compound (Fig 6.8).
Having providing significant evidence to suggest that the signalling network was remodelled
in the resistant cell-lines (Figs 6.4-6.8), it was next sought to determine whether this remodelling
was merely a result of changes in the abundance of individual CTAM groups, or whether signals
were flowing through different routes in the network. To achieve this, the phosphoproteomes
of the parental and MCF7-G cells were assessed following treatment with EGF at four different
time-points (Table 6.3). This analysis revealed widespread differences in the way in which EGF-
induced signals propagated in these cells (Fig 6.9), as many phosphorylation sites demonstrated
significantly different kinetics between the parental and resistant cells. PC analyses of these
data and their corresponding CTAM network analysis led to clear separation of the resistant and
parental cell time-points, indicating substantially different responses of the phosphoproteome to
EGF stimulation and suggesting that signals were flowing through different routes in the network
(Fig 6.10).
Finally, in order to provide a mechanistic basis for why the resistant cells responded to EGF dif-
ferently, the degradation of EGFR was monitored over the EGF-stimulation time-course by West-
ern blotting (Fig 6.11). This revealed that, although the parental cells degraded EGFR as would be
expected291, the resistant cells either degraded the receptor more quickly (MCF7-G1) or allowed
its accumulation (MCF7-G2 and -G3). Western blots for a canonical readout of MAPK signalling
activity showed that, as observed in the MS/CTAM data (Fig 6.10), this pathway responded to
EGF treatment in the resistant and parental cells. Blots for a marker of Akt activity, however,
showed that the activation of the Akt-mTOR-p70S6K-PI3K CTAM group seen in the MS data, was
potentially independent of Akt activity. This further suggested that the resistant cells had rewired
their signalling networks to overcome chronic inhibition of PI3K.
Taken together, these experiments showed that the defined kinase signalling network under-
went significant remodelling upon acquisition of resistance to PI3K and mTORC1/2 inhibition. This
remodelling was different for the two inhibitors, in agreement with their increasingly distinct func-
tions of the kinases they target. Most strikingly, cells treated with the same inhibitor also evolved
subtly different responses to the two drugs, indicating that there may be an element of stochastic-
ity in the way in which signalling networks are rewired in response to targeted inhibitors.
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Chapter 7
Discussion
142
PI3K and mTORC1/2, and the networks they signal within, manage cellular reponses to exter-
nal and internal stimuli. Their roles are fundamental to the correct functioning of individual cells
and the higher-order structures they form. These kinases are also relevant to cancer biology, as
their dysregulation is closely linked to tumourigenesis. This project focused on three major areas
of investigation in order to examine how chronic inhibition of these kinases influences signalling
on a global level: (i) the development of sample preparation and mass spectrometric techniques
for phosphoproteomics experiments; (ii) the empirical definition of a kinase signalling network and
testing of its functional relevance; and (iii) how this network was remodelled in models of acquired
resistance to PI3K or mTORC1/2-targeted therapies.
Mass spectrometry-based phosphoproteomics has found great utility in the study of protein
phosphorylation; both in terms of localising modification sites on individual proteins, and studying
their function(s). This is due, in part, to its high-content and unbiased nature, which allows inves-
tigative and discovery experiments that are not tractable with traditional molecular biology tech-
niques. The success of phosphoproteomics experiments, however, is highly dependent on the
upstream sample processing methods (i.e. enrichment of phosphopeptides from a more complex
matrix) and the configuration of the instrumentation (e.g. MS2 ion activation methods). Building on
a previously described protocol, a more robust and efficacious phospho-enrichment method was
developed (Chapter 3). In addition to this, several instrument-based conditions were optimised so
as to produce the highest content phosphoproteomics datasets from the available instrumentation
(Chapter 3).
The topology and plasticity of kinase signalling networks are integral to fundamental and dis-
ease biology. Consequently, the characterisation of these in diverse experimental settings is an
important component of cell signalling research. Many network characterisation attempts have
relied on multi-source protein and PTM interaction data from the literature, which, often limited,
can result in inaccurate network models. In an effort to define a cell type-specific network, the
phospho-enrichment and MS methods optimised in Chapter 3 were utilised to empirically define
a kinase signalling network in MCF7 cells. This was achieved through the treatment of these
cells with twenty structurally distinct kinase inhibitors and two phosphatase inhibitors, and their
subsequent analysis by nLC-MS/MS (Chapter 4). The validity and functional relevance of this
network and the underlying computational methods for its analysis were then confirmed through
an analysis of the network’s plasticity under well-characterised conditions (Chapter 5).
The way in which kinase signalling networks are remodelled in response to chronic, targeted
kinase inhibition is a key aspect of acquired therapeutic resistance. Despite this, such remodelling
has not been comprehensively investigated in an unbiased and global manner. Therefore, having
established its functional relevance, the plasticity of the defined network was assessed in MCF7
cell-line models resistant to PI3K and mTORC1/2 inhibitors. This revealed widespread network
remodelling that was not solely predicated on the initial conditions of the system and this raises
interesting questions regarding the nature of the evolution of resistance (Chapter 6).
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7.1 Phospho-enrichment and mass spectrometric methods for maximising
phosphoproteome coverage
7.1.1 Principles of single-shot phospho-enrichment methods
As discussed in Chapter 1, phospho-enrichment methods are essential to the analysis of phos-
phorylated proteins and peptides from complex biological matrices. Many such methods – and the
technologies they rely on – have undergone continuous development since their first applications.
TiO2 has been shown in numerous studies to be well-suited to the enrichment of phosphopep-
tides due to its relative ease of use, well understood retention mechanism, relatively high yield,
and enrichment specificity141,190,237,239,240,244,268.
“Single-shot” enrichments, where each sample is only enriched in a single dimension (e.g. not
involving multi-dimensional liquid chromatographic fractionation), are essential to label-free phos-
phoproteomic workflows, as each sample is processed independently. Therefore, each single-
extraction step must be optimised to afford the greatest depth of analysis possible and thus negate
the lack of more in-depth fractionation of each sample. In addition, such methods should be highly
reproducible and not lead to the introduction of significant technical bias. Single-shot enrichment
methods have been investigated and, despite not reaching the depth afforded by 2D-LC methods,
have proved efficacious for label-free approaches141,244.
Due to the large numbers of samples that were to be compared in subsequent experiments,
an effective single-shot enrichment method was crucial for this project. The protocol described in
Montoya et al.141 facilitated the identification of approximately 500 phosphopeptides per sample
at 90% specificity. Despite this, as discussed in Chapter 3, it was noted that a large amount of
phosphopeptides enriched using this method were N-formylated – this being a potential source
of quantitative and qualitative inaccuracies (Fig 3.1). In this study, this method was further tested
to reduce the formation of this unwanted modification, whilst it was also sought to increase the
number of identifications that could be made from a single extraction.
7.1.2 Technical considerations and limitations of the developed phospho-enrichment meth-
ods
7.1.2.1 Effects of on-line desalting on phosphopeptide recovery
In order to remove or reduce the presence of N-formylation on the recovered phosphopeptides,
it was hypothesised that the C18 reversed-phase layer held within the micro spin-columns could
be used to retain the phosphopeptides as they were eluted from the TiO2. This would then allow
their immediate desalting to remove residual NH4OH, ammonium formate, and formic acid (Fig
3.2), and therefore significantly reduce the time the samples were exposed to formic acid.
The experiment performed in this study to compare the newly developed on-line method to that
previously described (as in ref141) demonstrated that the former was able to drastically reduce
the presence of N-formylated phosphopeptides, whilst increasing the number of identified phos-
phopeptides by approximately 1.6-fold. This increase in identifications resulted in a concomitant
decrease in the enrichment specificity however, due to the co-purification of non-phosphorylated
peptides (Fig 3.2). Inconsistent with the findings presented in Montoya et al., an additional am-
monium acetate wash did not improve the enrichment specificity (Fig 3.3). This was likely due
to the fact that, although the ammonium acetate may have been effective in the removal of non-
phosphorylated peptides from the TiO2 layer, these may have then able to bind the C18 due to
the relatively low proportion of ACN in the buffer (25%) and would therefore be present in the final
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eluates.
7.1.2.2 Effects of off-line desalting on phosphopeptide recovery
The off-line method developed in this study was able to purify approximately 1.6-fold more phos-
phopeptides than the aforementioned on-line method, whilst simultaneously increasing the en-
richment specificity (Fig 3.4). These data, corroborating other studies292, also showed that GC
(combined with C18) was more effective at retaining phosphopeptides than C18 alone. This is
likely due to the additional ion-exchange retention mechanism afforded by GC aiding in the reten-
tion of hydrophilic moieties292.
Further optimisation of this method – testing the effects of TiO2 concentration, elution buffer hy-
drophobicity, and TiO2 incubation buffers – demonstrated that increasing the ratio of TiO2/protein
and percentage of ACN in the elution buffer resulted in a greater number of phosphopeptide iden-
tifications, with no effect on the enrichment specificity (Fig 3.5A-B). The former finding, that a ratio
of 50:1 TiO2 (g)/protein (g) provided a substantial number of identifications without sacrificing
specificity, is consistent with other studies141. Despite this, these data are at odds with other
findings suggesting that a ratio of 2:1-8:1 TiO2 (g)/protein (g) is optimal for phosphopeptide
enrichment, as the higher the ratio, the lower the enrichment specificity293. The discrepancy be-
tween these datasets may in part be due to the presence of glycolic acid in the loading buffers
used in the experiments shown in Fig 3.5 – this contributing to greater specificity of phospho-
peptide binding to TiO2 beads and therefore greater yield239. Taken together however, the data
shown in Fig 3.5 and throughout Chapter 3 provide significant evidence to suggest that a ratio of
50:1 TiO2 (g)/protein (g) yields a large number of phosphopeptides with high specificity, albeit
with a slight increase in the material cost per enrichment.
The data in Fig 3.5 also show that, in agreement with published studies239, the addition of
5% TFA in the TiO2 loading/incubation buffer increased the specificity of enrichment (Fig 3.5C).
A lack of TFA in this buffer, however, was compensated for by an increase in the concentration
of the relevant -hydroxy acid binding competitor (glycolic or lactic acid). This is contrary to data
presented by Kettenbach and Gerber240, which demonstrates that an increase in the proportion
of TFA in the loading buffer reduced the number of identified phosphopeptides. These differences
are likely explained by the fact that the experiments presented in Fig 3.5C were enrichments per-
formed on total cell lysates as opposed to pre-SCX-fractionated samples enriched for populations
of particularly acidic or basic phosphopeptides.
7.1.2.3 Effects of removing phosphopeptide acidification
The large majority of the current literature concerning TiO2-MOAC-based phosphopeptide
enrichment involves the acidification of phosphopeptides following their elution from the
TiO2 141,244,241,239,247,294. In order to determine whether this acidification step was unnecessary,
and whether it was actually detrimental to the recovery of phosphopeptides, an acidification-free
method ( snap-freezing prior to vacuum-drying) was compared to the previously optimised off-
line method (Fig 3.6). Consistent with the notion that the rate of phosphopeptide -elimination
(and therefore loss) is only significant under conditions of very high pH and high temperature271
(such as those used for chemical derivatisation of phosphopeptides221,222), removal of the acidi-
fication and subsequent desalting steps from the enrichment protocol did not reduce the number
of identified phosphopeptides (Fig 3.6). This observation only remained true for those samples
that were snap-frozen immediately following NH4OH-based elution from the TiO2 beads, how-
ever. Unexpectedly, the removal of the acidification step did not increase the number of identified
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phosphopeptides despite producing a visibly larger peptide pellet following vacuum-drying. The
lack of difference in the number of phosphopeptides identified notwithstanding, it was clear that
these two methods resulted in the enrichment of different portions of the phosphoproteome, as the
samples produced using the newer method were much more complex in the hydrophobic region
of their respective chromatograms (Fig 3.6D). The differences in the populations of phosphopep-
tides identified using these two methods were assessed further and this demonstrated that only
43% of identifications were common between the two methods; lower than can be accounted for
by the stochastic nature of DDA-based experiments274. Moreover, these analyses showed that
the method lacking acidification resulted in the enrichment of longer and more highly charged
phosphopeptides (Fig 3.7).
The lack of increase in phosphopeptide identifications observed using the acidification-free
method may have been a result of several factors. Firstly, as more highly charged phosphopep-
tides are less amenable to CID-based fragmentation methods295, their increased recovery with
the acidification-free method may have been to the detriment of the number that could be effec-
tively sequenced by MS2. Secondly, although a visibly larger peptide pellet was recovered with the
newer method, these extra phosphopeptides may have been subsequently lost through the use
of a low-organic (100% H2O) and low pH (0.1% TFA) reconstitution buffer for MS analysis. Fur-
ther work comparing different MS2 ion activation methods, alongside different MS reconstitution
buffers (e.g. a higher pH buffer such as triethyl ammonium bicarbonate with a higher proportion of
organic solvent), may resolve the differences between the two enrichment schemes more clearly.
Lastly, as the instrument may have been operating at capacity – i.e. the maximum number of
ions that could be identified in a 45 min run with the utilised settings – a longer gradient length
or more sensitive instrument may also resolve the differences between the two methods more
effectively. Overall, however, the acidification-free method produced an equally substantial num-
ber of phosphopeptide identifications, whilst significantly reducing the protocol’s time and material
cost. Importantly, this rendered the comparison of large numbers of samples more amenable,
thus lending itself to label-free experiments.
7.1.3 Principles of gas-phase fractionation
The selection of precursor ions in MS1 scans is an essential process in the data-dependent acqui-
sition of MS2 data. This selection is predominantly based on the intensity and charge state of the
precursor ions present in the initial survey scan. This creates a bias towards the most abundant
precursor ions in each scan, therefore leading to the semi-random identification of only the most
abundant proteins/peptides in a sample. Several alternative precursor ion selection strategies
have been developed to overcome these limitations, including: DIA163,164, exclusion and inclusion
lists272, and gas-phase fractionation273. Gas-phase fractionation relies on a restriction on the
m/z of precursor ions that can be selected for MS2. To this end, pre-selected m/z windows are
used for each MS run, and precursor ions outside of these windows, however intense, are not be
fragmented (Fig 3.8). Crucially for this project, as the MS1 data used for label-free quantification
are identical in each run, GPF could facilitate deeper analyses of the phosphoproteome without
increasing overall MS analysis time.
7.1.3.1 Effectiveness and limitations of gas-phase fractionation
The effectiveness of gas-phase fractionation for label-free phosphoproteomics experiments was
assessed and compared to full-scan precursor ion selection. The m/z windows were derived from
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previous MS-based phosphoproteomics data produced from the same MCF7 cell-line. This exper-
iment showed that, despite the instrument’s ability to effectively fractionate precursor ions in the
gas phase, this reduced the number of phosphopeptide identifications that could be made from an
identical sample (Fig 3.8). This was unexpected as, theoretically, gas-phase fractionation should
afford an increased depth of analysis, as lower abundance ions that may have been ignored in
full-scan mode may then have a chance to be selected for fragmentation in each restricted m/z
window. Several factors may explain this discrepancy between theory and observation. Firstly, the
Orbitrap-XL instrument used for these experiments was operating with a single 100 ms micro-scan
to produce each MS2 spectra, corresponding to the fastest duty cycle available to the instrument.
As noted by Scherl et al., a lengthened duty cycle, utilising three 100 ms micro-scans, produces
both higher quality and reproducible MS2 spectra, whilst amplifying the gains afforded by GPF273.
Secondly, as Fig 3.8F-G demonstrate, the instrument was not operating at full MS2 occupancy,
as many MS1 scans produced only enough ions to warrant one or two subsequent fragmentation
events (rather than the maximum of three). This may be due to software limitations of the instru-
ment itself, or perhaps because the next most intense ions within the particular m/z window were
not intense enough for their charge state to be determined and therefore were not selected. As
a result, repetition of this experiment on a more sensitive, state-of-the-art instrument may provide
more promising results. Finally, the number of ions identified in each gas phase fraction was
heterogeneous, despite the rational design of the m/z windows from previously acquired data.
Therefore, further optimisation of these windows based on these, or genomic data, may yield
greater efficacy of the technique.
7.1.4 Principles of MS2 ion activation methods
MS2 fragmentation or ion activation methods are integral to the quality and quantity of the data
output from LC-MS/MS experiments. Several independent groups have investigated various meth-
ods’ utilities with regards to proteomics experiments248–250,275. These investigations have broadly
shown that the optimal fragmentation technique is highly dependent on the peptide’s physico-
chemical properties, as the PTMs present on the peptide and its charge state can heavily influence
its fragmentation patterns. This has led to the development of hybrid fragmentation techniques
such as EThcD249,250 and decision-tree algorithms for choosing the most suitable method on-the-
fly251. These methods are not yet widely available, however, and so the objective of this study was
to compare the two most commonly employed methods for the fragmentation of phosphopeptides:
CID-MSA and HCD.
7.1.4.1 Effectiveness and limitations of CID-MSA and HCD for phosphoproteomics analy-
ses
The utility of CID-MSA and HCD methods was compared using an LTQ-Orbitrap-Velos instrument.
To achieve this, four independent TiO2 enrichments of an identical cell lysate were run in quadru-
plicate on the instrument. For each replicate injection a different MS2 scheme was employed: (i)
CID top 10, (ii) CID top 15), (iii) HCD top 7, and (iv) HCD top 10. It emerged from this comparison
that, regardless of the top N spacing used, CID-MSA was able to identify a significantly greater
number of unique phosphopeptides ions than HCD (Fig 3.9). This is consistent with other studies
indicating that, due to the shortened duty cycle, CID-MSA provides substantially richer datasets
on hydrid orbitrap instruments248. In addition, this comparison showed that, in-line with previously
published data, the increase in identifications afforded by CID-MSA was accompanied by a re-
duction in the accuracy of phosphorylation site localisation and peptide identification155,248 (Fig
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3.9). This is most likely as a result of the higher mass accuracy and resolution of the fragment ion
measurement (contributing to better charge state determination), wider measurable m/z range,
and greater dynamic range afforded by HCD.
Contrary to the expected, this study also demonstrated that, independent of the ion activation
method used, a greater number of MS2 events between each MS1 scan did not significantly
increase the number of identifications made. A possible explanation for this could be that, as
long (3 hour) gradients were utilised for the experiment, the instrument was fragmenting a large
proportion of the available precursor ions even at lower top N spacings (e.g. CID-MSA top 10 and
HCD top 7). Therefore, it could be hypothesised that repetition of this experiment with shorter LC
gradients may provide greater resolution of the differences between an increase in top N spacing.
Overall, this study suggests – corroborating other datasets – that CID-MSA provides the great-
est depth of phosphoproteome analysis on LTQ-Orbitrap-Velos instruments. The data also sug-
gest that HCD produces more accurate peptide and phosphosite identifications. The increase
in the number of phosphopeptide identifications facilitated through the use of CID-MSA (approx-
imately 1.5-fold), however, outweighs the small increase in accuracy gained through the use of
HCD when seeking to maximise the number of identifications that can be made from single ex-
tractions. In addition, due to the shorter duty cycle of CID-MSA methods, more MS1 data-points
are collected, thus allowing more accurate determination of precursor ion XIC peaks and there-
fore more accurate computation of their area and/or heights. Finally, as approximately 81% of
the identifications made using HCD were common to those made using CID-MSA, the use of the
latter does not exclude the analysis of a large proportion of the phosphoproteome (extracted with
this phospho-enrichment method). This observation is seemingly only robust when analysing the
most abundant phosphopeptide ions155; however, as the objective of this study was to optimise
these methods for an unfractionated, single-shot extraction method, this was not as pertinent an
issue.
7.1.5 Implications and future work
Taken together, the phospho-enrichment methods that were developed and presented in Chapter
3 facilitated the almost complete removal of unwanted N-formylation (Fig 3.2), whilst consistently
increasing the number of phosphopeptide identifications when compared to the original method
(Figs 3.3-3.6). This culminated in the ability to reliably identify approximately 1600 unique phos-
phopeptide ions from a single extraction derived from a 0.5 mg protein lysate. Considering that
this only required a single, short MS run (45 minute gradient on an Orbitrap-XL instrument), this
was competitive with other single-shot methods and even those combined with extensive sample
fractionation240,293. The most important advantage of these methods however, was that, due to
their simplicity and relative speed, they can be used in a relatively high-throughput manner to
compare a large number of experimental conditions.
This study also reinforced the notion that CID-MSA fragmentation methods remain optimal
for high-content phosphoproteomics experiments on early generation LTQ-Orbitrap hybrid instru-
ments, despite the slight loss in peptide identification and PTM localisation accuracies. This is
irrelevant on newer orbitrap instruments, however, as CID is either unavailable (e.g. Q-Exactive)
or the optimal method can be selected on-the-fly (e.g. Fusion Tribrid instruments).
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7.2 Empirical determination of a kinase signalling network
The topology of kinase signalling networks is critical to their function and output. Defining these
topologies de novo is a significant analytical challenge and the majority of efforts to date have re-
lied on the amalgamation of multiple literature sources296,297. Although informative, this approach
is hampered by the fact that this amalgamation often obscures the cell- and context-specific con-
nections that occur in true biological systems, therefore limiting the biological relevance of the
resulting networks191. These ‘averaged’ or synthesised signalling networks, as often depicted
in canonical signalling pathway diagrams, are derived from evolutionarily and functionally distant
organisms and cell types. Therefore, these are not necessarily representative of biological kinase
signalling networks. An advantage therefore of defining a signalling network empirically – using
experimental data derived from a single system – is that cell-type and cell-context dependent con-
nections are preserved; rendering the network a more reliable snapshot of kinase signalling and
a valuable tool for the study of such a model.
Having established a highly specific and efficacious phospho-enrichment method amenable
to the analysis of a relatively large sample numbers, alongside the comparison of mass spec-
trometric methods to allow maximal depth of analysis from single enrichments, the topology of a
kinase signalling network was defined empirically in MCF7 cells. This was achieved through the
measurement of the MCF7 phosphoproteome under treatment with a large array of structurally
distinct kinase and phosphatase inhibitors targeting nodes of PI3K- and MEK-oriented signalling
pathways (Table 2.2; Fig 4.1).
7.2.1 Technical considerations of the MS and computational methods
The network defining experiment consisted of the phosphoproteomic comparison of MCF7 cells
treated with twenty-two structural distinct kinase/phosphatase inhibitors. This resulted in the quan-
titative comparison of 144 individual nLC-MS/MS runs. Combination of the identifications (as
determined by Mascot) from these samples resulted in a database consisting of 13,405 unique
phosphopeptide ions at an FDR = 5%. It is critical to control the peptide FDR at this stage, as
false identifications can easily lead to misinterpretation of the biological meaning of such datasets.
Many methods have been developed for the estimation of FDRs; however, the majority rely on the
concomitant search of a randomised, shuffled, or reversed protein sequence database for the esti-
mation of false positive identifications298. A quality control analysis of the identifications produced
from this experiment demonstrated that, despite the threshold of 5%, the vast majority (>95%) of
the identifications possessed a q < 0.01 (Fig 4.2A). Although such thresholds are largely arbitrary,
and that protein identity would not be inferred from these peptides, a cut-off of 5% (corresponding
to a q < 0.05) was deemed reasonable for this experiment.
MS1-based label-free quantification strategies are highly dependent on liquid chromatographic
stability and reproducibility. This is particularly true for the iteration of the PESCAL method used
in this and other experiments, as sample-specific retention times for each phosphopeptide ion are
calculated through the formation of linear models between the retention times of spiked-in enolase
standard peptides. Therefore, although slight shifts in retention time of these can be easily toler-
ated, the elution order of these standard peptides must be consistent between nLC-MS/MS runs.
An assessment of this and the overall effectiveness of the method was performed and this clearly
demonstrated that: (i) the enolase peptide retention times aligned between individual runs in a
reproducibly linear fashion (Fig 4.2B-C), and (ii) the elution order of these peptides was preserved
across the 144 nLC-MS/MS runs (Fig 4.2E).
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Despite consistent XIC peak height intensity distributions between the nLC-MS/MS runs, the
quantitative data were quantile normalised to reduce the influence of technical variability and
systematic biases on the dataset (Fig 4.2D). The process of quantile normalisation renders the
statistical properties of each of the intensity distributions identical and has been shown to ef-
fectively reduce bias and variance whilst improving statistical power in similar datasets265,299,300.
The magnitude and statistical significance of changes in phosphopeptide abundance across the
24 conditions (two biological replicates and three technical replicates for each) were assessed
using a previously described linear modelling and empirical Bayesian shrinkage methods262,266.
These analytical strategies have demonstrated significant utility in the analysis of microarray and
proteomics datasets; both drastically reducing the number of false positive results and increasing
statistical power in a practical and computationally efficient manner266,283,284. The results of this
analysis demonstrated that the effect of small-molecule inhibitors of the targeted kinases on the
phosphoproteome was heterogeneous (Table 4.1). This strongly supported the reasoning for the
use of two inhibitors against each targeted kinase in the experiment, as this heterogeneity was
observed even for inhibitors targeting the same kinase (e.g. Akt inhibitor VIII and MK-2206). As
would be expected for inhibitors of kinase activity, each compound induced a greater number of
significant reductions in phosphopeptide abundance than significant increases. Taken together,
through the use of high quality quantitative data, combined with sophisticated statistical methods,
robust changes in phosphopeptide abundance were identified from the raw MS data.
7.2.2 Validation of kinase inhibitor efficacy
The efficacy of targeted kinase inhibitors is often questionable, and some studies have demon-
strated that incubation with an inhibitor can paradoxically increase the kinase’s activity301. To
provide evidence that the inhibitors employed in this study were indeed reducing the activity of
their target kinase, Western blots were performed for their known downstream phosphorylation
site substrates (where reliable reagents were available – Fig 4.3). These experiments showed
that inhibitors of PI3K, mTORC1/2, PKC, EGFR, MEK and p70S6K each substantially reduced
the phosphorylation of their respective substrates, with some showing complete abrogation below
the limit of detection. Although blots for the total amount of unmodified substrate protein are not
shown, the experiment was performed over a relatively short time-course (1 hour) and so these
are unlikely to have changed significantly. Further work profiling the effects of the inhibitors not
included in this analysis would provide further support to the MS data, although evidence of their
efficacy has been described elsewhere302–308.
7.2.3 Analysis of kinase relationships
In order to examine the similarities and differences between the effects of each of the compounds
on the phosphoproteome, the phosphopeptides that demonstrated a statistically significant de-
crease in abundance (in at least one treatment) were extracted from the dataset. This filtered
dataset was then deemed to be enriched for phosphorylation sites that were responsive to the in-
hibitory action of at least one of the surveyed compounds. The relationships between the effects
of each of twenty-two compounds on this filtered dataset were then assessed by means of sev-
eral multivariate analyses (Fig 4.4). These analyses suggested that inhibitors of the same kinase
had very similar impacts on the filtered portion of the phosphoproteome as they correlated very
strongly with each other and grouped closely in three-dimension PC-space. These data reinforced
known relationships between the tested kinases, whilst the phosphatase (PP2A) inhibitors sep-
arated well from the other compounds in each analysis. For example, the effects of inhibitors of
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mTOR, p70S6K and PI3K on the filtered phosphopeptides were strongly correlated and grouped
well in three-dimensional PC-space (Fig 4.4A-C). This was also observed for inhibitors of the
MAPK pathway (EGFR, MEK, and ERK).
Consistent with their canonical associations, inhibitors of Akt demonstrated statistically sig-
nificant correlations with the inhibitors of mTOR and PI3K. Unexpectedly however, the Akt in-
hibitors partitioned more closely to CAMK2 and EGFR inhibitors in PC-space than to those of
mTOR and PI3K. This was also observed in hierarchical clustering analysis of each inhibitor’s
quantitative effect on known consensus phosphorylation motifs (Fig 4.4D). Although somewhat
counter-intuitive, this observation is consistent with several previous studies highlighting cross-
talk between Akt/mTOR/PI3K and MAPK signalling in human malignancies120,121, particularly via
BRAF122. In addition, this phenomenon was unlikely to be as a result of experimental bias, as
the linear modelling approach utilised to analyse the data included factors to account for this
variability. Furthermore, as a total of six analytical replicates represented each data-point, this
observation was statistically robust. Thus, although the confounding off-target effects of each in-
hibitor pair cannot be fully removed from these analyses, the high volume of replicates, alongside
the inclusion of two inhibitors per kinase, aided in a substantial reduction of their overall impact.
7.2.4 Derivation of CTAMs from phosphoproteomics data
In this study, it was reasoned that the inclusion of two inhibitors per targeted kinase, alongside
the robust statistical framework applied to the resulting data, would allow further classification of
the phosphopeptides identified in the experiment. Consequently, it was hypothesised that phos-
phopeptides whose abundance was significantly reduced by both inhibitors targeting the same
kinase would be enriched for markers of that kinase’s activity. As the inhibitors possess off-target
effects however, these populations of phosphopeptides would also represent the true kinases in-
hibited by each compound pair. Thus, the identified groups of phosphopeptides were dubbed
compound-target activity markers (CTAMs).
A number of thresholds for CTAM identification were tested. As would be expected, an in-
crease in the stringency of said thresholds reduced the number of CTAMs identified from the
dataset (Fig 4.5). Due to the high-content nature of the experiment (afforded by the depth of
analysis provided by the phospho-enrichment and mass spectrometric methods) it was reasoned
that specificity was more critical than sensitivity. As a result, the most stringent thresholds were
applied for the final analysis. The final thresholds controlled for false positive CTAM identifications
on three levels: (i) phosphorylation site localisation probability (based on -score); (ii) magnitude
of abundance change; and (iii) statistical robustness of abundance change. Most importantly,
however, these criteria had to be satisfied for both inhibitors against the same kinase in order for
a phosphopeptide to be identified as a CTAM (Fig 4.6).
Application of the CTAM classification algorithm to each inhibitor pair resulted in the iden-
tification of 610 CTAMs (Appendix 1). Analysis of these demonstrated that a large number of
phosphopeptides were identified as being CTAMs of more than one kinase/inhibitor pair (Fig
4.7). Based upon these observations, the identified CTAMs were further classified into groups
of CTAMs, according to which kinase activities they represented. For example, the phosphopep-
tide representing MAPK1 (Thr185 and Tyr187) was determined to be a marker of both EGFR and
MEK activities and was therefore classified into the EGFR-MEK CTAM group. Analysis of the
data in this way produced 55 CTAM groups with varying numbers of members (Appendix 2). As
would be expected, a number of known “signalling pathways” emerged from this analysis, includ-
ing: Akt-mTOR-PI3K, Akt-mTOR-p70S6K-PI3K, and EGFR-MEK, and these served to validate
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the approach. These groups contained several known substrates of these kinases (e.g. RIC-
TOR Thr1135 in the Akt-mTOR-p70S6K-PI3K group61), alongside those previously undescribed.
In addition to the known pathways represented in the data, a number of as yet uncharacterised
connections between different kinases and inhibitors were also revealed (Fig 4.7).
Principal component analysis of the CTAM data enabled a more objective assessment of the
relationships between the kinases interrogated in this study (Fig 4.7C). This demonstrated, similar
to the analyses shown in Fig 4.4, that each inhibitor pair targeting the same kinase grouped well
in PC-space, suggesting that their effects on the 610 CTAMs’ quantitative behaviour were closely
related. The unanticipated separation of Akt from PI3K and mTOR was also seen in these data;
however, Akt, PI3K and mTOR possessed similar values in the third PC dimension (Fig 4.7C),
suggesting a degree of similarity. Plotting the CTAM data in the form of a bipartite, undirected
network graph further facilitated an assessment of how each of the kinases related to each other
in these cells (Fig 4.8). Consistent with previous knowledge regarding their common signalling,
and observations made within this study, this demonstrated that PI3K, mTOR, and p70S6K shared
a large number of CTAMs. Similarly, MAPK-associated kinases also shared a large number of
CTAMs with each other. Akt, as would be expected, shared a majority of its identified CTAMs
with mTOR, PI3K, and p70S6K. In agreement with the observations noted in Figs 4.4, 4.6, and
4.7, Akt also possessed many common CTAMs with EGFR, CAMK2, and ERK. Most interestingly,
a large number of Akt CTAMs were not shared with any other kinase node within the network,
pointing towards a role for Akt outside of its canonical activators and other kinases probed in
these experiments.
The role of Akt signalling outside of its most well-characterised partners PI3K and mTOR –
and indeed vice versa – is a currently understudied aspect of these kinases’ biology. Several
studies, concordant with the observations made in Chapter 4, have hinted towards a greater
role of PI3K/mTOR-independent Akt signalling and Akt-independent PI3K/mTOR signalling than
has been previously appreciated309. For example, Akt has been shown to interact with, and be
activated by, several tyrosine kinases in a PI3K-independent manner (e.g. Ack1/TNK2, PTK6, and
Src). These kinases have been shown to phosphorylate Akt at sites within its kinase domain (e.g.
Tyr176 and Tyr315=326), independent of those canonically associated with its activity (i.e. Thr308
and Ser473)310–312. Thus, the data presented in Chapter 4 provide further evidence to suggest
that Akt’s signalling is not solely defined by its associations with PI3K and mTOR, nor does its
association with MAPK signalling fully account for this.
7.2.5 CTAM identification: limitations of the methodology
The CTAM identification criteria discussed above were justified on the basis that a true marker of
the activity of a kinase should demonstrate a modest reduction in its abundance under treatment
with an inhibitor of said kinase. Consequently, a log2 fold-ratio  -1 (adjusted P  0.1), or a fold-
ratio  -0.75 with greater significance (adjusted P  0.05) were deemed reasonable. Despite the
success of this algorithm in identifying CTAMs in this experiment (Fig 4.6B), it could be argued
that the magnitude of abundance change for each of the inhibited phosphopeptides is dependent
on the time the cells were incubated with the relevant inhibitor. Indeed, the rate at which a phos-
phorylation site decreases in abundance with kinase inhibition (i.e. reducing kphos; Fig 1.16) is
also dependent on the rate at which that phosphorylation site is removed by phosphatases (i.e.
k–phos; Fig 1.16). Thus, the CTAMs identified within these experiments are limited by the fact that
they are inherently biased towards phosphorylation sites which are relatively quickly removed by
their phosphatase. As a result, variation in the incubation time used for each kinase inhibitor may
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alter the CTAMs, and therefore network, which can be identified using this methodology.
It may also be argued that in order to improve the specificity of CTAM identification and reduce
the impact of the off-target effects of each compound, a greater number of compounds or com-
plementary RNAi technologies could be used313. A number of issues present themselves with
this argument however. Firstly, although label-free MS methodologies allow the comparison of a
theoretically unlimited number of samples, this is severely limited by the time-consuming manual
processing of individual samples. Improvements in, and increasing availability of, robotic liquid
handling systems will greatly improve this however294. Secondly, it remains the case that for a
large number of kinases, the availability of structurally distinct and specific inhibitors is often poor.
Finally, although an attractive alternative, RNAi technologies are potentially flawed for such sig-
nalling studies as they abolish the non-catalytic functions that many kinases provide (reviewed
in ref314). Thus, as RNAi reduces the absolute expression of the targeted kinase (and often re-
quires a long incubation time with the RNA to achieve this), this can cause more widespread
perturbations, therefore complicating downstream analysis of the data.
7.2.6 Implications and future work
This study, whilst highlighting the utility of discovery-based MS methods for these types of ex-
periments and the efficacy of label-free methods in this context, serves to expand our knowledge
regarding the complexity of the relationships that exist between kinases and the networks they
form. These data also illustrate that, despite some previous exploration of the cross-talk between
these kinases and the networks the constitute120–122, our knowledge of this complexity remains
limited. The complexity of kinase signalling networks underpins their ability to receive, amplify,
interpret, and respond to a large variety of biological signals124. A greater understanding of this
will further our ability to manipulate these networks in the context of disease. Indeed, recent work
concerning the combinatorial targeting of BRAF/MAPK and Akt/mTOR/PI3K signalling in certain
cancers has proved fruitful, suggesting that this is an avenue worth pursuing315,316. As previously
discussed, this study also strongly supports the notion that Akt plays a much greater role outside
of its well-studied interactors than has been previously acknowledged. Further exploration of this
may provide both deeper insight into Akt’s functions, with the potential to expose novel therapeutic
opportunities.
This study could be expanded through the characterisation of a greater number of kinases, as
those profiled in these experiments only represent approximately 2% of those encoded by the hu-
man genome. Although limited by the availability and specificity of targeted kinase inhibitors, the
system-specific CTAMs of many biologically important kinases (e.g. ALK, AMPK, PKA, GSK3,
Aurora A/B, etc.) could be profiled with this technology. Furthermore, due to the availability of
isoform-specific inhibitors for some kinases, this study could also be expanded to include isoform-
specific CTAMs (e.g. PI3K, , and ). As previously discussed, the increased availability of
robotic technology, alongside the ever-increasing sensitivity and speed of mass spectrometers,
will render larger experiments such as these more tractable in the future.
7.3 Analysis of signalling network plasticity in response to EGF/IGF-1 stim-
ulation
Although the topology of kinase signalling networks underpins their basal function, signalling net-
works are not static structures. The dynamism of the strength of the connections that constitute
the network – often termed plasticity – is key to the adaptability of biological systems in response
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to intra- or extracellular perturbations317 . The experiments presented in Chapter 5 aimed to
demonstrate that the network defined in Chapter 4 was biologically relevant, and more impor-
tantly, whether it could be used to assess signalling plasticity in a global and unbiased manner.
Crucially for this project, it was reasoned that if the aforementioned hypotheses were true, the
network could be used to interrogate the changes in signalling that occur in response to chronic
kinase inhibition and the subsequent development of acquired resistance.
7.3.1 Phosphoproteomics of growth factor-treated MCF7 cells
To test the aforementioned hypotheses, MCF7 cells were serum-starved and treated with EGF
or IGF-1 over five time-points. The phosphoproteome of these cells was then measured by nLC-
MS/MS and the CTAMs represented in the resulting data were extracted and analysed computa-
tionally in order to infer the activity of the signalling network.
Initial analyses of the quantitative mass spectrometry data revealed that EGF and IGF-1 had
different effects on the phosphoproteome, as the number of significantly changing phosphopep-
tides at each time-point was heterogeneous between the two growth factors (Table 5.1). EGF
and IGF-1 are known to stimulate the activity of MAPK signalling and a supervised extraction of
known EGF and IGF-1-responsive phosphorylation sites representing this pathway demonstrated
that the MS data were consistent with such an activation286. This was characterised by an acute
increase in the abundance of phosphorylation sites on MAPK1/3 (ERK1/2), MAP2K2 (MEK2),
RAF1, and SOS1. EGF and IGF-1 are also known to stimulate the activity of PI3K/Akt signalling;
however, IGF-1 is thought to activate this more potently287. In-line with this idea, the MS data
demonstrated a significant increase in the abundance of a phosphorylation site within the activa-
tion loop of Akt under both EGF and IGF-1 treatment; however, this increase was markedly more
sustained under treatment with the latter (Fig 5.2). The observation that both MAPK and PI3K/Akt
was stimulated in these cells, and the differences in Akt phosphorylation between the two growth
factors, was validated with Western blots for these phosphorylation sites (Fig 5.3). Taken together,
these data provided strong support for the validity of the MS data and subsequent analyses based
on these.
7.3.2 Utility of CTAM-based network analysis of independent experiments
To demonstrate the utility of the defined signalling network in the unbiased assessment of sig-
nalling in the same system in an independent experiment, the temporal dynamics of each of the
CTAM groups represented within the EGF and IGF-1-treated dataset were analysed systemat-
ically (Fig 5.4). This revealed that the identified CTAM groups (i.e. branches of the signalling
network) were modulated by the two growth factors with the expected kinetics286,287. This served
to validate the biological accuracy of the approach and the biological relevance of the defined
network. Moreover, this demonstrated the ability of the technique to provide an informative snap-
shot of network activity for each condition derived from an independently generated dataset (Fig
5.5). Multivariate analysis of the CTAM network state at each time-point provided insight into
the differences in the CTAM network’s plasticity between EGF and IGF-1 treatment (Fig 5.6).
This analysis, in-line with the observations made in Fig 5.2-5.5, showed that IGF-1 induced more
sustained changes in the network’s activity compared to EGF. As a whole, these analyses demon-
strated that this method of network analysis was not only able to recapitulate the known impacts
on PI3K/Akt/mTOR and MEK signalling, but was also able to resolve the differences in the kinetics
of network plasticity induced by the two growth factors.
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It can be argued that, if the CTAM groups representing the network are true reflections of
biochemical signalling pathways, individual phosphorylation sites within each CTAM group should
demonstrate consensus in their activation kinetics. Analysis of the intra-group variability in re-
sponse to the two growth factors revealed that the majority of CTAMs showed relatively similar
behaviour at each time-point (Fig 5.7). Importantly, visual assessment of both a densely and lightly
populated CTAM group demonstrated that this observation was largely independent of group size
(Fig 5.8).
7.3.3 Strengths and limitations of CTAM measurement
The monitoring of network activity through the use of empirically defined CTAMs has several
advantages. This method of analysis confers the experimenter with the ability to assess global
network dynamics in an untargeted manner and without bias towards particular branches of the
network. The inference of signalling pathway activity from large-scale phosphoproteomics experi-
ments is a significant technical challenge. Several bioinformatic approaches, based on literature-
derived signalling networks have been used for this purpose (e.g. Ingenuity Pathway Analysis318
and KEGG297). As previously discussed, however, these methods neglect cell-specific interac-
tions between kinases and their substrates. Although efforts have been made to include context-
specific interactions within these models319, these still do not afford the resolution of changes at
the level of individual phosphorylation sites. Therefore, as the CTAM-based profiling of the net-
work is specific to the biological system under interrogation (i.e. MCF7-defined CTAMs are used
to analyse independent experiments with MCF7 cells), and provides phosphorylation site-level
resolution, this method of analysis provides a model closer to the biological reality. Furthermore,
in contrast to other methods used for the untargeted profiling of kinase activites, such as mul-
tiplexed kinase inhibitor beads (MIBS)-MS – where the activity of individual kinases is probed
and inferred in isolation320,321 – the CTAM grouping method provides information regarding the
circuitry of kinase activation.
Despite the advantages afforded by CTAM-based network analyses, several disadvantages
present themselves. Firstly, although there may be a portion of CTAMs that are common be-
tween independent biological systems, to truly render the analysis context-specific, CTAMs must
be empirically defined for each model to be studied. Although this is relatively straightforward in
a well-controlled, well-established cell-line or easily cultured primary model, it would be challeng-
ing in an in vivo setting. Secondly, as the network currently only contains approximately 2% of
theoretical human kinome, it is inherently biased towards a pre-determined selection of kinase
activities. This, as previously discussed, would be improved with a more comprehensive analysis
of kinases within the network using state-of-the-art instrumentation. Finally, as the magnitude and
kinetics of the change in abundance of individual phosphorylation sites in response to external
stimuli is tightly controlled – and indeed variations in signal intensity and frequency can have dis-
tinct downstream impacts322 – computing the mean of these intensities in order to infer the activity
of the group as a whole leads to a loss of this information. For example, the EGFR-MEK group
(shown in Fig 5.8B) contained four quantifiable CTAMs in this experiment. Although the temporal
kinetics of each of the four CTAMs followed an almost identical increase in abundance and sub-
sequent decay (suggesting that they do indeed represent a biochemical pathway), the magnitude
of these changes is substantially different. Despite the fact that these differences may be integral
to the function of the pathway, this information is lost when the mean, and therefore total group
activity, is computed (Fig 5.8B, red line).
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7.3.4 Implications and future work
The kinase signalling network defined in Chapter 4 was utilised to successfully profile EGF and
IGF-1-induced network plasticity in an untargeted manner. These data serve to validate both the
method by which the network was defined, and provides proof-of-concept of measuring its plas-
ticity in independent MS experiments. Therefore, this provides a platform by which this signalling
network can be profiled in these (and potentially other) cell-line models, under any given condition.
Systems-level analyses of EGF-induced phosphorylation kinetics have been performed by
several groups286,323; however, despite its importance in biology and disease, the global effects
of IGF-1 on the phosphoproteome are less well-characterised. Thus, whilst validating the CTAM-
based profiling of the signalling network, this study provides a valuable resource for the further
interrogation of IGF-1’s function.
In conjunction with the previously discussed expansion of the network with a greater number
of kinases, the work in this study could be expanded upon through the further subsetting of EGF
and IGF-1-responsive phosphorylation sites within each CTAM group. This would provide greater
resolution of the effects of these growth factors, as although two phosphorylation sites may indeed
belong to the same biological signalling pathway, they might not both be responsive to the same
growth factor(s).
7.4 Plasticity of the defined kinase signalling network in models of ac-
quired resistance
Targeted kinase inhibitors show great promise for the treatment of a number of malignancies.
Such therapies, although not effective in 100% of patients due to intrinsic resistance, are often
effective upon initial treatment. Unfortunately, initially responsive tumours almost inevitably ac-
quire resistance to the relevant inhibitor and relapse as a consequence. The mechanisms of this
form of drug resistance have been studied intensively in order to facilitate the rational design of
drug alterations/combinations to prevent or reverse its occurrence. Despite the uncovering of sev-
eral mechanisms by which cells can evade prolonged targeted kinase inhibition, it has become
increasingly clear that the global remodelling and plasticity of signalling networks level plays a
key role97,191,320. Thus, in this study, the plasticity of signalling networks in response to chronic,
targeted kinase inhibition was examined through the use of the network defined and validated in
Chapters 4 and 5.
7.4.1 Development of models of acquired resistance
In order to examine the effects of chronic PI3K and mTORC1/2 inhibition – by GDC-0941 and KU-
0063794 respectively – models of acquired resistance to these two compounds were developed.
To this end, a single parental MCF7 culture was homogenised and separated into six identical
populations of cells. Three of these were then intially treated with 100 nM GDC-0941 and three
with 100 nM KU-0063794 (Fig 6.1). A relatively low initial concentration of each drug was chosen
so as to allow the majority of cells to survive the initial treatment (as this concentration was below
the IC50 of both drugs – Fig 6.2) and to therefore minimise the outright selection of intrinsically
resistant cells. The concentrations of each of the drugs was then gradually increased over each
passage to a maximum of 1 M. This maximum was selected so as to minimise confounding
off-target effects of each inhibitor.
The resistance of the resulting cultures was determined by means of longitudinal proliferation,
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MTS and CV cell viability assays (Fig 6.3). These assays demonstrated that each of the cultures
had acquired resistance to the relevant inhibitor; however, a degree of heterogeneity was ob-
served in the proliferation rates of each of the resistant cell-lines. In-line with the observation that
the parental cells were initially more sensitive to GDC-0941, the cells treated with this inhibitor
were comparatively more resistant than those treated with KU-0063794 (Fig 6.3C-D). Interest-
ingly, alongside the validation of the cell-lines’ acquired resistance to these compounds, these
data demonstrated that, despite these cells’ ability to proliferate and increase in absolute number
in the presence of 1 M drug (Fig 6.3C-D, purple bars), their metabolic capacity – as inferred by
the MTS assay – was affected to a greater extent (Fig 6.3C-D, orange bars). This was particularly
prominent with regards to the cells resistant to the mTORC1/2 inhibitor; this being consistent with
mTOR’s central role in metabolic regulation49,54.
7.4.2 Phosphoproteomic, CTAM network and phenotypic analyses of the resistant cell-
lines
Having established the drug resistance of the cell-line models, their phosphoproteomes and total
proteomes were compared to that of the parental cells by mass spectrometry. This culminated
in the reliable quantification of 11,307 unique phosphopeptide ions and 2,593 proteins across
the seven cell-lines. The log2 fold-ratios (vs parental) for each phosphopeptide ion were subse-
quently normalised to the log2 fold-ratios (vs parental) for each protein (where these data were
available), producing a stoichiometry ratio. Initial analyses of these data demonstrated that a
large number of phosphopeptides and proteins were significantly altered in abundance in the re-
sistant cells (Table 6.2). Consistent with published studies demonstrating remodelling of kinase
signalling in response to chronic kinase inhibition324,325, CTAM network profiling of these cells
revealed widespread differences in network branch activity in comparison to the parental cells
(Fig 6.4). Due to the depth of this analysis however, these data emphasise the extent to which
signalling networks are globally remodelled in order to overcome the chronic inhibition of single
nodes. These experiments also showed that, as substrates of the CTAM groups comprised of
mTOR and PI3K (e.g. Akt-mTOR-PI3K and Akt-mTOR-p70S6K-PI3K) remained inhibited in the
resistant cells, their acquired resistance was likely not as a result of reactivation of these kinases
or an up-regulation of drug-efflux pump expression – both of which being common mechanisms of
resistance to small-molecule inhibitors such as these – but rather via activation of compensatory
branches of the network. These observations were supported through Western blot analysis of
PI3K, Akt, and mTOR activation markers (Fig 6.6).
Further exploration of the CTAM network data (Fig 6.4) through the use of multivariate analy-
ses revealed the extent of the differences in network activity between the resistant cells and the
parental cells. This also highlighted the differences in network remodelling between the MCF7-G
and -K cells (Fig 6.5). This strongly supported the idea that cells chronically treated with GDC-
0941 remodelled their network differently to those treated with KU-0063794, despite PI3K and
mTORC1/2’s canonical association with one another. These data also suggested that, due to the
separation of cell-lines resistant to the same drug in PC-space (e.g. MCF7-K1, -K2 and -K3),
these cells had evolved subtly different responses to the same compound.
In order to examine whether remodelling of the defined signalling network in the resistant cells
manifested itself in a phenotypic outcome, and whether the differences in network remodelling
between the parental and resistant cells could be recapitulated with an independent technique,
the responses in viability of each of the resistant cell-lines to a panel of small-molecule kinase
inhibitors were tested. It was reasoned that, as the wiring of the signalling network defines the
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sensitivity of cells to targeted kinase inhibition, remodelling of this network should alter the way
in which the resistant cells responded to these drugs. These data demonstrated that, not only
were the resistant cells’ responses substantially different from those of the parental cells, but the
differences between MCF7-G and -K cells, and those between cells resistant to the same drug,
were maintained (Fig 6.7). Multivariate analyses of these data reinforced these observations;
separating the parental cells, MCF7-G and MCF7-K cells from one another (Fig 6.8). These
experiments lend further credence to the idea that cells treated chronically with GDC-0941 or
KU-0063794 remodel their network differently, whilst promoting the notion that even cells treated
with the same compound can evolve divergent responses. Taken together, the CTAM network and
phenotypic profiling of the resistant cells accentuate the complex relationship between PI3K and
mTORC1/2; one that is yet to be fully elucidated. These data are consistent however, with the
observation that phosphorylation sites modulated by mTORC1/2 and PI3K inhibitors only partially
overlapped (Chapter 4; Fig 4.8) and with recent data highlighting mTOR’s independence from
PI3K in some systems326.
7.4.3 Rewiring of the signalling network in cells resistant to GDC-0941
The experiments presented in Section 6.4 provided evidence to suggest that the defined sig-
nalling network had been remodelled upon acquisition of kinase inhibitor resistance, and that this
remodelling was distinct between parental, MCF7-G, and MCF-K cells. To determine whether
the network was indeed rewired (i.e. signals being propagated via different routes) or whether
this remodelling was as a result of a simple increase in abundance of particular CTAMs, EGF-
induced changes in the phosphoproteome were compared between the parental and MCF7-G
cell-lines (Table 6.3). Although these experiments were performed on a lower performance instru-
ment (Orbitrap-XL), 4,228 unique phosphopeptide ions were able to be compared across the 16
conditions. Analysis of the phosphopeptides showing significant alterations in their abundance
in conjunction with CTAM network profiling of these data, revealed that the temporal dynamics
of EGF-responsive signals were substantially altered in the resistant cells when compared to the
parental cell-line (Fig 6.9-6.10). Further examination of these using multivariate analyses cor-
roborated these observations; separating the EGF-induced responses of the resistant cells from
those of the parental cell-line (Fig 6.11). These analyses, mirroring the heterogeneity in network
remodelling observed in Fig 6.5 and 6.8, also highlighted that the signalling networks of these
cells relaxed back towards their basal states through profoundly different routes in PC-space. Al-
though these phosphoproteomics data were not normalised to total protein amounts (and there-
fore changes in phosphopeptide abundance over time may have been as a result of changes in
absolute protein amount), they still highlight that the EGF-induced signals were processed differ-
ently between the cell-lines. For example, even though it is not possible to determine whether a
phosphorylation site increased in abundance after 120 minutes of EGF exposure is stoichiomet-
rically valid, the fact that the protein’s abundance may also be increasing (and not in the other
cell-lines) demonstrates that there remains a difference in signal processing.
Having provided evidence to suggest that the signalling network had indeed been rewired in
the MCF7-G cells and that this rewiring was different between these three cell-lines, it was hypoth-
esised that this may have been as a result of a difference in EGFR internalisation and degradation.
Consistent with recently published data, Western blots for total EGFR in the parental cells showed
that the receptor is gradually degraded upon prolonged exposure to EGF291 (Fig 6.12A). These
data also showed however, that these kinetics were profoundly different in each of the MCF7-G
cell-lines. Akt has been shown to control the trafficking and degradation of EGFR291, and as
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such, it is perhaps unsurprising that chronic inhibition of its upstream activator (PI3K) resulted
in an interference of this process in MCF7-G2 and -G3 cells. Interestingly, these experiments
suggested that MCF7-G1 cells were able to correctly degrade EGFR in a PI3K/Akt-independent
manner, suggesting that the lack of Akt activity may have been compensated for by an alternate
signalling pathway (summarised in Fig 7.1). Further work assessing the pathway responsible and
investigation of the spatial processing of EGFR in these cells would elucidate this mechanism to
a greater extent.
Figure 7.1: Models of EGFR recycling and degradation in parental and resistant cells. (A) Parental cells: EGFR
dimerises and autophosphorylates upon binding to EGF. Receptor complexes are then trafficked into early endosomes
where they continue to signal. Akt phosphorylation of PIKfyve aids in the correct endosomal progression of EGFR and
its ultimate degradation. (B) MCF7-G1 cells: chronic inhibition of PI3K abrogates activation of Akt and therefore its phos-
phorylation of PIKfyve. The lack of Akt-dependent PIKfyve phosphorylation is potentially compensated for by unknown
parallel processes and EGFR endosomal progression is restored. (C) MCF7-G2 and -G3 cells: chronic inhibition of PI3K
abrogates activation of Akt and PIKfyve as in (B). EGFR does not properly progress through early and late endosomes
and therefore is not degraded in the correct manner, leading to its accumulation.
Consistent with the mass spectrometry data summarised in Fig 6.9 and 6.10, ERK1/2 phos-
phorylation and activation remained responsive to EGF in the resistant cells (Fig 6.12B). In con-
trast, despite the clear activation of the Akt-mTOR-PI3K CTAM group observed in Fig 6.10, yet
consistent with a maintained inhibition of PI3K (Fig 6.6B), phosphorylation of Akt at Ser473 was not
responsive to EGF stimulation in these cells (Fig 6.12B). These data therefore suggest that the
resistant cells had evolved a PI3K/Akt activation-independent manner by which the downstream
substrates of these kinases could retain their responsiveness to growth factor stimulation.
7.4.4 Evolutionary routes to acquired resistance: lessons from chaos theory
Taken together, the experiments presented in Chapter 6 strongly supported the idea that the de-
fined signalling network had been remodelled and rewired in the cells chronically treated with
inhibitors of PI3K and mTORC1/2. These data suggested that, with respects to the GDC-0941-
resistant cells, growth-stimulatory signals were re-routed through the network in order to maintain
their proliferative effect(s) and bypass the continued inhibition of PI3K. These results are consis-
tent with recent publications indicating that, rather than there being a single route by which cells
can acquire resistance to a given therapy, there is a plethora of ways in which signalling networks
can be rewired given prolonged kinase inhibition327,328. It is not known, however, whether the way
in which cancer cells acquire resistance is predetermined by the molecular imprinting of cancer
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cells at presentation – i.e. whether the acquisition resistance is entirely non-random (determin-
istic) or whether it involves some random elements (indeterministic). This understanding has
potential implications for cancer therapeutics as, if the acquisition of resistance is deterministic
and therefore reliant on genomic or other molecular factors present in tumour cells at presenta-
tion, then analysing the initial conditions of cancer cells could be used to predict the resistance
mechanism likely to occur in such a tumour.
In this study, the same cell-line was split into six isogenic cultures, which were then main-
tained in the same concentrations of inhibitors by the same operator for the same amount of
time and passage numbers. Despite this homogeneity in treatment, as previously discussed, the
remodelling of the network and the subsequent sensitivity of the cells to multiple inhibitors was
remarkably heterogeneous. Intra-tumoural heterogeneity has been documented at the genomic
level329 and this study suggests therefore, that diversity at the kinase signalling and functional
levels also evolves as a result of chronic treatment with kinase inhibitors. Thus, as identical ex-
perimental conditions resulted in the evolution of distinctly remodelled signalling networks and
drug-resistance phenotypes, the initial conditions of the system were not predictive of the evo-
lutionary route that led to resistance. Although this study was performed in an in vitro system,
it may be argued that the heterogeneity and complexity in in vivo systems can only be greater.
Therefore, in support of an indeterministic model of acquired resistance, these data suggest that
it may not be possible to predict the particular mechanism of resistance of a given tumour through
knowledge of its molecular constitution at presentation. On the contrary, however, this apparent
stochasticity may be as a result of deterministic chaos.
Chaos theory constitutes the study of the behaviour of highly dynamic and interconnected
systems that are heavily dependent on their initial conditions – i.e. an arbitrarily-sized difference
between the initial conditions of two otherwise identical systems can give rise to exponentially dif-
ferent future behaviours of each system (described by the Lyapunov exponent, Fig 7.2). Thus, al-
though these systems may be fundamentally deterministic, the prediction of their future behaviour
is exceptionally difficult. This phenomenon is therefore referred to as deterministic chaos. This
has clear implications for the development of cancers (as has been previously investigated330,331);
however, the application of models of this nature to the acquisition of resistance remains unex-
plored.
The data in Chapter 6 strongly suggest that, due to the complexity of the system and poten-
tially stochastic variation of its evolution, the identification of resistance mechanisms at a global
signalling level in individual tumours will require the ability to measure said network – with depth
and without bias – after the emergence and detection of resistance. On the contrary, if the system
is truly deterministic as stated by chaos theory, an increase of the accuracy with which the initial
conditions can be determined may increase its predictability. In practice, however, due to the com-
binatorial complexity of the number of variables involved in tumourigenesis and resistance (e.g.
genomic aberrations, epigenetic factors, kinase signalling dynamics, metabolic abnormalities and
environmental factors), this may prove to be an impossible task. Therefore, the aforementioned
notion of measuring these signalling networks by mass spectrometry once resistance has been
acquired, may be a reasonable strategy in the management of this phenomenon. Further work
determining the utility and power of this type of profiling in the prediction of rational secondary
drug therapies, alongside advancements in mass spectrometric (and other) technologies, will
determine whether this is indeed a viable approach. Alongside this, the application of chaotic
mathematical models to the evolution of kinase signalling networks may provide a deeper under-
standing of how this occurs. Indeed, longitudinal analyses of these resistant cell-lines’ or other
resistance models’ signalling network at different points in their evolution (i.e. Zt ), would provide
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insight as to the predictability of these systems332.
Figure 7.2: An illustration of deterministic chaos. Two seemingly identical systems (grey and white) start at defined
points in space (Z0) and possess a slight difference in their initial conditions (Z0). As the systems evolve (e.g. due
to chronic treatment with a kinase inhibitor), they diverge as a function of time (t), at a rate defined by the Lyapunov
exponent () 333. The rate of this change is dependent on the magnitude of Z0 and the initial spatial direction with which
this divergence occurs. The inverse of this function, the Lyapunov time, represents the time for Zt to increase by a factor
of e 332.
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7.5 Concluding remarks
PI3K and mTORC1/2 are two kinases with great importance to human biology and disease. Ther-
apeutic targeting of these and other kinases shows great promise in the continued improvement of
cancer chemotherapeutics. Mass spectrometry-based phosphoproteomics has enabled the inves-
tigation of kinase signalling to depths that were previously impossible. The depth of such analyses
has highlighted that kinase signalling is much more complex than has been previously appreciated
and has demonstrated the utility of treating these systems as interconnected networks. Knowl-
edge such as this continues to provide insights towards the ultimate goal of personalised cancer
therapies. Furthermore, as the control signalling networks exert on biological processes is not
restricted to cancer, these advances will have wide-reaching implications for other diseases.
The evolution of kinase signalling networks upon the acquisition of resistance to kinase in-
hibitor therapies has not yet been investigated at a global, network level. Therefore, the work
within this thesis sought to first improve upon existing mass spectrometric and sample process-
ing technologies for phosphoproteomics analyses, and to then apply these to the global study of
acquired resistance.
The results of these investigations have provided insight into the architecture of kinase sig-
nalling networks and how these evolve in response to chronic single-node inhibition. These find-
ings raise interesting questions about the nature of the acquisition of resistance and the impli-
cations of this for the future clinical management of this phenomenon. It remains to be deter-
mined whether these systems are truly deterministic and whether it is possible to predict resis-
tance mechanisms at initial disease presentation. Although a challenging problem, the continued
improvement of mass spectrometric technologies, alongside the potential for the application of
chaotic mathematical models to these data, may provide a step towards answers to these ques-
tions.
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Appendix 1
Summary of CTAM identifications (Chapter 4).
CTAM group Phosphorylation site
Akt-CAMK2-EGFR-ERK-MEK-mTOR PHF12(S977)
Akt-CAMK2-EGFR-ERK-MEK-mTOR PRCC(S267)
Akt-CAMK2-EGFR-ERK-MEK-mTOR SERPINA10(T297)
Akt-CAMK2-EGFR-ERK-MEK-mTOR SSFA2(S737+S739)
Akt-CAMK2-EGFR-ERK-MEK EIF3G(T41+S42)
Akt-CAMK2-EGFR-ERK-MEK JUND(S90)
Akt-CAMK2-EGFR-ERK-MEK PBK(T24+S32)
Akt-CAMK2-EGFR-ERK-MEK RPLP2(S102+S105)
Akt-CAMK2-EGFR-ERK-ROCK ANXA13(Y291+S294)
Akt-CAMK2-ERK-MEK-mTOR USP13(S630)
Akt-CAMK2-mTOR-p70S6K-PI3K RICTOR(T1135+S1138)
Akt-ERK-mTOR-p70S6K-PI3K ZNF687(S1118)
Akt-mTOR-p70S6K-PI3K-PKC WWTR1(S93)
Akt-CAMK2-EGFR-ERK DSP(S38)
Akt-CAMK2-EGFR-ERK KAT7(T302+S303)
Akt-CAMK2-EGFR-ERK KLF16(S230)
Akt-CAMK2-EGFR-ERK NOS1AP(S371+S374)
Akt-CAMK2-EGFR-ERK PER2(S77)
Akt-CAMK2-EGFR-ERK TNKS1BP1(S494+S504)
Akt-CAMK2-EGFR-mTOR PLEC(T4030)
Akt-CAMK2-EGFR-p70S6K GAPDH(T184)
Akt-CAMK2-ERK-MEK FBRSL1(T989+T1010)
Akt-CAMK2-mTOR-PI3K EIF4EBP1(T41+S44)
Akt-EGFR-ERK-mTOR DLGAP4(S973)
Akt-mTOR-p70S6K-PI3K C10orf47(S43)
Akt-mTOR-p70S6K-PI3K C2orf78(S624+S625)
Akt-mTOR-p70S6K-PI3K CHD1(S1385)
Akt-mTOR-p70S6K-PI3K CHD1(S1387)
Akt-mTOR-p70S6K-PI3K CIC(S299)
Akt-mTOR-p70S6K-PI3K CLMN(S921)
Akt-mTOR-p70S6K-PI3K CNBP(S47)
Akt-mTOR-p70S6K-PI3K CTDSPL2(S28)
Akt-mTOR-p70S6K-PI3K EHMT2(S232)
Akt-mTOR-p70S6K-PI3K EPRS(T956)
Akt-mTOR-p70S6K-PI3K GTPBP4(T201+T202)
Akt-mTOR-p70S6K-PI3K HMGCR(S872)
Akt-mTOR-p70S6K-PI3K IFT122(Y146+S157)
Akt-mTOR-p70S6K-PI3K KRT8(S477)
Akt-mTOR-p70S6K-PI3K MACF1(S1376)
Akt-mTOR-p70S6K-PI3K MACF1(S1378)
Akt-mTOR-p70S6K-PI3K MTDH(S494)
Akt-mTOR-p70S6K-PI3K MYO5A(S1652)
Akt-mTOR-p70S6K-PI3K NEK9(S332)
Akt-mTOR-p70S6K-PI3K NOLC1(S686+S698)
Akt-mTOR-p70S6K-PI3K PCBP2(S272)
Akt-mTOR-p70S6K-PI3K PLEC(S4406)
Akt-mTOR-p70S6K-PI3K PLEC(T4411)
Akt-mTOR-p70S6K-PI3K RBL2(S1138)
Akt-mTOR-p70S6K-PI3K RBM14(S618)
Akt-mTOR-p70S6K-PI3K RICTOR(T1135)
Akt-mTOR-p70S6K-PI3K RPS6KB1(S427)
Akt-mTOR-p70S6K-PI3K SART1(S448)
Akt-mTOR-p70S6K-PI3K SETD1A(S1171)
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Akt-mTOR-p70S6K-PI3K SPATS2L(S135)
Akt-mTOR-p70S6K-PI3K UCK1(S253)
Akt-mTOR-p70S6K-PI3K WDHD1(S374)
Akt-mTOR-p70S6K-PI3K YBX1(S209)
Akt-mTOR-p70S6K-PI3K ZFP36L1(S334)
p70S6K-PI3K-PKC-ROCK ZYX(S143)
Akt-CAMK2-EGFR ATG4B(S383)
Akt-CAMK2-EGFR DSP(T2612)
Akt-CAMK2-EGFR FAM177A1(S70+T71)
Akt-CAMK2-EGFR LSR(S643+S646)
Akt-CAMK2-EGFR MAP7D1(S834)
Akt-CAMK2-EGFR NCOR2(S1018)
Akt-CAMK2-EGFR NOTCH2(S1804)
Akt-CAMK2-EGFR PTGES3(S148)
Akt-CAMK2-EGFR RANBP2(S2628)
Akt-CAMK2-EGFR RANGAP1(S428+S442)
Akt-CAMK2-EGFR ROCK2(S1134+S1137)
Akt-CAMK2-EGFR SMARCAD1(S124+S127)
Akt-CAMK2-EGFR SRRM2(S1398+S1404)
Akt-CAMK2-EGFR TRMT112(S119)
Akt-CAMK2-EGFR YWHAQ(S230)
Akt-CAMK2-ERK GORASP2(T423+S451)
Akt-CAMK2-ERK PRKCD(T507)
Akt-EGFR-ERK AHNAK(S1298)
Akt-EGFR-ERK MAP2K4(T391+S394)
Akt-EGFR-ERK MAVS(S258)
Akt-EGFR-ERK MCM3(S711+T722)
Akt-EGFR-MEK RSF1(S1359+S1375)
Akt-ERK-MEK PPP1R12A(T696)
Akt-mTOR-PI3K AKT1S1(S183)
Akt-mTOR-PI3K ARFGAP2(S368)
Akt-mTOR-PI3K BAHD1(S121)
Akt-mTOR-PI3K BCL7C(S126)
Akt-mTOR-PI3K CCNL1(S335+S338)
Akt-mTOR-PI3K CTTN(T440)
Akt-mTOR-PI3K EEF2K(S71+S74)
Akt-mTOR-PI3K EIF4EBP1(S65+T68)
Akt-mTOR-PI3K EIF4EBP1(T37+T41)
Akt-mTOR-PI3K EIF4EBP1(T68+T70)
Akt-mTOR-PI3K EIF4EBP2(S65+T70)
Akt-mTOR-PI3K EIF4EBP2(T70)
Akt-mTOR-PI3K EIF4EBP2(Y34+T46)
Akt-mTOR-PI3K FAM54A(S305)
Akt-mTOR-PI3K FAM83H(S1024)
Akt-mTOR-PI3K FOXK1(S249+S253)
Akt-mTOR-PI3K FOXK1(S257)
Akt-mTOR-PI3K FOXK2(S369)
Akt-mTOR-PI3K FOXK2(S385)
Akt-mTOR-PI3K GSK3B(S9)
Akt-mTOR-PI3K LAMTOR1(S98)
Akt-mTOR-PI3K LARP1(S1058)
Akt-mTOR-PI3K LARP1(S774)
Akt-mTOR-PI3K LIMA1(S230)
Akt-mTOR-PI3K MYC(S62)
Akt-mTOR-PI3K MYCBP2(S2833)
Akt-mTOR-PI3K PCBP1(S246)
Akt-mTOR-PI3K PCBP1(S262)
Akt-mTOR-PI3K PCBP1(S263)
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Akt-mTOR-PI3K PDE3B(S494)
Akt-mTOR-PI3K PUM1(S209)
Akt-mTOR-PI3K RITA(S248)
Akt-mTOR-PI3K RN3L1(S44)
Akt-mTOR-PI3K RPS6KB1(S447+S452)
Akt-mTOR-PI3K SEC14L1(T234)
Akt-mTOR-PI3K SUN2(S20)
Akt-mTOR-PI3K TBX2(S657)
Akt-mTOR-PI3K TP53BP1(S1430)
Akt-mTOR-PI3K TPR(T650)
Akt-mTOR-PI3K UBA1(S816)
Akt-mTOR-PI3K USP32(S1361)
Akt-mTOR-PI3K USP32(S1366+S1371)
Akt-mTOR-PI3K VWA7(S305+S325)
Akt-mTOR-PI3K WDHD1(S374+S383)
Akt-mTOR-PI3K ZNF185(S64)
EGFR-ERK-MEK INCENP(T145+S148)
EGFR-PI3K-PKC SPTBN1(S2358)
mTOR-p70S6K-PI3K BOD1L1(S635)
mTOR-p70S6K-PI3K BOD1L1(S637)
mTOR-p70S6K-PI3K C14orf43(T698+S700+S718)
mTOR-p70S6K-PI3K C5orf30(S167)
mTOR-p70S6K-PI3K F12(S335+T337)
mTOR-p70S6K-PI3K RBM14(S620)
mTOR-p70S6K-PI3K WWTR1(S89)
p70S6K-PI3K-PKC ZYX(S142)
Akt-CAMK2 ARHGAP35(S975+S985)
Akt-CAMK2 CACNB1(T217+S228+Y242)
Akt-CAMK2 CARHSP1(S30+S32+S41)
Akt-CAMK2 DDHD1(T726+S727)
Akt-CAMK2 EEF1B2(S106)
Akt-CAMK2 FAM122B(S222+S245)
Akt-CAMK2 FBXW7(S396)
Akt-CAMK2 FKBP15(S1114)
Akt-CAMK2 FOXO3(S75)
Akt-CAMK2 FSBP(S191+S193+T204)
Akt-CAMK2 GIT2(S418+S421)
Akt-CAMK2 GPKOW(S471)
Akt-CAMK2 INCENP(T239)
Akt-CAMK2 KIAA0284(S951+S954)
Akt-CAMK2 KIAA1429(S138)
Akt-CAMK2 KLHDC4(S413+S418)
Akt-CAMK2 MAP2K4(S257)
Akt-CAMK2 MARK4(T214)
Akt-CAMK2 MAVS(S152+T163)
Akt-CAMK2 MKL2(S207+T227)
Akt-CAMK2 NKX6-3(T8)
Akt-CAMK2 PARP4(T1119)
Akt-CAMK2 PRKACA(T198)
Akt-CAMK2 PRKACA(T202)
Akt-CAMK2 PRKCD(T511)
Akt-CAMK2 PRKCI(T410)
Akt-CAMK2 RAB11FIP2(S150)
Akt-CAMK2 RPUSD1(S271)
Akt-CAMK2 RRM2(S20)
Akt-CAMK2 SAP30BP(S18+S22)
Akt-CAMK2 SERHL2(T272)
Akt-CAMK2 SMN1(S28+S31)
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Akt-CAMK2 STRN(S245)
Akt-CAMK2 TFG(S193+S197)
Akt-CAMK2 TOP2B(S1522+S1524)
Akt-CAMK2 TRIP12(S1317+S1322)
Akt-CAMK2 UBAP2L(S428)
Akt-CAMK2 UNC13D(S150)
Akt-CAMK2 WAPAL(S77)
Akt-EGFR DCAF5(S648)
Akt-EGFR EIF4G1(T205+T207)
Akt-EGFR GAPVD1(S1105)
Akt-EGFR KDM1A(T59)
Akt-EGFR MFAP1(T267)
Akt-EGFR PA2G4(S2+T11)
Akt-EGFR PFDN4(S125)
Akt-EGFR PXN(S126+S130)
Akt-EGFR TNFRSF10A(S466)
Akt-ERK AGAP2(S808)
Akt-mTOR EP400(T1738)
Akt-mTOR NSD1(S979)
Akt-mTOR RAPGEF6(S1070)
Akt-mTOR SERBP1(S392)
Akt-mTOR UBA1(S816+S820)
Akt-p70S6K BTF3(S161)
Akt-p70S6K RAD18(S99)
Akt-PI3K CCNL1(T325+S341+S342)
Akt-PI3K CDC42EP2(S109)
Akt-PI3K FOXK1(S236+S257)
Akt-PI3K GAPVD1(S566+S569)
Akt-PI3K SEMA4B(S825)
Akt-PI3K STIP1(S16)
Akt-PKC YEATS2(T1149+T1165)
CAMK2-EGFR NUP153(S209)
CAMK2-EGFR SCRIB(S1306+S1309)
CAMK2-EGFR SPICE1(S760+S764)
CAMK2-EGFR TRIM28(S43)
EGFR-ERK C14orf43(S700+S709)
EGFR-MEK MAPK1(T185+Y187)
EGFR-MEK RANBP2(S1869)
EGFR-MEK TPR(S2155)
EGFR-p70S6K TMCC1(S382)
ERK-mTOR C14orf43(S461)
ERK-p70S6K RXRA(T23)
MEK-PKC ERF(S532)
mTOR-p70S6K USP5(S785)
mTOR-PI3K ATRX(S594)
mTOR-PI3K ATRX(S598)
mTOR-PI3K BCAS3(S838)
mTOR-PI3K CTTN(S438)
mTOR-PI3K EEF2K(S74)
mTOR-PI3K FOXK2(T389+S392)
mTOR-PI3K HDGFRP2(S454)
mTOR-PI3K IBTK(Y996+S1004)
mTOR-PI3K LARP1(S1056)
mTOR-PI3K LARP4B(S568)
mTOR-PI3K LIMA1(S225)
mTOR-PI3K MAF1(S60+S68)
mTOR-PI3K MKI67IP(S218+T240)
mTOR-PI3K MREG(S213)
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mTOR-PI3K NDRG3(S331)
mTOR-PI3K PCBP1(S264)
mTOR-PI3K PLEKHA3(S244)
mTOR-PI3K PXN(S137)
mTOR-PI3K PXN(T136)
mTOR-PI3K SPHKAP(T741)
mTOR-PI3K USP24(S2561)
mTOR-PI3K USP24(T2565)
p70S6K-PI3K AKAP11(S18)
p70S6K-PI3K CD2AP(S234)
p70S6K-PI3K CPSF7(T67+Y72+S75)
p70S6K-PI3K FKBP15(S1012)
p70S6K-PI3K FKBP15(S346)
p70S6K-PI3K PFKFB2(S483)
p70S6K-PKC EPS8L2(S459)
p70S6K-PKC EPS8L2(S466)
p70S6K-PKC OR1A1(T280+Y288)
p70S6K-PKC TPD52(S176)
p70S6K-PKC UBL7(S230)
p70S6K-PKC YAP1(S61)
PI3K-PKC KIAA1598(S249)
PI3K-PKC NCBP1(S22)
PI3K-PKC PAK2(S197)
PI3K-PKC SCNN1D(S6)
PKC-ROCK EMD(S173)
Akt ACACA(S29)
Akt AFTPH(S411)
Akt AHNAK(S4360)
Akt AHNAK(T4766)
Akt AKAP13(S790)
Akt ANK3(S1326+S1327+T1334)
Akt ANLN(S661)
Akt ARAP1(S229)
Akt ASXL2(S834+S842)
Akt ATF2(S90)
Akt ATXN2L(S559)
Akt B4GALT1(S9+S11+S18)
Akt BAG3(S377+S386)
Akt BAG3(S385)
Akt BAIAP2L1(T416)
Akt BANP(S90)
Akt BPTF(S1060+T1064)
Akt BRD9(S588)
Akt BZW2(S412+S414)
Akt C17orf85(S25)
Akt CAMSAP2(S611)
Akt CAMSAP3(S1048)
Akt CAMSAP3(S1048+S1051)
Akt CBL(S452)
Akt CCDC43(T139)
Akt CCDC6(S254)
Akt CCDC6(T436)
Akt CHAMP1(S282)
Akt CIC(S77)
Akt CIZ1(T872)
Akt CLIP1(S152)
Akt CLNS1A(S197)
Akt CP(T528)
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Akt CSTF2(S524)
Akt CTNND1(T177)
Akt CTPS1(S574+S575)
Akt CYP2S1(T295+T304+T314)
Akt DAP(S51)
Akt DAXX(S688+S702)
Akt DCAF5(S531)
Akt DCP1A(S180)
Akt DCTPP1(T170)
Akt DIDO1(S898)
Akt DIP2A(T279)
Akt DIP2B(S153)
Akt DNMT1(S394)
Akt DPF2(Y172)
Akt DSP(S2821+S2825)
Akt DYNC1LI1(S207)
Akt EIF4G1(S204)
Akt EIF4G1(T211)
Akt EIF5B(S135+S137)
Akt ERBB2IP(Y920+S932)
Akt EXOC1(S501)
Akt EXOSC9(S392+S394)
Akt FAM102B(S320)
Akt FGFR1OP(S160)
Akt FKBP15(S311)
Akt FKBP3(S152)
Akt FLNA(S2163)
Akt FTH1(S183)
Akt FUBP1(S630)
Akt FYTTD1(S23)
Akt GAB2(T287)
Akt GAPDH(T75)
Akt GAPVD1(S569)
Akt GAPVD1(S758+S761)
Akt GATAD2B(S129+S135)
Akt GEMIN5(S778)
Akt GOLGB1(S17)
Akt GORASP2(S451)
Akt GRIPAP1(S692)
Akt GSG2(S179)
Akt GTF2I(S679)
Akt GYS1(S727)
Akt HCFC1(S1507)
Akt HMGCS1(S495)
Akt HNRNPK(S116)
Akt INF2(S1149)
Akt KDM2A(S718)
Akt KDM2A(T713+S718+T720)
Akt KIAA0284(S655)
Akt KIAA1429(S133)
Akt KIAA1522(S161+T162)
Akt KIAA1731(S407+S411+T415)
Akt KLHL20(S263+T270+S273)
Akt KRT19(S10)
Akt LAD1(S121+S123)
Akt LARP4(S597)
Akt LRIG1(S1044)
Akt MACF1(S3927)
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Akt MAP4(S507+T521)
Akt MCM3(S711)
Akt MCRS1(S282)
Akt MFF(T138)
Akt MIIP(S303)
Akt MKI67(S2471)
Akt MKI67IP(T227)
Akt MKI67IP(T234+T238)
Akt MTMR3(S613)
Akt MTMR4(S610)
Akt MUC5AC(T2223+S2224+T2225)
Akt MYL9(S20)
Akt MYL9(T19+S20)
Akt NACA(S166)
Akt NAGK(S76)
Akt NAP1L1(T39)
Akt NCAPG(S1015)
Akt NCOR2(S2057+S2065+S2068)
Akt NRP1(S894)
Akt NUCKS1(S19)
Akt NUMA1(S1945)
Akt NUMA1(T2106)
Akt NUP153(S343)
Akt OR6C65(T277+S278+Y288)
Akt PAK2(S141)
Akt PBRM1(S39)
Akt PDIA6(S428)
Akt PHF8(S857)
Akt PHKA1(S868+T877+S884)
Akt PHKA2(S1015)
Akt PKN1(T774)
Akt PKP3(S313+S314)
Akt POGZ(S333)
Akt PPP1R2(S87)
Akt PREX1(S319)
Akt PTGES3(S151)
Akt PXN(S340)
Akt RAB11FIP1(S501)
Akt RAB11FIP5(S176)
Akt RAB3IP(S288)
Akt RABGEF1(Y601)
Akt RABL6(S425+S427)
Akt RAD21(S449)
Akt RAD50(T690)
Akt RAD9A(S277)
Akt RAI1(S683)
Akt RAI1(S924)
Akt RALGAPA1(S773)
Akt RALGAPA1(S797)
Akt RANBP2(S2263+S2270)
Akt RBBP6(S1277)
Akt RFFL(S240)
Akt RHBDL1(S193+S202+Y214)
Akt RPL24(T83)
Akt RPLP0(S304+S307)
Akt RPLP0(S307)
Akt RPRD2(S976)
Akt RPS17L(S113)
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Akt RPS17L(S115)
Akt RPS6KA1(S221)
Akt RWDD2B(T175)
Akt SAC3D1(S402)
Akt SAP30(S131+S138)
Akt SAP30BP(S52)
Akt SCAF1(S239)
Akt SCAF1(S453)
Akt SCAF1(T994+S997)
Akt SCFD1(S373)
Akt SCNM1(S183)
Akt SCRIB(S1348)
Akt SEC16A(S414+T415+S417)
Akt SF1(S80+S82)
Akt SF3B1(S129+T142)
Akt SF3B2(T780)
Akt SGSM1(S67)
Akt SH2D3A(S125)
Akt SIPA1L1(S174)
Akt SIPA1L1(Y206+T209)
Akt SLC3A2(S134)
Akt SMARCA5(S66)
Akt SMEK1(S771)
Akt SMEK2(S840)
Akt SNAPIN(S133)
Akt SON(S1556)
Akt SOX6(T180+S183)
Akt SRRM2(S1401+S1404)
Akt SSR3(S11)
Akt STK24(T184)
Akt STRN3(S257)
Akt STRN4(S276)
Akt SYAP1(S267)
Akt TAB2(S524)
Akt TBC1D10B(S656+S661)
Akt TBC1D22A(S132)
Akt TCF3(S134+S139)
Akt TDRD7(S859)
Akt TEX15(S194+S195+Y210)
Akt TFDP1(S23)
Akt TNS3(S776)
Akt TP53BP1(S294)
Akt TSC2(S1798)
Akt TWF1(S143)
Akt U2AF2(T119+T124+S142)
Akt UBAP2L(T425)
Akt UNG(T60)
Akt UPF1(S1107)
Akt USP13(T122)
Akt USP32(S1423)
Akt USP5(T623)
Akt VAMP4(S30)
Akt VTI1B(S138)
Akt WDHD1(S367)
Akt YTHDF1(S291)
Akt ZFC3H1(T823)
Akt ZNF276(S599)
Akt ZNHIT3(S80)
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Akt ZNRF1(S52+S53)
Akt ZZEF1(S1518)
CAMK2 ARHGEF2(S151)
CAMK2 ARSI(Y263)
CAMK2 CAC1A(S2275+T2277)
CAMK2 CCDC86(S18+S21)
CAMK2 DNMT3A(S6+S7+T12)
CAMK2 HUWE1(S649)
CAMK2 JUND(S255+S259)
CAMK2 KCTD15(S35+S38)
CAMK2 MKI67IP(S230+T234+T238)
CAMK2 PPP1R11(T109)
CAMK2 PRKCD(S664)
CAMK2 PTGES3(S113)
CAMK2 RPRD2(S628)
CAMK2 RRM2(S377)
CAMK2 SCRIB(S1439)
CAMK2 SMEK1(S117+S126)
CAMK2 TRIM33(T1102+S1105)
EGFR AHNAK(S5448)
EGFR ARHGAP17(S625)
EGFR EHMT2(S140)
EGFR EIF4G1(S1092)
EGFR FASN(T2204)
EGFR GCFC1(S557+S558)
EGFR GORASP2(T433)
EGFR ITGB4(S1457)
EGFR LSM14A(S178+S182)
EGFR NSFL1C(S114)
EGFR PDS5B(S1177)
EGFR RIPK2(S363)
EGFR SRRM1(S769+S775)
EGFR SRRM2(S2118+S2121)
EGFR TNRC6B(S1816)
EGFR TOP2A(S1393)
EGFR WNK2(S1862)
ERK CEP128(S217)
MEK AHCTF1(S1283)
MEK BCL2L11(S77)
MEK ERF(S327)
MEK MAPK1(Y187)
MEK MAPK3(Y204)
mTOR ALKBH5(S361)
mTOR ASAP2(S822)
mTOR CASZ1(S741)
mTOR DOS(S361)
mTOR EIF4EBP1(S65)
mTOR EIF4EBP1(T70)
mTOR EIF4EBP1(Y34+T45)
mTOR EIF4EBP2(T46)
mTOR FA13B(S14)
mTOR FOXK1(S441+S445)
mTOR FOXK2(S428)
mTOR HN1(S87+S88)
mTOR KLF16(S224+S246)
mTOR MKI67(S2223)
mTOR MKI67(S2708)
mTOR NDRG3(S333+S334)
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mTOR PHF2(S539)
mTOR RPS10P5(S157)
mTOR ULK1(S556)
mTOR ULK1(S638)
mTOR WIZ(S1146)
mTOR ZFP106(S861)
p70S6K CELSR1(S1320)
p70S6K CIB3(T6+T9+Y16)
p70S6K CLSPN(S1289)
p70S6K ITLN2(S18)
p70S6K KRT18(S34)
p70S6K MAP6(S793)
p70S6K MAP7(S365)
p70S6K MED1(S953)
p70S6K PPP1R10(S591)
p70S6K PRKAG1(Y280+T284+T287)
p70S6K RFX7(S1081)
p70S6K RHBDF1(S51)
p70S6K THRAP3(S682)
p70S6K WBP11(S237)
p70S6K WDHD1(S333)
p70S6K ZNF217(S795)
PI3K AHNAK(S570)
PI3K DLG5(S1075)
PI3K DOCK7(S2131)
PI3K EHBP1L1(S310)
PI3K FAM102B(S350)
PI3K FAM21C(S288)
PI3K FBP2(T13)
PI3K FKBP15(S344+S356)
PI3K FOXK2(S369+S373)
PI3K GGT5(S474)
PI3K KLC1(S524)
PI3K LARP1(S824)
PI3K MUC5B(T490)
PI3K PACS1(S355)
PI3K PAK2(S141+T154)
PI3K PKP3(S313)
PI3K PREX1(S1179)
PI3K PREX1(S1182)
PI3K PUM1(S75)
PI3K SPAG9(S203+T217)
PI3K STMN1(S16)
PI3K ULK1(S623)
PKC ABCF1(S140)
PKC AHNAK(S5841)
PKC ARFGAP1(T135)
PKC CCDC88C(S1887)
PKC CDC40(S45)
PKC EIF4B(S442+S445)
PKC EIF4B(S459)
PKC GOLGA5(S116)
PKC MAP2K2(S26)
PKC MARK3(S419)
PKC MARK3(T530)
PKC MKI67(S713)
PKC NAA10(S182)
PKC NAV1(S17)
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PKC NFATC2IP(S366)
PKC NOP58(S502+S514)
PKC NPM1(S70)
PKC NRBF2(S120)
PKC NUP214(T1021)
PKC OR5K4(T134)
PKC PPP4R2(S224)
PKC PVRL1(S422)
PKC RANBP2(S1160)
PKC SHANK1(S958)
PKC SPTBN2(S2384)
PKC TPT1(S46)
PKC TRA2B(T201)
PKC TWISTNB(S328)
PKC YTHDC1(S424)
ROCK AAK1(S637)
ROCK AHNAK(S819)
ROCK DIP2A(S94)
ROCK DIP2B(S100)
ROCK DIP2B(Y98)
ROCK FBXW12(S286)
ROCK IQSEC1(S180)
ROCK MKI67(S1329)
ROCK MKI67(S1937)
ROCK MKI67(T1315)
ROCK MPRIP(S1014)
ROCK PPP1R12A(S445)
ROCK PPP1R12A(S903)
ROCK PPP1R13L(S134)
ROCK SAPCD2(T219)
ROCK SPECC1L(S887)
ROCK SPTBN1(S2341)
ROCK SVIL(T852)
ROCK SVIL(Y850)
ROCK WHSC2(S363)
Appendix 2
Summary of CTAM groups (Chapter 4).
CTAM group Number of members (t)
Akt 209
Akt-CAMK2 39
Akt-CAMK2-EGFR 15
Akt-CAMK2-EGFR-ERK 6
Akt-CAMK2-EGFR-ERK-MEK 4
Akt-CAMK2-EGFR-ERK-MEK-mTOR 4
Akt-CAMK2-EGFR-ERK-ROCK 1
Akt-CAMK2-EGFR-mTOR 1
Akt-CAMK2-EGFR-p70S6K 1
Akt-CAMK2-ERK 2
Akt-CAMK2-ERK-MEK 1
Akt-CAMK2-ERK-MEK-mTOR 1
Akt-CAMK2-mTOR-p70S6K-PI3K 1
Akt-CAMK2-mTOR-PI3K 1
Akt-EGFR 9
Akt-EGFR-ERK 4
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Akt-EGFR-ERK-mTOR 1
Akt-EGFR-MEK 1
Akt-ERK 1
Akt-ERK-MEK 1
Akt-ERK-mTOR-p70S6K-PI3K 1
Akt-mTOR 5
Akt-mTOR-p70S6K-PI3K 34
Akt-mTOR-p70S6K-PI3K-PKC 1
Akt-mTOR-PI3K 45
Akt-p70S6K 2
Akt-PI3K 6
Akt-PKC 1
CAMK2 17
CAMK2-EGFR 4
EGFR 17
EGFR-ERK 1
EGFR-ERK-MEK 1
EGFR-MEK 3
EGFR-p70S6K 1
EGFR-PI3K-PKC 1
ERK 1
ERK-mTOR 1
ERK-p70S6K 1
MEK 5
MEK-PKC 1
mTOR 22
mTOR-p70S6K 1
mTOR-p70S6K-PI3K 7
mTOR-PI3K 22
p70S6K 16
p70S6K-PI3K 6
p70S6K-PI3K-PKC 1
p70S6K-PI3K-PKC-ROCK 1
p70S6K-PKC 6
PI3K 22
PI3K-PKC 4
PKC 29
PKC-ROCK 1
ROCK 20
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Appendix 3
Quality control analysis for EGF and IGF-1 stimulation experiments (Chapter 5).
Appendix 3. (A) Distribution of q-values for the identified phosphopeptides. (B) Representative pairwise alignment of
enolase ion retention times used to predict phosphopeptide retention times in samples where the phosphopeptide was not
identified. (C) Distribution of Pearson’s r values for each pairwise enolase ion retention alignment. (D) Upper panel: box
plots demonstrating the distribution of log2-transformed phosphopeptide peak intensities pre-normalisation. Lower panel:
log2 phosphopeptide peak intensities distributions post-quantile normalisation. (E) Enolase ion retention time vs sample
(in chronological order of nLC-MS/MS run). Each line represents an individual enolase ion.
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Appendix 4
Quality control analysis of resistant cell-line phosphoproteome comparisons (Chapter 6).
Appendix 4. (A) Distribution of q-values for the identified phosphopeptides. (B) Representative pairwise alignment of
enolase ion retention times used to predict phosphopeptide retention times in samples where the phosphopeptide was not
identified. (C) Distribution of Pearson’s r values for each pairwise enolase ion retention alignment. (D) Upper panel: box
plots demonstrating the distribution of log2-transformed phosphopeptide peak intensities pre-normalisation. Lower panel:
log2 phosphopeptide peak intensities distributions post-quantile normalisation. (E) Enolase ion retention time vs sample
(in chronological order of nLC-MS/MS run). Each line represents an individual enolase ion.
203
Appendix 5
Quality control analysis of MCF-G and -P cell-line EGF stimulation experiments (Chapter 6).
Appendix 5. (A) Distribution of q-values for the identified phosphopeptides. (B) Representative pairwise alignment of
enolase ion retention times used to predict phosphopeptide retention times in samples where the phosphopeptide was not
identified. (C) Distribution of Pearson’s r values for each pairwise enolase ion retention alignment. (D) Upper panel: box
plots demonstrating the distribution of log2-transformed phosphopeptide peak intensities pre-normalisation. Lower panel:
log2 phosphopeptide peak intensities distributions post-quantile normalisation. (E) Enolase ion retention time vs sample
(in chronological order of nLC-MS/MS run). Each line represents an individual enolase ion.
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